2017N327572_07 CONFIDENTIA L
GlaxoSmithKline group of companies 204686
1TITLE PA GE
Protocol Title: A Phase I, Open -Label Study of [COMPANY_004]1795091 Administered in 
Combination with Immunotherapi[INVESTIGATOR_90502] : 204686 Amendment 06
Short Title : Study  of a combination of [COMPANY_004]1795091 and immu notherapi[INVESTIGATOR_90503] s with a dvanced solid tumors
Compound 
Number s:[COMPANY_004]1795091
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_99770]
Collegeville, PA [ZIP_CODE], [LOCATION_003]
Telephone: 
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline ([COMPANY_004]) 
Affiliate Compan y (or designee). If applicable, the details of the alternative Sponsor and 
contact [CONTACT_90582].   
Medical Monitor Name [CONTACT_9352] [CONTACT_90583] 
(SRM)
Regulatory Agency Identifying Number(s):
Investigational New Drug (IND) number: IND136203
EudraCT numbe r: 2017 -003545 -23
Approval Date: 08-SEP-2020
Copy right 2020 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
[COMPANY_003]
1From:
Sent: Thursday, September 10, 2020 7:29 PM
To:
Cc:
Subject: FW: Prot-Amend6-204686-sponsign
From:  Hesham Abdullah  
Sent: Tuesday, September  08, 2020 3:04 PM 
To:  
Cc:
Subject: RE: Prot‐Amend6‐204686‐sponsign  
Dear  , 
As Chair  of the Oncology  PRF and Head of Oncology  Clinical Development,  I approve Amendment  [ADDRESS_99771], 
Hesham 
From :  
Sent: Tuesday, September  8, 2020 2:32 PM 
To: Hesham Abdullah 
Subject: Prot ‐Amend6‐204686‐sponsign  
Dear Sponsor, 
To approve the clinical  protocol indicated  below, reply to this email and state your approval.  
PROTOCOL  NUMBER:           204686 
DOCUMENT  IDENTIFIER:     2017N327572_07  
AMENDMENT  NUMBER:      6PROTOCOL  TITLE:      A Phase I, Open‐Label Study of [COMPANY_004]1795091  
Administered  in Combination  with Immunotherapi[INVESTIGATOR_90504]:     Hesham  
Abdullah,  MD, MSc, RAC  
Title of Sponsor Signatory:    SVP,  Head 
Clinical Development,  Oncology  R&D 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2017N327572_07 CONFIDENTIA L
204686
3PROTOCOL A MENDMENT SUMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date
Amendment 6 08-SEP -2020
Amendment 5 02-MAR -2020
Amendment 4 12-AUG -2019
Amendment 3 14-SEP -2018
Amendment 2 25-JUL-2018
Amendment 1 CAN -1 06-MAR -2018
Amendment 1 08-DEC -2017
Original Protocol 28-SEP -2017
Amendment 6: 08-SEP-2020
Overall Rationale for the Amendment: There will be no further enro lment and Part 2 
of the study  will not open as the development of [COMPANY_004]1795091 was discontinued by  [CONTACT_23983].  
This decision was based on strategic prior itorization of the portfolio and is not due to the 
safet y profile of [COMPANY_004]1795091.
2017N327572_07 CONFIDENTIA L
204686
4Section # and 
NameDesc ription of Change Brief Rationale
Section 1, 
SynopsisLanguage is added to close enrolment, 
discontinue efficacy follow -up and specify 
that one survival follow -up is required (if 
applicable). 
Discontinue plans for Part 2 and deleted 
language regarding Pa rt 2.The development of [COMPANY_004]1795091 
has been discontinued. This decision 
was based on strategic prioritization 
of the portfolio and is not due to the 
safety profile of [COMPANY_004]1795091.
Section 2, 
Schedule of 
ActivitiesUpdates made to reflect closed enrolment,
discontinued efficacy follow -up and 
specify that one survival follow -up is 
required (if applicable).
Table 3 Part 2 is removed. 
Table 4 Part 2 is removed.As above.
Section 5 Study 
DesignLanguage is added to close enrolment, 
discontinue efficacy follow -up and specify 
that one survival follow -up is required (if 
applicable). 
Discontinue plans for Part 2
Number of participants is updated to 
reflect removal of Part 2. 
End of study language is updated to be 
defined as when the last subject has 
completed/di scontinued study treatment, 
completed the Treatment Discontinuation 
Visit (TDV) assessments, and the OS FU 
visit is completed (as applicable).
Study Schematic is updated to reflect Part 
2 removal. As above.
Section 7 
TreatmentsLanguage updated to reflec t removal of 
Part 2.As above.
Section 8 
Discontinuation 
CriteriaLanguage is added to close enrolment, 
discontinue efficacy follow -up and specify 
that one survival follow -up is required (if 
applicable). As above.
2017N327572_07 CONFIDENTIA L
204686
5Section # and 
NameDescription o f Change Brief Rationale
Section 9 Time period for collection AE and SAE 
data is updated to reflect collection will be 
from the time a participant consents to 
participate in the study up to [ADDRESS_99772] dose of study treatment(s) or until 
the st art of another anti -cancer therapy, 
whichever is first. 
PK will no longer be collected; however, 
event driven collections will be performed. 
Biomarkers will no longer be collected.As above.
Section 10 Stats Language Updated to reflect removal of 
Part 2.
Definition of study populations updated to 
accomodate generation of screen failure 
summaries.As above
Appendix 14 : 
COVID -19Appendix added. This appendix has been added to 
outline the changes that have been 
made in response to the COVID -19 
pandemic
2017N327572_ 07 CONFIDENTIA L
204686
6TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE................................ .....3
1.SYNOPSIS ................................ ................................ ................................ ............. 10
2.SCHEDULE OF ACTIVITI ES (SO A)................................ ................................ .......15
3.INTRODUCTION ................................ ................................ ................................ ....24
3.1. Study Rationale ................................ ................................ .......................... 24
3.2. Brief Background ................................ ................................ ........................ 26
3.2.1. [COMPANY_004]1795091 Background ................................ ........................... 26
3.2.1 .1. [COMPANY_004]1795091 Nonclinical Activity ................................ 26
[IP_ADDRESS]. [COMPANY_004]1795091 Development Plan and Clinical 
Experience ................................ ................................ .27
[IP_ADDRESS].1. Hepatic adverse events .......................... 29
3.2.2. [COMPANY_004]3174998 Background ................................ ........................... 30
[IP_ADDRESS]. [COMPANY_004]3174998 Nonclinical Activity ................................ 31
[IP_ADDRESS]. [COMPANY_004]3174998 Clinical Experience ............................... 31
3.2.3. [COMPANY_004]3359609 Background ................................ ........................... 32
[IP_ADDRESS]. [COMPANY_004]335960 9 Nonclinical Activity ................................ 32
[IP_ADDRESS]. [COMPANY_004]3359609 Clinical Experience ............................... 33
3.2.4. Pembrolizumab Background ................................ ........................ 35
[IP_ADDRESS]. Pembrolizumab Clinical Experience in 
Combination with ot her TLR Agonists ......................... 35
3.2.5. [COMPANY_004]1795091 Combination Background ................................ ......35
[IP_ADDRESS]. [COMPANY_004]1795091 In Vivo Studies ................................ .....35
[IP_ADDRESS]. [COMPANY_004]1795091 In Vitro Studies ................................ .....40
[IP_ADDRESS].1. [COMPANY_004]1795091 and [COMPANY_004]3174998 ............. 40
[IP_ADDRESS].2. [COMPANY_004]1795091 and [COMPANY_004]3359609 ............. 41
[IP_ADDRESS].3. [COMPANY_004]1795091 and pembrolizumab .......... 41
[IP_ADDRESS]. Clinical Combinations of [COMPANY_004]179509 1 and 
[COMPANY_004]3174998 ................................ .............................. 41
3.3. Benefit/Risk Assessment ................................ ................................ ............ 42
3.3.1. Risk Assessment ................................ ................................ ......... 43
3.3.2. Overall Benefit: Risk Conclusion ................................ .................. 47
4.OBJECTIVES AND E NDPOINTS ................................ ................................ ........... 48
5.STUDY DESIGN ................................ ................................ ................................ ....50
5.1. Overall Design ................................ ................................ ............................ 50
5.1.1. Part 1: Dose Escalation of [COMPANY_004]1795091 administered in 
combination with either [COMPANY_004]3174998, [COMPANY_004]3359609, or 
pembrolizumab ................................ ................................ ............ 52
[IP_ADDRESS]. Description of the Continual Reassessment 
Method ................................ ................................ .......53
[IP_ADDRESS]. Logistic Model for N -CRM ................................ ........... 54
5.1.2. PK/Pharmacodynamic Cohort(s) ................................ .................. 54
5.1.3. Dose -Limiting Toxicity ................................ ................................ ..54
5.1.4. Part 2: Expansion Cohort ................................ ............................. 56
5.1.5. Oversight ................................ ................................ ..................... 56
2017N327572_ 07 CONFIDENTIA L
204686
75.1.6. Tumor Types Enrolled During Parts 1 ................................ .......... 56
5.1.7. Intra-Participant Dose Escalation ................................ ................. 56
5.1.8. Study Treatment ................................ ................................ .......... 56
5.2. Number of Participants ................................ ................................ ............... 57
5.3. Participant and Study Completion ................................ ............................... 57
5.4. Scientific Rationale for Study Design ................................ .......................... 57
5.5. Dose Justification ................................ ................................ ........................ 58
5.5.1. Overview ................................ ................................ ...................... 58
[IP_ADDRESS]. Starting dose for TLR4 agonist [COMPANY_004]1795091 ............. 58
[IP_ADDRESS]. Dose for OX -[ADDRESS_99773] [COMPANY_004]3174998 ........................ 59
[IP_ADDRESS]. Dose for ICOS agonist [COMPANY_004]3359609 ......................... 60
[IP_ADDRESS]. Pembrolizumab dose ................................ .................. 61
[IP_ADDRESS]. Combination consideration s................................ .......61
[IP_ADDRESS].1. Combination of [COMPANY_004]1795091 and 
[COMPANY_004]3174998 ................................ .......... 62
[IP_ADDRESS].2. Combination of [COMPANY_004]1795091 and 
[COMPANY_004]3359609 ................................ .......... 62
[IP_ADDRESS].3. Combination of [COMPANY_004]1795091 and 
pembrolizumab ................................ ....... 63
5.5.2. Dose Escalation and Top Dose ................................ .................... 64
6.STUDY POPULATION ................................ ................................ ........................... 64
6.1. Inclusion Criteria ................................ ................................ ......................... 65
6.2. Exclusion Criteria ................................ ................................ ........................ 67
6.3. Lifestyle Restrictions ................................ ................................ ................... 70
6.3.1. Meals and Dietary Restrictions ................................ .................... 70
6.3.2. Caffeine, Alcohol, and Tobacco ................................ ................... 70
6.3.3. Activity ................................ ................................ ......................... 70
6.4. Screen Failures ................................ ................................ ........................... 70
7.TREATMENTS ................................ ................................ ................................ .......70
7.1. Treatments Administered ................................ ................................ ............ 70
7.2. Dose Modification ................................ ................................ ....................... 72
7.2.1. General Guidelines for Cytokine -Related Adverse Events 
and Infusion Reactions ................................ ................................ 74
[IP_ADDRESS]. Management of Cytokine Related Adverse 
Events and Cytokine Release Syndrome .................... 75
[IP_ADDRESS]. Management of Infusion Reactions ............................ 77
7.2.2. General Guidelines for Immune -Related Adverse Events ............ 80
[IP_ADDRESS]. General Principles of Immune -Related Adverse 
Events Identification and Evaluation ........................... 81
[IP_ADDRESS]. General Guidelines f or Clinically Significant 
Toxicities Not Otherwise Specified ............................. 81
[IP_ADDRESS]. Management of Hepatotoxicity ................................ ...82
[IP_ADDRESS]. Management of Gastrointestinal Events 
(Diarrhea or Colitis) ................................ .................... 82
[IP_ADDRESS]. Management of Skin Toxicity ................................ ......84
[IP_ADDRESS]. Management of Endocrine Events .............................. 84
[IP_ADDRESS]. Management of Pneumonitis ................................ ......85
[IP_ADDRESS]. Management of Hematologic Event s.......................... 87
[IP_ADDRESS]. Uveitis/Iritis ................................ ................................ .87
[IP_ADDRESS]. Management of Left Ventricular Dysfunction .............. 88
2017N327572_ 07 CONFIDENTIA L
204686
[IP_ADDRESS]. Management of Valvular Toxicity ................................ 89
7.3. Method of Treatment Assignment ................................ ............................... 89
7.4. Blinding ................................ ................................ ................................ .......89
7.5. Preparation/Handling/Storage/Accountability ................................ .............. 89
7.6. Treatment Compliance ................................ ................................ ................ 90
7.7. Conco mitant Therapy ................................ ................................ .................. 90
7.8. Treatment after the End of the Study ................................ .......................... 90
7.9. Dose Delay ................................ ................................ ................................ .91
8.DISCONTINUATION CRIT ERIA ................................ ................................ ............. 91
8.1. Discontinuation of Stu dy Treatment ................................ ............................ 91
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................ ................ 92
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_99774] to Follow Up ................................ ................................ ........................ 95
9.STUDY ASSESSMENTS AN D PROCEDURES ................................ ..................... 96
9.1. Efficacy Assessments ................................ ................................ ................. 97
9.1.1. Evaluation of Anti -Cancer Activity ................................ ................ 97
9.2. Adverse Events ................................ ................................ ........................... 98
9.2.1. Time Period and Frequency for Collecting AE and SA E 
Information ................................ ................................ ................... 99
9.2.2. Method of Detecting AEs and SAEs ................................ ............. 99
9.2.3. Follow -up of AEs and SAEs ................................ ....................... 100
9.2.4. Regulatory Reporting Requirements for SAEs ........................... 100
9.2.5. Cardiovascular and Death Events ................................ .............. 100
[IP_ADDRESS]. Cardiovascular and Death Events ............................ 101
9.2.6. Disease -Related Events and/or Disease -Related 
Outcomes Not Qualifying as SAEs ................................ ............. [ADDRESS_99775] ................................ ...102
9.3. Treatment of Overdose ................................ ................................ ............. 102
9.4. Safety Assessments ................................ ................................ ................. 102
9.4.1. Physical Examinations ................................ ............................... 102
9.4.2. Vital Signs ................................ ................................ .................. 103
9.4.3. Electrocardiograms ................................ ................................ ....103
9.4.4. Clinical Safety Laboratory Assessments ................................ ....103
9.5. Pharmacokinetics ................................ ................................ ..................... 105
9.5.1. Blood Sample Collection ................................ ............................ 105
9.5.2. Blood Sample Analysis ................................ .............................. 105
9.6. Pharmacodynamics ................................ ................................ .................. 105
9.7. Genetic s................................ ................................ ................................ ...105
9.8. Biomarkers/Pharmacodynamic Markers ................................ ................... 106
9.8.1. Blood Biomarkers ................................ ................................ ......106
9.8.2. Tumor Tissue ................................ ................................ ............. 106
9.8.3. Stool Collection for Microbiome Analysis ................................ ...107
9.9. Medical Resource Utilization and Health Economics ................................ 107
9.10. Qualitative Telephone Interview ................................ ................................ 107
10.STATISTICAL CONSIDER ATIONS AND DATA ANAL YSES ............................... 108
2017N327572_ 07 CONFIDENTIA L
204686
910.1. Sample Size Determination ................................ ................................ ......108
10.2. Populations for Analyses ................................ ................................ .......... 108
10.3. Statistical Analyses ................................ ................................ ................... 109
10.3.1. Primary Analyses ................................ ................................ ....... 109
[IP_ADDRESS]. Safety Analyses ................................ ........................ 109
[IP_ADDRESS]. Extent of Exposure ................................ ................... 109
[IP_ADDRESS]. Adverse Events ................................ ........................ 110
[IP_ADDRESS]. Clinical Laboratory Evaluations ................................ 110
[IP_ADDRESS]. Other Safety Measures ................................ ............. 110
10.3.2. Secondary Analyses ................................ ................................ ..111
[IP_ADDRESS]. Anticancer Activity Analyses ................................ .....111
[IP_ADDRESS]. Pharmacokinetic Analyses ................................ ........ 111
[IP_ADDRESS].1. Pharmacokinetic Parameters ................ 111
[IP_ADDRESS].2. Statistical Analysis of 
Pharmacokinetic Data ........................... 112
[IP_ADDRESS]. Immunogenicity Analyses ................................ ......... 112
10.3.3. Other Analyses ................................ ................................ .......... 113
[IP_ADDRESS]. Translational Research Analyses ............................. 113
[IP_ADDRESS].1. PK/Pharmacodynamic/ Analyses .......... 113
[IP_ADDRESS].2. Biomarker(s) Analyses .......................... 113
[IP_ADDRESS]. Pharmacogenetic Analyses ................................ ......114
[IP_ADDRESS]. Qualitative Telephone Interviews .............................. 114
10.3.4. Interim Analyses ................................ ................................ ........ 114
10.4. N-CRM Analysis for Dose Escalatio n................................ ........................ 114
10.4.1. Implementation of N -CRM ................................ ......................... 114
10.4.2. Bayesian Prior for the Logistic Model ................................ ......... 114
11.REFERENCES ................................ ................................ ................................ .....116
12.APPENDICES ................................ ................................ ................................ ......121
12.1. Appendix 1: Abbreviations and Trademarks ................................ .............. 121
12.2. Appendix 2: Clinical Laboratory Tests ................................ ....................... 124
12.3. Appendix 3: Study Governance Considerations ................................ ........ 125
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ................................ .....129
12.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information ................................ ................................ ................................ 135
12.6. Appendix 6: Genetics ................................ ................................ ................ 138
12.7. Appendix 7: Liver Safety: Required Actions and Follow -up 
Assessments and Study Treatment Rechallenge Guidelines .................... 140
12.7.1. Liver Safety Drug Restart or R echallenge Guidelines ................ 142
12.8. Appendix 8: Country -specific requirements: Canada ................................ 146
12.9. Appendix 9: Guidelines for Assessment of Disease, Disease 
Progression and Response Criteria –adapted from RECIST version 
1.1................................ ................................ ................................ ............ 148
12.10. Appendix 10: CKD -EPI [CONTACT_46974] ................................ ............................... 154
12.11. Appendix 11: Adverse Events of Special Interest ................................ ......155
12.12. Appendix 12: ECOG Performance Statusa................................ ................ 157
12.13. Appendix 13: mAb Monotherapy Dosing Period ................................ ........ 158
12.14. Appendix 14: COVID -19................................ ................................ ........... 159
12.15. Appendix 15 : Protocol Amendment History ................................ .............. 160
2017N327572_07 CONFIDENTIA L
204686
101. SYNOPSIS
Protocol Title: A Phase I, Open -Label Study  of [COMPANY_004]1795091 in Combination with 
Immunotherapi[INVESTIGATOR_90505] s with Selected Advanced Solid Tumors
Short Title: Study  of combination sof [COMPANY_004]1795091 and immunotherapi[INVESTIGATOR_90506] s 
with advance d solid tumors
Rationale: The c ombination of two or more immunotherapi[INVESTIGATOR_90507].  One model of a “cancer -immune cy cle” describes a series of feed -
forward steps b ywhich the immune sy stem recognizes and kills tumor ce lls, a cy cle 
which is counterbalanced by  [CONTACT_90584] -tumor 
immune activation .  These steps include:
-Release of cancer cell antigens
-Cancer antigen presentation
-Priming and activation
-Trafficking of T-cells to tumors
-Infiltration of T-cells into tumors
-Recognition of cancer cells by  T-cells
-Killing of cancer cells
Rational combination strategies, such as i mmunotherapi[INVESTIGATOR_90508],could produce meaningful and s ynergistic activity  comp ared to
monotherapi[INVESTIGATOR_014].  Combining a TL R4 agoni st with a checkpoint modulator targets two 
complementary  steps in the cancer -immunity  cycle; TL R engagement results in the 
production of various inflammatory  cytokines/chemokines such as tumor necrosis factor 
(TNF ), interleukin (IL) 6, granulocy te colon y-stimulating factor (G-CSF), and ty pe I 
interferons ( i.e., IFN, IFN ) and enhanced uptake, processing , and presentation of 
antigens.   Based on nonclinical data, the combination sof [COMPANY_004]1795091 (a TL R4 agonist) 
and [COMPANY_004]3174998 (an OX40 agonist) , [COMPANY_004]3359609 (an ICOS agonist) or 
pembrolizumab (a PD -1inhibitor) is anticipated to have antitumor activit y greater than 
anyof the monotherapi[INVESTIGATOR_014].  
Objectives and Endpoints :
With the implementation of amendment 06, the stu dy is closed to enrolment and Part 2 
will not be opened .
Objectives Endpoints
Primary
To evaluate the safety and tolerability of 
[COMPANY_004]1795091 when administered in 
combination with either [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumab .Adverse event s(AEs) , serious adverse 
event s, dose -limiting toxicities , withdrawals 
due to AEs, dose reductions or delays, and 
changes in safety assessments (e.g., 
laboratory parameters, vital signs, and 
cardiac parameters).
2017N327572_07 CONFIDENTIA L
204686
11Objectives Endpoints
Secondary
To evaluate the antitumor activity of 
[COMPANY_004]17950 91 when administered in 
combination with either [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumabObjective response rate (ORR) and 
disease control rate (DCR) (complete 
response [CR]+ partial response [PR]+ 
stable disease [SD] ≥12 weeks), time to 
response, duration of response, 
progression -free survival (PFS), and 
overall survival. .
To characterize the pharmacokinetics ( PK)
of [COMPANY_004]1795091 when administered in 
combination with either [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumab .[COMPANY_004]1795091 concentrations in plasma 
and assessment of PK parameters (e.g.,
maximum observed concentration [ Cmax], 
AUC (0-τ)andtrough plasma concentration 
[Ctrough ])if data permit .
To evaluate the immunogenicity of 
[COMPANY_004]3174998 ,[COMPANY_004]3359609, or 
pembrolizumab when administered in 
combination with [COMPANY_004]1795091 .  Number and percentage of participants 
who develop detectable anti-drug 
antibodies again st [COMPANY_004]3174998 , 
[COMPANY_004]3359609 , or pembrolizumab .
Exploratory
To evaluate the immunologic effects of 
[COMPANY_004]1795091 when administered in 
combination with either [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumab .  Assessments of OX40 orICOS recep tor 
expression and occupancy of 
[COMPANY_004]3174998 or [COMPANY_004]3359609 on immune 
cells in the peripheral blood .  
Asses sment of the p henotype, quantity, 
and activation state of T cells and other 
immune cells in peripheral blood.
Assessment of tumor biopsies by
[CONTACT_90585] -infiltrating 
lymphocytes and other cells expressing 
key phenotypic markers.
To explore the association between 
treatment with [COMPANY_004]1795091 when 
administered in combination with either
[COMPANY_004]3174998 ,[COMPANY_004]3359609, or 
pembrolizumab and measures of gene 
expression and immune function .  Assessment of gene expression and 
immune function from study participants 
tumor tissue and/or blood samples may 
include but is not limit ed to immune related 
gene expression (RNA expression or 
RNAseq) ,gene signatures, and T-cell 
receptor DNA sequences . 
Asses sment of soluble factors from study 
participants blood samples and/or tumor 
may include but is not limited to cytokines 
and stress -related proteins , cell free DNA 
2017N327572_07 CONFIDENTIA L
204686
12Objectives Endpoints
(cfDNA), and exosomes.
To explore the association between 
treatment with [COMPANY_004]1795091 when 
administered in combination with either 
[COMPANY_004]3174998 ,[COMPANY_004]3359609, or 
pembrolizumab and biomarkers which may 
be associated with response . Toexplore 
the utility of these measures to enrich for 
clinical efficacy and /ordevelopment of a 
diagnostic test.Comparison between antitumor activity and 
baseline biomarker samples from study 
participants blood and/or tumor which may 
include but are not limited to DNA, gene 
expression (RNA ),protein s, immune cell 
phenotypes, and immune response 
markers .
Analysis of the data to identify potential 
selection biomarkers for participant 
enrichment.
To cha racterize the PK of [COMPANY_004]3174998, 
[COMPANY_004]3359609, or pembrol izumab when 
administered in combination with 
[COMPANY_004]1795091.  [COMPANY_004]3174998, [COMPANY_004]3359609, or
pembrolizumab concentrations in 
plasma /serum and assessment of PK 
parameters (e.g., maximum observed 
concentration [C max], AUC (0-τ)and trough
concentration [C trough ]) ifdata permit.
To explore PK -Pharmacodynamic 
relationships, such between PK 
parameters and antitumor activity, safety or 
pharmacodynamic markers after treatment 
with [COMPANY_004]1795091 when administered in 
combination with either [COMPANY_004]3174998, 
[COMPANY_004]3359609, or pembrol izumab.Evaluation of the relationship of antitumor 
activity as assessed by [CONTACT_3168], DCR, safety
and/or pharmacodynamic markers with PK 
parameters (e.g., C max). 
Pharmacogenetics (PGx): To evaluate the 
association of genetic variations in the host 
DNA and res ponse to therapy.Germline genetic evaluations may be 
conducted to test for association with :
Response to treatment , including 
[COMPANY_004]1795091 when administered in 
combination with either [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumab or any 
concomitant medicines.
Disease susceptibility, severity, and 
progression and related conditions.
To explore the gut microbiome composition 
and relationship to treatment response.Sequencing of the microbiome from stool 
samples.  Analysis of the data to identify 
potential selectio n biomarkers for 
participant enrichment
Evaluation of the relationship between 
antibiotic/probiotic use prior to treatment 
and antitumor activity
To evaluate disease -and treatment -related Qualitative telephone interview .
2017N327572_07 CONFIDENTIA L
[ADDRESS_99776] on function and 
health -related quality -of-life.
Overall Design:
This is a Phase I, open -label, non -randomized, multicenter and multi -country  study  
designed to evaluate the safet y, tolerabilit y, PK, pharmacod ynamic, and preliminary  
clinical activity  of [COMPANY_004]1795091 admin istered in combination with other 
immunotherapi[INVESTIGATOR_90509].  
In Part 1,the safety  and tolerability  of escalating doses of [COMPANY_004]1795091 and a single dose 
level of a monoclonal antibody  (mAb) combination partner ( [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumab )will be evaluated in separate cohorts of participants
with advanced solid tumor cancer saccording to a nNeuenschwander -Continual 
Reassessment Method ( N-CRM )design to identify doses for evaluation in Part2.  Part 1 
will incl ude a [COMPANY_004]1795091 run -in period of 2 weeks (i.e., [COMPANY_004]1795091 administration 
on Days 1 and 8) prior to administration of the combination partner beginning at Day 15.  
Approximately  5 dose levels of [COMPANY_004]1795091 in combination with a single fixed dose 
level of the combination partner are planned to be evaluated in Part 1. Following 
protocol amendment, [COMPANY_004]1795091 may  also be further evaluated b y additional routes of 
administration .
With the implementation of amendment 06, the study  is closed to further enrolleme nt and 
Part 2 will not be opened.
PK/Pharmacod ynamic cohort sfor each combination will be opened to enrol lment during 
Part [ADDRESS_99777] of the combination tre atments on the immune cells and 
status of the tumor microenvironment ,in conjunction with PK and pharmacody namic 
markers obtained from blood . Tumor biopsies are required for enro llment to the 
PK/Pharmacod ynamic cohort s, whereas biopsies are strongl y encou raged but not 
mandatory  for Part 1 dose escalation cohorts. For each combination, p articipants in the 
PK/Pharmacod ynamic cohort smay be enrolled to any dose level which has already  been
completed and supported by [CONTACT_90586] y and tolerability  from dose escalation for that 
combination .Up to a maximum of 45 participants may be enrolled into the 
PK/Pharmacod ynamic cohort s with approximately  6per dose level for each combination .
Number of Participant s:
Approximately  72participants will be enrolled into Part 1 (dose -escalation) of the study .  
Additionally , for each combination, up to 6participants in each dose cohort ,and a 
maximum of approximately  45participants in total,may be enrolled into the 
PK/Pharmacod ynamic cohort of Part 1 . Additional cohorts (up to a maximum of 12total 
participants) may be enrolled in Par t 1 to allow for evaluation of more dose levels .
2017N327572_07 CONFIDENTIA L
204686
14Treatment Groups and Duration:
Participants will receive the combination of [COMPANY_004]1795091 with either [COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab .  In Part1, escalating doses of [COMPANY_004]1795091 will be 
evaluated as guided by [CONTACT_90587]-CRM approach .  
The study  includes a screening period, a treatment period, a nd a follow -up period.  
Participants will be screened for eligibility  beginning [ADDRESS_99778] has completed/discontinued study  treatment , 
completed the Treatment Discontinuation Visit ( TDV )assessments ,and the OS FU visit 
is completed (as applicable) .
2017N327572_0 7 CONFIDENTIA L
204686
152. SCHEDULE OF ACTIVITI ES (S OA)
Two bullets below do not apply  to those sites in Canada.
The timing and number of planned study  assessments, including safet y, 
laboratory , imaging, tumor biopsy , pharmacokinetic (PK) , and 
pharmacod ynamic/biomarker assessments included in the tables below may be 
altered during the course of the study  based on newly  available data (e.g., to 
obtain data closer to the time of peak plasma concentrations) to ensure 
appropriate monitoring. 
Any changes in the timing or addition of time points for any  planned stud y 
assessments must be documented and approved by  [CONTACT_90588], but will not 
constitute a protocol amendment. The Institutional Review Board (I RB)/
Independent Ethics Committees (IEC) will be informed of an y safety issues that 
require alteration of the safet y monitoring scheme or amendment of the informed 
consent form ( ICF).
With the implementation of Amendments 5 and 6, specific assessments are not 
required. Please see Table 1and Appendix 13 for further details.
2017N327572_07 CONFIDENTIA L
204686
16Table 1 Part 1 Dose Escalation and PK/Pharmacody namic Cohort s: Safety, Laboratory , Efficacy , Study  Treatment 
Procedures v   (Darker Gray denotes act ivities that are discontinued based on amendment 06)
Scrn a/b[COMPANY_004]1795091 
MonotherapyCombination T reatment: [COMPANY_004]1795091 + treatment mAb aFollow -up
Week a≤4 1 2 3 4 5 6 7 8 9 10 11 12>12 -
105cTDVdPFS 
FUeSFUf
Day ≤28 1 2s8 15 16s22 29 36 43 50 57 58s64 71 78 >78-
736Q12W Q12W 
Informed Consent X
Record all antibiotics and 
probiotics taken 60 days prior 
to dosingX
Inclusion/Exclusion X X
Demographics, Medical History, 
Prior Medications, Disease 
CharacteristicsX
Concomitant Medications Continuous: assess at each visit from first dose of study treatment
Participant Re gistration X
Anti-Cancer Treatment X X X
Study Treatment (note: administer [COMPANY_004]1795091 at least 1 hour after the end of the treatment mAb infusion)
Administer mAb treatment g
([COMPANY_004]3174998, 
[COMPANY_004]3359609, or 
pembrolizumab)X X X X Q3W
Administer [COMPANY_004]1795091 gX X X X X X X X X X X X Q3W
Safety
AE/SAE AssessmentAssess at each visit from first dose until the TDV visit for AEs and until [ADDRESS_99779] dose for AESI and 
SAEs d
ECOG PS X X X X X X X X X X X X X Q6W X
2017N327572_07 CONFIDENTIA L
204686
17Scrn a/b[COMPANY_004]1795091 
MonotherapyCombination T reatment: [COMPANY_004]1795091 + treatment mAb aFollow -up
Week a≤4 1 2 3 4 5 6 7 8 9 10 11 12>12 -
105cTDVdPFS 
FUeSFUf
Day ≤28 1 2s8 15 16s22 29 36 43 50 57 58s64 71 78 >78-
736Q12W Q12W 
Physical Examination hX X X X X X Q6W X
Vital Signs iX X X X X X X X X X X X X X X X Q3W X
12-lead ECGlX X X X X X X X Q12W X
EchocardiogramqX
Laboratory Assessments (Safety) –perform assessments pre -dose on each dosing day (-1 day window)
Hepatitis BandC X
Pregnancy Test Serum β -
hCG at screening r≤3d Monthly (urine or serum) X
Clinical Chemistry X X X X X X X X X X X X X X X XQ3W
24 hr ,
Wk 15 
onlysX
Hema tology X X X X X X X X X X X X X Q3W X
Thyroid function X X X Q6W X
Calculated CrCl X X X X X X Q3W X
Urinalysis X X X X X X Q3W X
Lipid panel uX
Disease Assessments
Tumor imagingjX XpX Q12W X
Patient Reported Outcomes
Telephone Interview XmXn
Telephone call for survival 
status fX
2017N327572_07 CONFIDENTIA L
204686
18Scrn a/b[COMPANY_004]1795091 
MonotherapyCombination T reatment: [COMPANY_004]1795091 + treatment mAb aFollow -up
Week a≤4 1 2 3 4 5 6 7 8 9 10 11 12>12 -
105cTDVdPFS 
FUeSFUf
Day ≤28 1 2s8 15 16s22 29 36 43 50 57 58s64 71 78 >78-
736Q12W Q12W 
Tumor Biopsies
Archived tumor kX
Fresh tissue samplekX X X
Progressive disease tissue 
sample oX
Microbiome Specimen
Stool Sample tX X
Abbreviations: AE = Adverse Event; AESI = Adverse Events of Special Interest; -hCG = Beta -Human Chorionic G onadotropin; CrCl = Creatinine Clearance; ECG = 
Electrocardiogram; ECOG PS = Eastern Cooperative Oncology Group Performance Status; PFS FU = Progression -Free Survival Follow -up;Q3W = every 3 weeks; Q6W = every 6 -
weeks; Q9W= every 9 weeks; Q12W = every 12 weeks; SAE = Serious Adverse Even t; Scrn = Screen; SFU =Survival Follo w-up; TDV = Treatment Discontinuation Visit
a. Visit Windows: With the exception of Screening/baseline and Day 1 visits and unless otherwise specified, assessments performe d at 3-week intervals will have a 3 day 
window and assessments performed at > 3-week intervals will have a 1-week window. For Screening/Baseline and Day [ADDRESS_99780] a -1 day window at all visits.
b. Screening assessments orprocedures tobeperformed up to 4weeks (28days) before thefirstdose (unless otherwise specified, withtheexception ofthescreening serum
pregnancy testwhich must beperformed within 3days ofthefirstdose ofstudy treatment). Informe d consent must be signed before any study specific assessments are 
performed.
c. The frequency of assessments collected at the intervals stated “beginning from Week 1 2onwards ”will be as follows (unless stated otherwise in the table) :
1. Every dosing day (pre -doseevery 3 weeks ): clinical chemistry, hematology, urinalysis , calculated CrCl, vital sign s(predose and EOI+2h)
2. Every 6 weeks: thyroid function tests, ECOG PS assessments, physical examination (including weight) 
3. Every 12 weeks: [ADDRESS_99781] be completed prior to the start of subsequent anti-cancer therapy . The window for
thisvisitis+10days. AllAEs andconcurrent medications willbecollected until atleast 30days afterthelastdose ofstudy treatment or the start of a new anti -cancer therapy, 
whichever o ccurs first.All AESIs and SAEs and any concurrent medications relevant to the reported AESIs and SAEs will be collected until at least [ADDRESS_99782]. If a new anti -cancer therapy is started before the TDV, the OS visit is not required. See Appendix 13 for amendment 05 changes. Particpants 
can opt o ut of the telephone interview. 
g. As of amendment 05, dosing with [COMPANY_004]1795091 was suspended. Dosing of treatment mAb ([COMPANY_004]3174998, [COMPANY_004]3359609, or pembrolizumab) will be at every 3 -week intervals. Dosing of 
[COMPANY_004]1795091 will be at every 1 -week intervals (Q1W) from Week 1 through Week 12 including the 2-week monotherapy run in period (Week 1 and Week 2) . Starting at Week 1 2, 
[COMPANY_004]1795091 will be administered at every 3 -week intervals (Q3W) to coincide with treatment mAb dosing. Participants will be dosed for a maxim um of 2 years.
Infusion/injection of one or both study treatments may be up to 3 days before or after the planned date for administrative re asons only (e.g., routine scheduling, scheduling an 
infusion around a holiday).  However, such changes from the plan ned date should not result in consecutive doses of [COMPANY_004]1795091 being administered within [ADDRESS_99783] be completed per the S oA. A complete physical examination (including height and weight) must be performed at screening and TDV per Section 9.4.1 . A 
brief physical examination (including weight) may be performed at other visits. 
i. Vital Sign Schedule: See Appendix 13 for amendment 05 updated schedule. 
On Day 1, vital signs must be collected predose [COMPANY_004]1795091 and at the following times after the end of injection (EOI) of [COMPANY_004]1795091:  EOI+30m, EOI +2h, EOI 
+4h, EOI + 6h.Vital signs should be assessed (and recorded ) at all timepoints later than EOI + 6h as clinically indicated (optional EOI +8h, EOI +12h, EOI +16h)
until changes in body temperature, heart rate, and/or blood pressure attributable to cytokine production are resolving. 
On Day [ADDRESS_99784] be collected at predose treatment mAb infusion ( [COMPANY_004]3174998 , [COMPANY_004]3 359609, or pembrolizumab) predose [COMPANY_004]1795091 , EOI 
[COMPANY_004]1795091 + 2h, +4h, and +6 h.Vital signs should be assessed (and recorded) at timepoints later than EOI +6h as clinically indicated ( optional EOI +8h, EOI 
+12h, EOI +16h).
On Days 2, 16, and 58, vital sign s corresponding to approximately EOI +24h will be assessed.
On all other visits, vital signs must be collected predose treatment mAb infusion ( [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab) (when administered), predose 
[COMPANY_004]1795091 and EOI [COMPANY_004]1795091 +2h.Additional timepoints should b e collected as clinically indicated (optional EOI +4h, EOI +6h, EOI +8h, EOI +12h, EOI 
+16h) .From week 12 , these will be ta ken Q3W correspo nding to dosing days .
j. Tumor Imaging Schedule:
Screening tumor imaging must beobtained up to 4 weeks ( 28days) before thefirstdose.
Tumor imaging willbeperformed every 12weeks (±1week) until disease progression hasbeen confirmed by [CONTACT_90589]; Participant s whose disease progresses are 
encouraged to have a confirmatory scan performed at lea st [ADDRESS_99785] may beused todetermine treatment decisions forPD.
Participants in the PK/Pharmacodynamic Cohort have an additional tumor imaging ass essment on Week 9
Ifaparticipant hasachieved acomplete response ( CR)orpartial response ( PR)intheprevious radiologic assessment, arepeat scan should beperformed asapartof
theconfirmation ofresponse, no less than 4 weeks (28 days) after the c riteria for response are first met
AttheTDV, tumor imaging isonly required ifthelastdisease assessment didnotshow PDandwas performed 6weeks before TDV.
With the implementati on of Amendment 6 PFS assessment is no longer required. DuringthePFS FU visits (performed when aparticipant haspermanently
discontinued study treatment before disease progression hasbeen documented), tumor imaging willbeobtained every 12weeks (1week) until PD, initiation of a 
new anticancer treatment, or death, whi chever comes first.  
k. Tumor Biopsies: With the implementation of amendment 06, tumor biopsies on treatment are no longer required.  
2017N327572_07 CONFIDENTIA L
204686
20NOTE: Tumor lesions planned forbiopsy must notbeused asindicator lesions forassessment ofdisease, unless discussed a nd agreed with the [COMPANY_004] Medical 
Monitor.
Archived tissue sample is required for all participants at the time of screening. If archival sample is not available, a fresh biopsy is required. 
For Part 1 (Dose Escalation), Screening and on -treatment fresh biops ies are strongly encouraged but otherwise optional for participants in Part 1.
Part 1 PK/Pharmacodynamic Cohort :a fresh tumor biopsy is required atscreening (before first dose) and Week 9 (±7 days). Tumor biopsy at Week 12 (±7 days) 
should be attempted i f feasible but is not mandatory.  
If a biopsy sample collection is missed due to a treatment delay, it may be collected at the next possible study visit or timepoint.
l. See Appendix 13 for amendment 05 updated ECG assessments schedule :  Day 1 ECG measurements will be performed in triplicate predose [COMPANY_004]1795091 and at the 
following times after the injection (EOI) of [COMPANY_004]1795091: EOI + 10m, EOI +2h, EOI + 4h,EOI +6 hr, EOI +24h.  All other ECG measurements are performed predose treatment
mAb infusion ( [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab) , predose [COMPANY_004]1795091 , EOI[COMPANY_004]1795091 +2h, and at screening as single ECG measurements.
m. See Appendix [ADDRESS_99786] the TDV within 30 days of the Day 64 interview are not required to repeat the interview
o. With the implementation of amendment 06, tumor biopsies are no longer required .  
p. Tumor imaging at Week 9 is for participants in the PK/Pharmacodynamic Cohort only; and is timed to coincide with the on -treatment tumor biopsy at Week [ADDRESS_99787] be performed after the tumor biopsy.
q. Multigated acquisition scan (MUGA) is acceptable if ECHO is not available. Assessments after Screening visit should be performed as clinically indicated.
r. Perform only in women of child -bearing potential (WOCBP) .  A serum pregnancy test must be performed at screening, and subsequent pregnancy tests may be either serum 
or urine. 
Final pregnancy test (serum or urine) must be performed in WOCBP [ADDRESS_99788] study treatment .
s. See 24hr sample collection on the Part 1 PK/Pharmacodynamic Table 2.  [ADDRESS_99789] a 8
hour window. At Week 15 only, Clinical Chemistry assessment corresponding to EOI+24 hr will also be assessed
t. The stool sample can be collected at any time during the scr eening period either at the participants home or during clinic visits using the provided collection kit .  The 
collection ki t will also be provided at the W eek 8visit and the sample may be collected dur ing the week leading up to the W eek 9visit
u. The lipid panel includes the following tests: Cholesterol (Total ), Triglycerides , HDL Cholesterol , LDL-Cholesterol (calculated ), Cholesterol/HDL Ratio (calculated) , and Non-
HDL Cholesterol (calculated)
v. See Appendix [ADDRESS_99790] ivities during mAb monotherapy .
2017N327572_07 CONFIDENTIA L
204686
21Table 2 Part 1 Dose Escalation and PK/P harmacody namics Cohort s: Pharmacokinetic, Pharmacodynamic, A nti-drug 
Antibod y, and Genetic Assessments k(Based on amendment [ADDRESS_99791] treatment visi tswill no longer be collected )
Treatment[COMPANY_004]1795091 
monotherapyPost 
treatment
Week 1 2 3 3 4 6 9 9 10 12 >12
Day 1 2 8 15 16 22 36 57 58 64 78 >78Within 
30d 
after 
last 
dose f12 
WK 
after 
last 
doseg
Pharmacodynamic / Immunogenicity Blood Specimens
Whole blood (Receptor 
occupancy /Immune 
phenotypi[INVESTIGATOR_007] )aPre 091 Pre,
4h24h Pre
4hd24h XbXb
PBMCsPre091 Pre Pre Pre Pre Pre
(Wk15 
onlyj)XbXb
Plasma 
(cytokines/ chemokines)Pre091, 
2h,4h, 
6h24h Pre091, 
2h, 4h dPre, 2h, 4h, 
6h24h Pre, 
2h, 
4h, 
6hPre, 
2h, 4h d24h Pre, 
2h, 
4hdPre, 2h, 
4hd, 24h
(Wk15 
only) jXbXb
Plasma (biomarkers)Pre091 Pre Pre
(Wk15 
only) jXb
Serum (biomarkers)Pre091 Pre Pre
(Wk15 
only) jXb
Serum ADA 
([COMPANY_004]3174998, 
[COMPANY_004]3359609, or 
pembrolizumab )h,iPre Pre Pre Pre Pree
(Q12W)X X
Pharmacokinetic Blood Specimens
Treatment mAb PK
([COMPANY_004]3174998 , 
[COMPANY_004]3359609, or 
pembrolizumab)Pre,
EOI, EOI+4hEOI+24h X Pre Pre, 
EOI, 
EOI+4hEOI+24h X Pre Pree
(Q12W)X X
[COMPANY_004]1795091 PK Pre091, 24h Pre091, Pre, 24h Pre091 Pre, 24h Pre091, 10min 10min e
2017N327572_07 CONFIDENTIA L
[ADDRESS_99792] 
treatment
Week 1 2 3 3 4 6 9 9 10 12 >12
Day 1 2 8 15 16 22 36 57 58 64 78 >78Within 
30d 
after 
last 
dose f12 
WK 
after 
last 
doseg
10min, 
2h, 4h, 
6h10min, 
4hd10min, 4h 10min, 
4hd10min (Q12W)
Genetics Research Blood Specimen
Genetics samplecX
Abbreviations: Ab = an tibody; ADA = anti -drug antibody ; EOI = end of infusion; PBMC = peripheral blood mononuclear cell; PK = Pharmacokinetics .
Dark gray denotes discontinued activities based on Amendment 06.
Timepoint Definitions for assessments associated with treatment mAb ( [COMPANY_004]3174998 , [COMPANY_004] 3359609 , orpembrolizumab )dosing:
X= Anytime during visit (sampling date/time must be recorded)
Pre= within 60 minutes before the start of the [COMPANY_004]3174998, [COMPANY_004]3359609 , or p embrolizumab infusion
EOI= within 5 -30 minutes after the end of [COMPANY_004] 3174998, [COMPANY_004]3359609 , or p embrolizumab infusion
EOI+2h = within 2 hours 30 minutes of the end of the [COMPANY_004]3174998, [COMPANY_004]3359609 , or p embrolizumab infusion
EOI+4h = within 4 hours 1 hour of the end of the [COMPANY_004]3174998, [COMPANY_004]3359609 , or p embrolizumab infusion
EOI+6h = within 6 hours 1hour of the end of the [COMPANY_004]3174998, [COMPANY_004]3359609 , or p embrolizumab infusion
EOI+24h = 24 hours 8hours after the end of the [COMPANY_004]3174998 , [COMPANY_004]3359609 , or p embrolizumab infusion
Timepoint Definitions for assessments associated with GS K1795091 dosing:
X= Anytime during visit (sampling date/time must be recorded)
Pre091= within 60 minutes before the start of the [COMPANY_004]1795091 injection
10min = within 10 minutes of the end of the [COMPANY_004]1795091 injection
2h= within 2 hours 30 minutes of the end of the [COMPANY_004]1795091 injection
4h= within 4 hours 1 hour of the end of the [COMPANY_004]1795091 injection
6h= within 6 hours 1hour of the end of the [COMPANY_004]1795091 injection
24h= 24 hours 8 hours after the end of the [COMPANY_004]1795091 injection (sample intended to be d rawn at same time as the EOI+24h sample associated with 
[COMPANY_004]3174998 ,[COMPANY_004]3359609 , or p embrolizumab ) 
2017N327572_07 CONFIDENTIA L
[ADDRESS_99793] 
opportunity a fter a participant has met all eligibility requirements, and can be done up to 28 days before Day 1 or onDay 1 .  Appendix 6describes 
requirements for genetic research.
d.Sample to be taken as clinically feasible within the protocol window (i.e., if participant has been discharged from the clinic prior to the allowed sample 
procurement window, this sample is notmandatory). 
e.Week [ADDRESS_99794] be completed prior to the start of subsequent anti-
cancer therapy. Procedures can be done 7 days, unless otherwise indicated.
g.Procedures can be done 7 days, unless otherwise indicated.
h.Serum samples are req uired t o be collected prior to dosing (i.e., pre -dose) on each dosing day and at the indicated assessment visits following study 
treatment discontinuation, and one sample collected [ADDRESS_99795] dose of study treatment. In addition to these scheduled immunog enicity assessments, 
“event -driven” testing will also be employed for those participants that experience anaphylaxis, serious hypersensitivity, or AEs re lated to study treatment 
administered that led to withdrawal from study treatment . See Section [IP_ADDRESS] for full details.
i.In the event of a hypersensitivity reaction that is either 1) clinically -significant in the opi[INVESTIGATOR_871], or 2) leads to the participant withdrawing from 
study treatment, serum samples should be taken from the participant for immunogenicity testing at the time of the event and again 30 days, 12 weeks, and 24 
weeks after. 
j.After week 12, PBMCs, Plasma (cytokines/chemokines), Plasma (biomarkers) and Serum taken at Week 15 only .  At Week 15, a plasma 
(cytokines/chemokines) assessment corresponding to EOI+24 hr will also be collected .
k.See Appendix 13 forinstruction son ac tivities during mAb monotherapy.
2017N327572_07 CONFIDENTIA L
204686
243. INTRODUCTION
3.1. Stud y Rationale
The model of a “cancer -immune cy cle” describes a series of feed -forward steps by  [CONTACT_90590], a cy cle which is counterbalanced by  
[CONTACT_90584] -tumor immune activation [Chen , 
2013 ; Chen , 2017].  The steps of tumor immune recognition and killing include release of 
cancer cell antigens, cancer antigen presentation, priming and activation, trafficking of T -
cells to tumors, recognition of cancer cells by  T-cells, and killing of cancer cells. I mmune 
suppressive factors which may  be operative in tumor microenvironment include 
checkpoint pathway s (e.g., programmed death receptor -1 [PD -1], cytotoxic T -
lymphocy te-associate d antigen 4 [ CTL A-4]) and a range of immunosuppres sive factors 
(e.g., IDO, TGF -β), as well as immune inhibitory  cell populations including T regulatory  
(Treg) cells, my eloid derived suppressor cells, and immune suppressive macrophages 
(M2-macrophages).  Thus, cancer persistence and growth results from aberrant cell 
replication together with a relative imbalance in favor of immune suppressive factors as 
compared to anti -tumor immune activating responses.
The therapeutic benefit of blocking the immuno -inhibit ory checkpoint pathway s PD-[ADDRESS_99796] and tumor micro environment factors do 
not favo r response to PD-1or CTLA -4.
Toll-like receptors (TLRs) are a famil y of ‘sensor’ proteins primaril y expressed on 
certain immune and epi[INVESTIGATOR_90510] -related molecules known as Pathogen -Associated Molecular 
Patterns (PAMPs).  PAMPs include molecul es such as nucleic acids, flagellar proteins, 
and lipopoly saccharide (LPS) , the protot ypi[INVESTIGATOR_90511] 4.  Ligand -driven 
activation of TLRs results in the production of various inflammatory  cytokines and 
chemokines such as tumor necrosis factor ( TNF ),IL-6, IL -8, IP-10, G -CSF, interferons 
(IFNs), and enhanced uptake, processing, and presentation of antigens b yantigen 
presenting cells .  Further effects of TLR4 agonism observed in animal models of cancer 
include reduction of T reg cells and promotion of macrophage phenot ypic switching from
animmunosuppressive M2 phenoty pe to an immune active M1 phenot ype.  
[COMPANY_004]1795091 is a sy nthetic TL R4 agonist that is being developed b y GlaxoSmithKline as 
an immunological adjuvant to be administered in combination with other immune sy stem 
modulators for the treatment of cancers. [COMPANY_004]1795091 is not being developed as a 
monotherap y given the lack of robust anti -tumor activity  that has been reported for the 
drug class in participant s with advanced malignancies [Guha , 2012; Weihrauch ,2015 ; 
Pashenkov ,2006 ].  Therefore, the first -time in human (FTIH) study of [COMPANY_004]1795091 was 
2017N327572_07 CONFIDENTIA L
204686
25performed in health y participant sto evaluate preliminary  safet y, PK, pharmacody namics , 
andtoidentify  a pharmacologicall y active starting dose to initiate studies in cancer 
patients [Refer to [COMPANY_004] Document Number 2015N236402_03 , Study  204685 ]. 
The adverse event (AE) profile in the [COMPANY_004]1795091 FTIH stud y was characterized by 
[CONTACT_90591] -related effects such as flu -like s ymptoms and changes in temperature and heart 
rate(Section [IP_ADDRESS] ). One (1) study  participant experienced an elevation in 
transaminases (Section [IP_ADDRESS].1 ).  Overall, the clinical profile of [COMPANY_004]1795091 as 
evaluated in healthy  participant s wasconsistent with that anticipated by  [CONTACT_90592] s and with the profiles of other TL R agonists 
reported in both healthy  participant s and cancer patients [ Kanzler , 2007; Bahador , 2007; 
Schmoll , 2014; Northfelt , 2014; Isambert , 2013]. Data from the FTIH study was used to 
support the starting dose and dose rationale in the present st udy (Section 5.5).
Other attractive immunotherap yanticancer targets include costimulatory  pathway s that 
enhance T -cell function.  OX40 is one such costimulatory  receptor expressed primarily  
on activated CD4+ an d CD8+ T -cells. OX40 agonists have been shown to increase 
antitumor immunity  and improve tumor -free survival in non -clinical models ,and OX40 
agonist monoclonal antibodies (mAbs) are currently  being evaluated in Phase I clinical 
trials.  [COMPANY_004]3174998 is a hu manized wild -type IgG1 anti -OX40 agonistic mAb being 
developed for the treatment of advanced malignancies. 
ICOS is another co stimulatory  receptor that is highly  induced on CD4+ and CD8+ T cells 
upon TCR engagement and activation [ Paulos , 2010; Wakamatsu , 2013].  A growing 
body  of literature supports the concept that activating ICOS on CD4+ and CD8+ T cells 
has antitumor potential, and multiple lines of nonclinical and clinical evidence have 
established the rationale for targeting ICOS in cancer.  [COMPANY_004]3359609 is a modified 
humanized IgG4 anti-ICOS mAb currentl y under study  in patients with advanced solid 
tumors.
Pembrolizumab is a humanized IgG4 kappa monoclonal antibody  that blocks the 
interaction between the PD-[ADDRESS_99797] -mediated inhibition of the immune response, 
including the anti -tumor immune response. Pembrolizumab is in clinical development as 
an IV immunothe rapy for advanced malignancies and indicated for the treatment of 
patients across a number of conditions . For more details on specific indications refer to 
pembrolizumab IB [ KEYTRUDA SPC, 2019] and approved labelling.
This study  will assess the safet y, PK, pharmacod ynamics, and preliminary clinical 
activity  of [COMPANY_004]1795091 admini stered in combination with other immunotherapi[INVESTIGATOR_90512] s with advanced solid tumors. [COMPANY_004]3174998 ,[COMPANY_004]3359609, and 
pembrolizumab are well -suited for combination with [COMPANY_004]1795091 based on mechanisms 
of action targeting complementary nodes of the cancer -immunity  cycle and compelling 
antitumor activity  observed in preclinical models. Subsequent combination partners
and/or additional routes of administration may be evaluated (following protocol 
2017N327572_07 CONFIDENTIA L
204686
26amendment /s) based on biologic rationale ,nonclinical data, and/or emerging clinical 
data.
3.2. Brief Background
3.2.1. [COMPANY_004]1795091 Background
An overview of [COMPANY_004]1795091 is provided below.  Detailed information concerning the 
biology , pharmacology , PK, and safet y characteristics can be found in the Investigators’ 
Brochure (IB) for[COMPANY_004]1795091 [[COMPANY_004] Document Number 2015N239078_0 4].  Clinical 
information is aligned to that available at the time of protocol development.
[COMPANY_004]1795091 was initially  developed in the course of structure -activity  studies on L PS
(also known as ‘endotoxin’) , the naturally  occurring ligand of TLR4. [COMPANY_004]1795091 is a 
monosaccharide from the aminoalky l glucosaminide [ADDRESS_99798] of TLR4 that induces immunologic responses in vitro and in vivo. [COMPANY_004]1795091, 
as a single -agent, stimulates cy tokine production (in vitro and in vivo), changes in 
immune cell populations (in vivo) and generates fever response (in vivo).
[IP_ADDRESS]. [COMPANY_004]1795091 Nonclinical Activity  
[COMPANY_004]1795091 has shown immunomodulatory  activity  in multiple in vitro and in vivo 
models.  [COMPANY_004]1795091 added to whole blood ex vivo induces cy tokine production, and 
when administered to BALB /c mice ,induces phenoty pic trends in peripheral blood 
leukocy tes including decreased regulatory  T-cells ( Tregs ), increased T -cell activation, 
and expansion of my eloid cells and monocy te/macrophages.  [COMPANY_004]1795091 administered 
to CT -26 tumor -bearing BALB/c mice resulted in an increase in survival compared to 
contro l groups. 
The in vitro and in vivo pharmacology  of [COMPANY_004]1795091 is consistent with other TLR 
agonists [Kanzler , 2007] . In vitro cy tokine induction (IL -1, IL-6, IP -10 and TNF ) by
[CONTACT_23983]1795091 is similar to that of L PS. In rabbits, a species used for assess ing endotoxin 
contamination of parenteral formulations due to their high sensitivity , [COMPANY_004]1795091 
produced a transient increase in bod y temperature similar to that which occurs following 
LPS administration . In the rep eat dose intravenous toxicity  studies in rats and monkey s, 
[COMPANY_004]1795091 was associated with the expected pro -inflammatory  actions of a TLR4 
agonist. The primary  systemic effect seen with weekly  dosing of [COMPANY_004]1795091 in rat 
(dosing up to 4 weeks) and monkey  (dosing up to 6 weeks) studies was increased levels 
of specific cy tokines; all other findings were transient and considered secondary  to this 
primary  response.  Adverse findings were onl y noted in rat and include microscopic 
changes in the heart valves and lymphocy tic inflammatory  cell infiltrates in the liver. 
The no-observed -adverse -effect -level ( NOAEL )is 15 g/kg/dose and 200 g/kg/dose, in 
the rat and monkey , respectivel y. Based on the predicted human exposure at the highest 
planned clinical dose of 250 ng (predicted maximum concentration [ Cmax] is 
approximately  0.036ng/mL ,andpredicted area under the plasma concentration -time 
curve [AUC ]is approximately  1.21ng·h/mL), the margin to the NOAEL dose in rat is 
2017N327572_07 CONFIDENTIA L
204686
27approximately  2061 Xfor Cmax and 214Xfor AUC and in monkey  is approximately  
40,000 X for Cmax and 24,132 XforAUC .
[IP_ADDRESS]. [COMPANY_004]1795091 Development Plan and C linical E xperience
This protocol describes Study  204686, evaluating the combination of [COMPANY_004]1795091 with 
other immunotherapi[INVESTIGATOR_014] .  The study  will be the second evaluation of [COMPANY_004]1795091 in 
humans and the first in participants with cancer . 
[COMPANY_004]1795091 is not planned for development as a monotherapy  in cancer participant s 
given that the TL R agonist drug class has not produced robust monotherap y antitumor 
activity in multiple prior clinical trials of participants with advanced malignancies.
However , the safet y,PK, and pharmacod ynamics results from the FTIH study  support the 
design and conduct of a clinical trial in cancer participant s where the benefits of 
[COMPANY_004]1795091 are more likely  to be realized as an adjuvant in combination with other 
immune therapi[INVESTIGATOR_90513] . Should the combination (s)
demonstrate robust anti -tumor activity  and a favorable safety  profile, monoth erapy stud y 
arms c ould be added by [CONTACT_90593] s.
Like [COMPANY_004]1795091, other TL R agonists including the prototy pi[INVESTIGATOR_90514]4 agonist, L PS, 
have been evaluated in both healthy  participant s and cancer patients for expe rimental and 
therapeutic purposes. Administration causes dose -dependent increases in cy tokines
including TNF , IL-6, and IL -8, which peak within [ADDRESS_99799] been similar for the two populations [Schmidt , 2015; Dietsch , 201 4].  Clinical safety  
data for the drug class is characterized b y a predictable tolerability profile of transient 
fever and flu -like s ymptoms (e.g. ,chills, nausea, malaise, etc.) attributable to cy tokine 
production [ Bahador , 2007 ]. A review of studies comprising thousands of healthy  
participants that have been administered L PS notes that long -term tox icities have not 
been described [Bahador , 2007]. Although elderl y participants have greate r decreases in 
blood pressure as compared to y oung participants administered 2 ng/kg doses of L PS 
[Krabbe , 2001 ], the difference in sensitivity  has not prevented administration of even 
higher doses (5 ng/kg) to cancer participants [Engelhardt , 1991 ].At these doses, peak 
TNF and IL-6 levels can exceed 5000 pg/ml , and further dose escalation has been
limited by  [CONTACT_90594] [Engelhardt , 1991 ]. In other trials of TL R4 agonists 
in participants with advanced malignancies ,cytokine -associated SAEs such as 
bronchospasm and h ypotension have been reported [Vosika , 1984; de Bono ,2000 ].  
Overall, the cy tokine -associated adverse events associated with TL R agonists overlaps 
minimally  with the profiles of checkpoint modulators. Thus, the safet y profile of TL R 
agonists is well suited for administration in combination with other immune therapi[INVESTIGATOR_90515] .
The FTIH study  of [COMPANY_004]1795091 was a randomized, double -blind (sponsor unblinded), 
placebo -controlled, ascending dose and parallel group study  inhealth y participants ([COMPANY_004] 
Document Numb er 2015N236402_03 , Study  204685 ).  In Part 1, single IV bolus doses of 
placebo or [COMPANY_004]1795091 7, 21, 60, or 100 ng were administered (n=6 [COMPANY_004]1795091, n=2 
placebo per dose level, except the 60 ng cohort which was repeated, i.e. ,n=12 
2017N327572_07 CONFIDENTIA L
204686
28[COMPANY_004]1795091, n=4 placebo).  Dose escalation was stopped , per protocol, following the 
100 ng cohort , in which 3 of 6 participants experienced AEs of moderate intensity . In 
Part 2, participants were to receive repeat doses of [COMPANY_004]1795091.  However, Part 2 was 
not startedfollowing an elevation in transaminases on study  day 30 for 1 participant in
cohort 4 (60 ng) of Part 1 (Section [IP_ADDRESS].1 ).  
Preliminary  PK assessments of [COMPANY_004]1795091 were perf ormed based on available data.  
No quantifiable concentrations were observed at the 7 ng dose (assay  lower limit of 
quantification [LLOQ] = 2 pg/mL), and insufficient PK concentrations were above the 
LLOQ at the 21 ng dose to enable calculation of AUC.  Median peak concentrations 
(Cmax) at doses 21 (n=6), 60 (n=12) and 100 ng (n= 6) doses were 3.90, 10.02 and 
23.26 pg/mL, respectively .The C max values from these three single doses were evaluated 
for dose -proportionality  using the power model loge (PK parameter) = a + b * loge (dose) 
where “a” is the intercept and “b”is the slope and was fitted by  [CONTACT_90595]. An estimate of the slope with corresponding 90% 
confidence interval ( CI)was obtained from the power model to assess the degree of dose -
propor tionality , wherein a slope equal to 1.0 is indicative of dose -proportionality . The 
90% confidence interval for the slope was (0.84, 1.20) and (0.96, 1.24) with inclusion and 
without inclusion, respectively , of a participant from the 100 ng dose cohort who showed 
an approximately  3-fold lower C max compared to other participant s from this cohort. 
These intervals were contained within the interval (0.8, 1.25) indicating that slope is 
around unity  impl ying that dose -proportionalit y is observed for C max within this dose 
range.  Half-life could not be reliabl y estimated for lower dose groups due to limited da ta 
above the assay  LLOQ.  The median half -life calculated from the 100 ng dose is ~72 h, 
which is in agreement with expectations based on extrapolation of p reclinical data.
The safet y profile of [COMPANY_004]1795091 in the FTIH study [[COMPANY_004] Document Number 
2015N236402_03 ], included AEs consistent with cytokine production and was generall y 
qualitatively  similar to profiles of other TLR agonists. Based on preliminary , unblinded 
safet y data, as of [ADDRESS_99800] common 
clinical findings were influenza -like illness (10 participants ), body  temperature increased 
(4 participants ), abdom inal pain, back pain, dizziness, headache, orophary ngeal pain, 
presyncope, (2 participants ).  No other AEs were observed in more than 1 participant.
The frequency  of safety  observations increased with dose as described below .  
Following administration of 7 or 21 ng [COMPANY_004]1795091 (6 participants in each 
group), the reported AEs and changes in vital signs resembled the placebo group.
Following administration of 60 ng [COMPANY_004]1795091 (12 participants), mild influenza -
like sy mptoms or headache were reported for 7 participants.  One (1) participant 
had moderate abdominal cramps considered possibly  related to study  treatment. 
One (1) participant experienced a 58 bpm increase in heart rate to a maximum of 
125bpm. One (1) participant experienced a 12 -fold increase in alanine 
aminotransferase ( ALT )(described Section [IP_ADDRESS].1 ).
Following administration of 100 ng [COMPANY_004]1795091 (6 participants), influenza -like 
symptoms were reported for 5 participants.  Three (3) participants experienced 
moderate AEsconsidered at least possibly  related to study  treatment b y the 
2017N327572_07 CONFIDENTIA L
204686
29investigator, including orthostatic presy ncope, muscle tremor, back pain , nausea, 
dizziness, influenza -like sy mptoms .  Because 3 of 6 participants experienced AEs 
of moderate intensit y dose es calation was stopped, per protocol. 
[IP_ADDRESS].1. Hepatic adverse events
In stud y 204685, 1 participant received a single 60 ng IV dose of [COMPANY_004]1795091 and 
experienced a 12-foldincrease in ALT.  The time course of the increase was notable in 
that t he participant had a s lightly  elevated ALT immediately  prior to dosing (53 U/L ; 
upper limit of normal [ ULN ]= 50 U/L), and the value remained of low grade but trended 
upward to 89.6 U/L on day  7post-dose and 122.5 U/L  on day  21.  On day  32, the ALT 
increased to 563.4 U/L ,and it peaked on day  34 (626.7 U/L ) before declining. Beginning 
with day  35, total bilirubin was elevat ed (29.9 mol/L ; ULN = 21 mol/L). Day 35
aspartate aminotransferase ( AST ), indirect bilirubin, and direct bilirubin were 254.5 U/L 
(ULN = 50 U/L), 25.8 mol/L (ULN = 17.6 mol/L ), and 4.1 mol/L  (ULN = 3.4 
mol/L), respectivel y. The participant experienced no other AEs on the trial and only  had 
mild increases in bod y temperature (0.6oC) and heart rate (14 bpm) relative to predose 
values .A thorough evaluatio n by a hepatologist including comprehensive laboratory  
studies and liver ultrasound provided no additional insight into the elevations in hepatic 
laboratory  values.  Of note, the participant had multiple elevations in transaminases and 
total bilirubin befo re or during other clinical trials at the investigative site, although all 
were of low grade (maximum AL T <[ADDRESS_99801]; maximum to tal bilirubin < 1.[ADDRESS_99802]).
The elevation in transaminase sand total bilirubin was considered possibly  related to 
[COMPANY_004]1795091 by [CONTACT_093]. In addition, the sponsor, in consultation with external 
hepatologists, considered an undefined, underl ying,low-grade hepatic pathology  to 
possibly  have contributed to the elevation in transaminases, given the participant’s 
history .A potential role for [COMPANY_004]1795091 as contributing to the observed increases 
cannot be ruled out based on the available information. Transamin ases were routinely  
measured in all participants in the study , and n o other participant experienced an 
increase.
In study 204686, as of the cutoff date of June 25, 2019 , 1 participant received study  
treatment ([COMPANY_004]1795091 150 ng and [COMPANY_004]3174998 24 mg) for [ADDRESS_99803] (peak ALT 461 IU/L, ULN ALT 41 
IU/L), AST 11x UL N (peak AST 461 IU/L, ULN AST 40 I U/L) and ALP 7.7x ULN 
(peak ALP 994 IU/L, ULN ALP 129 IU/ L). Total and direct bilirubin remained within 
normal limits. There was no nausea, vomiting, fever or abdominal pain. At the time of the 
hepatitis, the subject was also receiving antibiotic treatment (with ciprofloxacin and 
amox ycillin/clavulan ate) for an intra -abdominal abscess. Viral serology , autoantibody  
panel and imaging did not reveal an alternative cause for the event. Study  drugs were 
interrupted, the subject was treated with 1 mg/kg methy lprednisolone and the 
transaminases were resolvin g (ALT 283, AST 68) three day s after peak values. AL P 
remained elevated (865 IU/L ). Disease progression was noted on the imaging and the 
subject elected to withdraw from the stud y.  The investigator and sponsor considered the 
2017N327572_07 CONFIDENTIA L
204686
30event possibly  related to [COMPANY_004]1 795091 and [COMPANY_004]3174998. The sponsor, in consultation 
with external expert hepatologists also considered concomitant amoxy cillin/clavulanate 
as a possible cause.  A potential role for [COMPANY_004]1795019 and [COMPANY_004]3174998 cannot be ruled 
out based on available informati on.
3.2.2. [COMPANY_004]3174998 Background
An overview of [COMPANY_004]3174998 is provided below.  Detailed information concerning the 
biology , pharmacology , PK, and safet y characteristics can be found in the IB[[COMPANY_004] 
Document Number 2014N212091_0 5].Clinical information is aligned to that available at 
the time of protocol development.
[COMPANY_004]3174998 is a humanized wild -type IgG1 anti -OX40 agonistic mAb.  [COMPANY_004]3174998 
demonstrated several mechanisms of action in vitro including promoting effector CD4+ 
T-cell pr oliferation, inhibiting the induction of IL -10-producing CD4+ Ty pe 1 regulatory  
(Tr1) cells and blocking the suppressive function of natural Tregs (nTregs), and binding 
to the fragment cry stallizable region (Fc) receptor (FcR), which is anticipated to augm ent 
OX40 signaling via cross -linking of the antibody  via the Fc domain on FcR positive cells.  
Importantly , it has been shown that OX40 activation gives a costimulatory  signal to T -
cells, dependent on a T -cell receptor (TCR) engagement, suggesting that [COMPANY_004] [ADDRESS_99804] in the models tested which is supported by  [CONTACT_90596]. 
2017N327572_07 CONFIDENTIA L
204686
[IP_ADDRESS]. [COMPANY_004]3174998 Nonclinical A ctivity
[COMPANY_004]3174998 (and mouse surrogate antibodies) have shown activity  in multiple in vitro 
and in vivo models.  [COMPANY_004]3174998 d emonstrated several mechanisms of action in vitro, 
including promoting effector CD4+ T -cell proliferation, inhibiting the induction of IL -10 
producing CD4+ Tr1 cells and blocking the suppressive function of nTregs, and binding 
to FcR, which is anticipated to augment OX40 signaling via cross -linking of the antibody  
via the Fc domain on FcR positive cells. A surrogate mAb to murine OX40 (OX86) was 
administered to female BALB/c mice bearing CT26 mouse colon carcinoma tumors, and 
produced an increase in surviva l compared to control groups.  Together, these data 
provide rationale for [COMPANY_004]3174998 to be used as an immunotherap y for the treatment of 
cancer.
The cy nomolgus monkey was demonstrated to be an appropriate toxicology species due 
to human comparability  with OX40 protein sequence identity , [COMPANY_004]3174998 binding and 
activity . [COMPANY_004]3174998 was well tolerated in monkey  toxicology  studies following weekl y 
IV dosing for up to 4 weeks at doses up to 100 mg/kg/week with no adverse test article -
related findings noted. Anti -[COMPANY_004]3174998 antidrug antibodies ( ADAs )were detected in
most monkey s given 10mg/kg; however, the ability  to determine toxicity  in the
terminal necrops y animals was not compromised by  [CONTACT_90597]. No inf usion reactions were observed in monkey s,
including those with ADA.
[IP_ADDRESS]. [COMPANY_004]3174998 Clinical E xperience
Eight y-two (82 )participants with advanced solid tumors have been treated in the ongoing 
FTIH stud y [ADDRESS_99805] 2017 [[COMPANY_004] Document Number 2014N225045_02 , 
Study  201212 ]. Of the 82participants, 45 were treated with [COMPANY_004]3174998 monotherap y 
across 6 dose levels of (0.003 0.01, 0.3, 1 , 3, and 10 mg/kg), and 39 participants were 
treated with the combination of [COMPANY_004]3174998 and pembrolizumab 200 mg, at 
[COMPANY_004]3174998 doses of 0.003 0.01, 0.3, 1mg/kg . Two participants crossed over from 
monotherap y to combination therapy. To date, [COMPANY_004]3174998 was well tolerated in 
humans with no indication of dose -related increases in AEs based on current data.
In the [COMPANY_004] [ADDRESS_99806] common AEs 
were fatigue (11, 24%), back pain (9, 20%), diarrhea (9, 20%), nausea (8, 18%), asthenia 
(8, 18%), vomiting (8, 18%), anemia, (7, 16%), headache (5, 11%), d yspnoea (5, 11%), 
myalgia (4, 11%), pain in extremity  (5, 11%), and py rexia (5, 11%). The most common 
treatment related AEs included diarrhea (5, 11%) and fatigue (5, 11%).
In the [COMPANY_004]3174998 combination study  arm, no treatment related Grade 4 or Grade 5 
toxicities were reported. Two patients reported Grade 3 treatment -related AEs. One 
patient with head and neck cancer treated with 1 mg/kg [COMPANY_004]3174998 and [ADDRESS_99807] cancer (TNBC) treated with 3 mg/kg 
[COMPANY_004]3174998 reported Grade [ADDRESS_99808] common 
AEs were pleural effusion (9, 23% ), fatigue (6, 15%), decreased appetite, (5, 13%), 
pyrexia (5, 13%), arthralgia (4, 10%), and dy spnoea (4, 10%). The most common 
treatment related AEs i ncluded fatigue (5, 13%) and nausea (3, 8%).
Of note, there was noevidence for an acute cy tokine release s yndrome (CRS) associated 
with [COMPANY_004]3174998 administration at any  dose tested , despi[INVESTIGATOR_79615] a measured receptor 
occupancy  >80% in peripheral blood in the immediately  post -dose timeframe for all 
tested doses (seeFigure 8for additional information on [COMPANY_004]3174998 receptor 
occupancy ).  This is consistent with the mechanistic understanding of OX40 providing a 
costim ulatory  signal to T -cells dependent on a TCR engagement and not functioning as a 
super agonist.  Overall , the safet y profile of [COMPANY_004]3174998 does not appear to have 
overlappi[INVESTIGATOR_90516] s.
For further details on the safet y of [COMPANY_004]3174998, plea se refer to the IB [ [COMPANY_004] Document 
Number 2014N212091_0 5].
3.2.3. [COMPANY_004]3359609 Background
An overview of [COMPANY_004]3 359609 is provided below.  Detailed information concerning the 
biology , pharmacology , PK, and safet y characteristics can be foun d in the IB [[COMPANY_004] 
Document Number 2017N319717_02 ].Clinical information is aligned to that available at 
the time of protocol development.
[COMPANY_004]3359609 is a humanized IgG4 anti -ICOS agonistic mAb with specific, high -affinity  
bindi ng to and agonist activity  of ICOS, which is expressed on CD4+ and CD8+ T cells.
The desired pharmacology of [COMPANY_004]3359609 is to expand the total number and increase 
the activity  of tumor specific effector CD4+ and CD8+ T cell populations.  Tumor 
specific T c ells must be first primed through contact [CONTACT_90598]3359609 to 
bind and elicit an agonist effect.  Therefore, it is expected that [COMPANY_004]3359609 will be mos t 
active in disease settings where an antitumor immune response is primed as an inherent 
feature of the tumor or by [CONTACT_90599] y.  Additionally , [COMPANY_004]3359609 is expected 
to be active in combination with agents which p rime or modulate tumor immunity .
[IP_ADDRESS]. [COMPANY_004]3359609 Nonclinical A ctivity
[COMPANY_004]3359609 biophy sical properties and pharmacology  have been extensively  
characterized in a series of nonclinical experiments. In vitro binding and functional 
studies were performed with recombinant protein as well as cel l lines or primary  human 
immune cells cultured ex vivo. Because ICOS was weakl y expressed on resting T cells 
yet upon TCR engagement and activation became highl y induced on CD4+ and CD8+ T 
cells, all binding and functional studies performed were with anti -CD3 and/or anti -CD28 
activated PBMCs from healthy  human donors.
[COMPANY_004]3359609 bound to recombinant human ICOS with an affinit y of 1.34 nM as 
determined b y Biacore methodology . [COMPANY_004]3359609 bound in a concentration -dependent 
manner to pre -activated primary  CD4 + and CD8+ T cells from health y human donors. 
As expected, minimal binding of [COMPANY_004]3359609 to T cells was noted in the absence of 
activation.
2017N327572_07 CONFIDENTIA L
204686
33The nonclinical toxicology  program for [COMPANY_004]3359609 was conducted in cy nomolgus 
monkey s which were shown to be an app ropriate species since the mAb cross reacts 
equally  well with human and cy nomolgus monkey I COS receptors. There was no binding 
of [COMPANY_004]3359609 with rodent I COS receptors. Receptor occupancy  (evidence of 
[COMPANY_004]3359609 binding and decreased free receptor) was dem onstrated in vivo in monkey s 
on CD3+CD4+CD14-T cells in peripheral blood after administration of single and 
multiple doses of [COMPANY_004]3359609 and persisted throughout the dosing phase and off -dose 
period. Immunohistochemical assessment of ICOS distribution in normal human tissues 
showed positive membranous staining in specific cells or ly mphoid cell aggregates 
considered likel y to be T cells in the tissues examined including l ymphoid tissues, 
gastrointestinal tract, liver, pancreas and testes.
A range of in vit ro and in vivo studies have been conducted to investigate the primary  
pharmacology  of [COMPANY_004]3359609.   The pharmacokinetics of [COMPANY_004]3359609 were
investigated in two repeat dose cynomolgus monkey  IV toxicology  studies. Systemic 
exposure generall y increased prop ortionall y as the dose increased .A decrease in plasma 
concentrations was observed after, typi[INVESTIGATOR_90517] y response; all animals 
were confirmed to be positive for anti -drug antibody  (ADA).
[COMPANY_004]3359609 is not a super -agonist; as the ICOS agonist function of [COMPANY_004]3359609 
required TCR engagement. In the absence of anti -CD3 antibodies, there was minimal to 
no detectable increase in T cell activation or induction of pro -inflammatory cy tokines 
with either the immobilized or soluble form of [COMPANY_004]3359609. Activated CD4+ T cells 
treated with [COMPANY_004]3359609 resulted in a greater magnitude of T cell proliferation, and 
cytokine induction when the antibody  was immobilized as opposed to being added as a 
soluble protein to the supernatant of the T cell cultures. It is known that antibody  cross 
linking is required for T ce ll stimulation through other co stimulatory  receptors 
[Wacholtz , 1989]. Therefore, the bound -format in vitro assay s mimic the in vivo 
condition wherein an ICOSantibody  forms cell -to-cell cross -links through FcγR binding.
[IP_ADDRESS]. [COMPANY_004]335 [ADDRESS_99809] one dose of [COMPANY_004]3359609 in combination
with 200 mg pembrolizumab in the ongoing FTIH study  204691 [[COMPANY_004] Document 
Number 2015N238345_03 ].  These subjects are included in the safety analysis. 
Subjects received [COMPANY_004]3359609 monotherap y in dose escalation and expansion pha sesat 
the following dose levels: 0.001 mg/kg (n=1), 0.003 mg/kg (n=1), 0.01 mg/kg (n=2), 
0.03 mg/kg (n=8), 0.10 mg/k g (n=11), 0.30 mg/kg (n=12), 1 mg/kg (n=18), and 3 mg/kg 
(n=10). One subject enrolled in the 0.03 mg/kg dose level received at Cy cle1 a 
[COMPANY_004]3359609 dose that equated to 0.15 mg/kg.
Among the dose levels of [COMPANY_004]3359609 monotherapy  inves tigated (from 0.001 mg/kg to 
3mg/kg), a dose limiting toxicity  (DLT) was observed in [ADDRESS_99810] at the 3 mg/kg dose 
level. The subject that experienced the DLT following monotherap y [COMPANY_004]3359609, a 52 -
year-old female, enrolled in the PK/PD cohort, experienced AEs of Grade [ADDRESS_99811] , ALT,and gamma -glutam yltransferase (GGT) ; Grade 3 increases in lipase and 
bilirubin; Grade 2 increase in alkaline phosphatase ; and Grade [ADDRESS_99812] of these events (AST increased) occurred [ADDRESS_99813] and the 
presence of aliver lesion measuring 51 x 41 mm. As of the clinical cutoff date, no event 
was considered serious. Allthe events were ongoing , considered related to study  
treatment, and led to treatment discontinuation .
In the overall Part 1 population, 56 of 63 subjects (89%) experienced at least o ne AE
regardless of causality ; 46% of these AEs were Grade 1 or 2 in severity . Twenty -two 
subjects (35%) experienced at least one AE with a maximum severity  Grade of 3 in dose 
levels with > [ADDRESS_99814] 
one Grade 3 AE is: 50% (4 of 8 subjects) at 0.03 mg/kg; 36% (4 of 11 subjects) at 0.1 
mg/kg; 33% (4 of 12 subjects) at 0.3 mg/kg; 44% (8 of 18 subjects) at 1 mg/kg; 10% (1 
of 10 subjects) at 3 mg/kg. Four Grade 4 events were reported in two subje cts ([ADDRESS_99815] 
treated at 3 mg/kg, and tumor perforation in another subject treated at 0.1 mg/kg).  Three 
Grade [ADDRESS_99816] each at 3, 1, 0.03 mg/kg, respectivel y.SAEs reported in >[ADDRESS_99817] infection, all of 
which were reported in 2 subjects each. Three subjects ha d AEs leading to permanent 
discontinuation of study  treatment.
Forty-two (42) subjects received at least one dose of [COMPANY_004]3359609 in combination with 
pembrolizumab 200mg; this includes the dose escalation and expansion phases at the 
following dose levels:  G SK3359609 0.01 mg/kg (n=5), [COMPANY_004]3359609 0.03 mg/kg (n=5), 
[COMPANY_004]3359609 0.10 mg/kg (n=5), [COMPANY_004]3359609 0.30 mg/kg (n=20), and [COMPANY_004]3359609 
1mg/kg (n=7).
No DLTs were reported for an y of the 5 dose levels of [COMPANY_004] 3359609 in combination 
with pembrolizumab 200 mg inv estigated t hus far (from 0.010 mg/kg to 1 mg/kg).  
Grade 1 and 2 AEs were experienced b y 21 subjects (50%) that received [COMPANY_004]3359609 in 
combination with pembrolizumab 200 mg. Twelve subjects (29%) experienced AEs that 
were Grade [ADDRESS_99818](s), respectivel y.A Grade [ADDRESS_99819] one SAE was reported for 14 subjects in Part 2, of which 1 event of diarrhea was 
considered treatment related. No SAEs were reported in >[ADDRESS_99820] had an AE leading to permanent discontinuation of study  treatment in Part 2. 
For further details on the saf ety of [COMPANY_004]3359609, please refer to the IB [[COMPANY_004] Document 
Number 2017N319717_02 ].
2017N327572_07 CONFIDENTIA L
[ADDRESS_99821] the PD -1 protein, has been 
developed b y [COMPANY_006] & Co for the treatme nt of patients with cancer and has been 
approved for treatment of patients with multiple advanced malignancies . Refer to the 
pembrolizumab approved labelling for detailed background information [ KEYTRUDA
SPC, 2019; KEYTRUDA PI, 2019].
[IP_ADDRESS]. Pembrolizumab Clinical Experience in Combination with other TLR 
Agonists
Clinical trials of TL R agonists at doses associated with sy stemic cytokine -related AEs 
have not demonstrated frequent, severe, or unexpected toxicities when administered in 
combination with pembrolizumab [Flowers , 2017; Leung , 2017; Milhem , 2018] . For 
example, the TLR4 agonist G10 0wasadministered alone and in combination with 
pembrolizumab [Flowers , 2017].  The overall frequency  of treatment -related AEs was 
69% for G100 alone vs. 85% for G100 +pembrolizumab.  One (1) of 13 subjects 
experie nced Grade 3 adrenal insufficiency with colitis, hy ponatremia, and hy pocalcemia, 
attributable to pembrolizumab .  No other Grade 3 or greater even ts were described . The 
authors concluded that all AEs considered possibly  related to G100 were grade 1 or 2 and
the addition of pembrolizumab did not result in unexpected or worsening toxicity
[Flowers , 2017].  SD-[ADDRESS_99822] doses of 
pembrolizumab in subjects with metastatic melan oma experienced frequent AEs 
characteristic of TLR agonists, e.g. chills (17/22 subjects; 77.3%); headache (16/22 
subjects; 72.7%); my algia (15/22 subjects; 68.2%); nausea (7/22 subjects; 31.8%); 
pyrexia (7/22 subjects; 31.8%); and influenza -like illness ( 6/22 subjects; 27.3%).  
Grade 3 AEs were observed in 59.1% of patients (most common: my algia 13.6% and 
injection site pain 13.6%).  I mmune -related AEs occurred in 2 p atients.  [Leung , 2017].  
When SD -101 was administe red to subjects with metastatic SCCHN in combination with 
pembrolizumab, potential irAEs were reported at a frequency  of 3/22 subjects (14%) 
[Cohen , 2018].  The authors concluded that the combination neither exacerbate d the 
adverse event profiles of the monotherapi[INVESTIGATOR_90518] a unique safet y signal for the 
combination [Leung , 2017 ; Cohen , 2018] .  In an ongoing phase Ib dose escalation trial 
evaluating intratumoral TLR9 agonist CMP -001 in combination with pembrolizumab in 
63 subjects with advanced melanoma, 15 Grade 3/4 related AEs were reported, including 
hypotension (n=7), anemia (n=2), chills (n=2), h ypertension (n=2) and fever (n=2) 
[Milhem , 2018]. No maxi mum tolerated dose was identified during the dose escalation 
phase of the stud y.While acknowledging the limitations of direct comparisons to these 
studies, these results demonstrate that other TLR agonists administered at doses 
associated with s ystemic, cy tokine -associated AEs have been well-tolerated in 
combination with pembrolizumab by [CONTACT_90600] .
3.2.5. [COMPANY_004]1795091 Combination Background
[IP_ADDRESS]. [COMPANY_004]1795091 In Vivo Studies
Efficacy  Studies
Based on the potentially  complementary  mechanisms of action of [COMPANY_004]3174998 and 
[COMPANY_004]1795091, the combination was evaluated in BALB/c mice implanted with sy ngeneic 
CT-26 tumor xenografts.  Four groups of 10 BALB/c mice with intact immune sy stems 
2017N327572_07 CONFIDENTIA L
[ADDRESS_99823] -26 tumors.  The mice received one of the following treatments: 
placebo, [COMPANY_004]1795091 (TL R4 agonist), OX86 agonist (mouse surrogate OX40 agonist 
antibody ), or the combination of [COMPANY_004]1795091 and OX86 agonist.  While the 
monotherapi[INVESTIGATOR_90519] ( Figure 1), the combination treatment 
of [COMPANY_004]1795091 and OX86 produced greater activity  and durable responses.
Figure 1 CT-26 Tumor Gro wth in Balb/c Mice Treated with [COMPANY_004]1795091 (TLR4 
agonist) and/or OX86 (mouse surrogate for OX40) agonist
The reduction in tumor volume translated to significant improvement in the survival of 
animals ( Figure 2).  Approximately  70% of animals that received the combination of 
[COMPANY_004]1 [ADDRESS_99824], 10 -20% of the 
animals that received either monotherap y survived 100days.
Figure 2 Survival of Balb/c Mice Implanted with CT -26 Tumors and Treated 
with [COMPANY_004]1795091 (TL R4 ago nist) and/or OX86 agonist

2017N327572_07 CONFIDENTIA L
204686
37[COMPANY_004]1795091 and [COMPANY_004]3359609 combination was evaluated in BALB/c mice implanted 
with sy ngeneic CT -26 tumors .  Four groups of 10 BALB/c mice with intact immune 
systems were implanted with CT -26 tumors.  The mice received one of the following 
treatments: placebo, [COMPANY_004]1795091 (TL R4 agonist), 7E.17G9 agonist (mouse surrogate 
ICOS agonist antibody ), or the combination of [COMPANY_004]1795091 and 7E.17G9 agonist.  
While the monotherapi[INVESTIGATOR_90520] ( Figure 3), the 
combination treatment of [COMPANY_004]1795091 and 7E.17G9 produced greater activity  and 
durable responses. [COMPANY_004]1795091 and 7E.17G9 monotherapi[INVESTIGATOR_90521] 10% and 40% 
of mice that survived more than 100days respectively , while the combination t herap y 
resulted in 60% tumor free mice that survived more than 100days (Figure 4).
Figure 3 CT-26 Tumor Gro wth in Balb/c Mice Treated with [COMPANY_004]1795091 (TLR4 
agonist) and/or ICOS agonist antibody  (7E.17G9, m ouse surrogate 
for [COMPANY_004]3359609)

2017N327572_07 CONFIDENTIA L
204686
38Figure 4 Survival of Balb/c Mice Implanted with CT -26 Tumors and Treated 
with [COMPANY_004]1795091 (TLR4 agonist) and/or ICOS agonist antibody  
(7E.17G9, mouse surrogate for [COMPANY_004]3359609)
Figure 5 EMT -6 Tumor Gro wth in Balb/c Mice Treated with [COMPANY_004]1795091 
(TLR4 agonist) and/or PD-1 antibody  (RMPI -14, mouse surrogate for 
pembrolizumab)

2017N327572_07 CONFIDENTIA L
204686
39Figure 6 Survival of Balb/c Mice Implanted with EMT-6Tumors and Treated 
with [COMPANY_004]1795091 (TLR4 agonist) and/or PD-1 antibody (RMPI -14, 
mouse surrogate for pembrolizumab)
[COMPANY_004]1795091 and a PD -1 antibody  in combination were evaluated in BALB/c mice 
implanted with sy ngeneic EMT -6tumors .  Four groups of 10 BALB/c mice with intact 
immune sy stems were implanted with EMT -6tumors.  The mice received one of the 
following treatments: placebo, [COMPANY_004]1795091 (TLR4 agonist), RMP1 -14(mouse surrogate 
PD-1 antibody ), or the combination of [COMPANY_004]1795091 and RMP1 -14.  While t he 
monotherapi[INVESTIGATOR_90522] (Figure 5), the combination treatment 
of [COMPANY_004]1795091 and RMPI -14resulted in greater tumor growth inhibition .[COMPANY_004]1795091 
and RMPI -14 monotherapi[INVESTIGATOR_90521] 40% tumor free mice th at survived 60 to 80 
days, while the combination therapy  resulted in 90% tumor free mice that survived 60 to 
80 day s (Figure 6).
These preclinical efficacy  results for [COMPANY_004]1795091 have been reproducible across a range 
of studies (e. g., testing of different doses, dose frequencies, and routes of administration), 
and together with in vitro and in vivo pharmacologic data, provide rationale for 
evaluating the combination of [COMPANY_004]1795091 with either [COMPANY_004]3174998 , [COMPANY_004]3359609, or 
pembrolizumab in a clinical tria l for the treatment of cancer.
Safety  Studies
In a Safet y PK/Pharmacody namic stud y, groups of 3 cy nomolgus monkey s were 
administered [COMPANY_004]1795091 (2 µg/kg) monotherapy  or [COMPANY_004]1795091 in combination with 
[COMPANY_004]3174998 (10 mg/kg).  Changes in IL-6, IL -8, IL -10, MCP -1, and IP -[ADDRESS_99825] articles.  Minimal 
changes from baseline were observed for TNF , IFNγ, IL -2, and IL -1.  The ratios 
(combination:monotherapy ) of median values (from lowe st to highest) at [ADDRESS_99826] -
dose were 0.59, 0.77, 1.4, 1.6, and 2.5 for MCP -1, IL -8, IP -10, IL -6, and IL -10, 
respectivel y.  Overall, cytokine values were variable and the distributions were generally 
overlappi[INVESTIGATOR_90523] y and combin ation arms.  There were no 
changes in hematology  or clinical pathology  parameters.  
2017N327572_07 CONFIDENTIA L
204686
40A review of the nonclinical toxicology  findings with both [COMPANY_004]1795091 and 
[COMPANY_004]3174998 given as single agents indicate that additional combination toxicology  
studies in monke ys would not likely  provide additional relevant clinical risk assessment 
data.
A review of the data from the nonclinical combination efficacy  studies of [COMPANY_004]1795091 
and anti -ICOS as well as the nonclinical toxicology findings for both [COMPANY_004]1795091 and 
[COMPANY_004]3359 609 used as single agents was conducted and adequatel y provide support for 
their use in combination in the target patient population.  Additionally , the nonclinical 
toxicology  findings for both [COMPANY_004]1795091 and [COMPANY_004]3359609 given as single agents 
indicate that a combination toxicology  study  in monkey s would not likely  provide 
additional relevant clinical risk assessment data.
A review of the data from the nonclinical combination efficacy  studies of [COMPANY_004]1795091 
and anti -PD1 as well as the nonclinical toxicology f indings and clinical (pembrolizumab 
only) safet y information for both [COMPANY_004]1795091 and pembrolizumab used as single agents 
was conducted and adequately  provide support for their use in combination in the target 
patient population.  Additionally , the nonclini cal toxicology  findings for both 
[COMPANY_004]1795091 and pembrolizumab given as single agents indicate that a combination 
toxicology  study  in monkey s would not likely  provide additional relevant clinical risk 
assessment data.
[IP_ADDRESS]. [COMPANY_004]1795091 In Vi troStudies
The potenti al of [COMPANY_004]1795091 alone and in combination with [COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab to induce cy tokine release in vitro was evaluated in 
PBMCs isolated from 10 healthy  human donors (5 males and 5 females) under conditions 
of no anti -CD3 stimulation (re sting) and with anti -CD3 stimulation (pre -stimulation) , 
which was previously  shown to upregulate OX40 surface expression on T -cells.  
Cytokines (IL -2, IL -6, IL -10, IFN , and TNF ) were measured following 24 hours 
incubation with [COMPANY_004]1795091 (10, 100 or 1000 pg/mL ) and either [COMPANY_004]3174998, 
[COMPANY_004]3359609, or pembrolizumab mAbs (0. 01, 0.1, 1 or 10 g/mL).  Anti-CD28 and 
human IgG 1 or IgG4 (as appropriate) isoty pe control antibodies were included as positive 
and negative controls, respectivel y.Positive cy tokine in duction by  [CONTACT_23983]1795091 and 
[COMPANY_004]3174998, [COMPANY_004]3359609, or pembrolizumab combination was defined as 3-fold 
increase above that of [COMPANY_004]1795091 alone. 
[IP_ADDRESS].1. [COMPANY_004]1795091 and [COMPANY_004]3174998
No effects on cy tokine responses in resting or pre -stimulated PBMCs were detected at 
10pg/mL [COMPANY_004]1795091 in combination with any concentration of [COMPANY_004]3174998 . For 
concentrations ≥100 pg/mL  [COMPANY_004]1795091 ,addition of 1 µg/mL [COMPANY_004]3174998 to resting 
PBMCs produced minimal to mild increases (approx. 2 -4 fold) in IL -6, IL -10, and/or 
TNF in 2/10 donors ,and in 1/10 donors in pre -stimulated PBMCs incubated with 
1000 pg/mL [COMPANY_004]1795091 in comb ination with 1g/mL  [COMPANY_004]3174998.  There was high 
donor -to-donor variability  in cy tokine responses, and individual donors had inconsistent 
concentration -response curves amongst the various test conditions.  These results suggest 
that the potential for enha nced cy tokine release when these agents are administered in 
2017N327572_07 CONFIDENTIA L
204686
41combination in patients appears to be low, but cannot be eliminated due to the high 
amount of data variability .
[IP_ADDRESS].2. [COMPANY_004]1795091 and [COMPANY_004]3359609
No increases greater than 3 -fold over single treatment arm in IL -2, IL -6, IL -10, IFN -, or 
TNF -were detected in PBMCs treated with [COMPANY_004]1795091 in combination with 
[COMPANY_004]3359609 (at concentrations up to 1000 pg/mL and 10 g/mL, respectively ) 
compared to [COMPANY_004]1795091 alone, either in the presence or absence of anti -CD3
stimulation.  These results suggest that the potential for enhanced cy tokine release when 
these agents are administered in combination in patients appears to be low.
[IP_ADDRESS].3. [COMPANY_004]1795091 and pembrolizumab
When pembrolizumab ( ≥0.1 μg/mL) was combined with [COMPANY_004]179 5091 (10, 100 or 
1000 pg/mL) in rested PBMCs, there was an increase in the anti-inflammatory cytokine 
IL-10 [med ian increase 3.1 -fold (range 0.01 -to 119 -fold)] in up to 5 of 10 donors 
compared to the respective concentr ations of [COMPANY_004]1795091 plus human IgG4 isoty pe 
control.  Enhanced responses were also observed in rested PBMCs of one to three donors
(out of 10) for at least one inflammatory  cytokine :IL-2 [1.5 -fold (0.01 -to 4.5 -fold)], IL -6 
[1.8-fold(1.1-to 8.2 -fold)],or TNF -α[1.7-fold(0.2-to 7.8 -fold)]. There was high 
donor -to-donor variability  in cy tokine responses, and individual donors had inconsistent 
concentration -response curves amongst the various testconditions.  Given that a subset of 
the donors had increases in one or more pro-inflammatory  cytokines, IL -2, IL -6, and 
TNF -, the potential for enhanced cy tokine release when [COMPANY_004]1795091 and 
pembrolizumab are administered in combination in patients cannot be eliminated (see the 
Investigator’s Brochure , [COMPANY_004] Document Nu mber 2015N239078_0 4).
[IP_ADDRESS]. Clinical Combination sof [COMPANY_004]1795091 and [COMPANY_004]3174998
As of [ADDRESS_99827] 2018, preliminary  clinical data were available for 4 subjects that 
received [COMPANY_004]1795091 50 ng and in combination with [COMPANY_004]3174998 24 mg. Three (3) 
participants completed the 6 -week DLT evaluation period.  One (1) participant received 
the first doses of [COMPANY_004]1795091 and [COMPANY_004]3174998 in combination and remained on study  
without adverse events.   One (1) subject experienced a SAE (constipation), co nsidered 
unrelated to stud y treatment by [CONTACT_093].  One (1) subject, with a history of 
hypertension, experienced Grade 3 hy pertension that resolved with administration of 
Demerol 25 mg.  Based on preliminary  data, no adverse events considered relat ed to 
[COMPANY_004]1795091 during the monotherap y run -in period, increased in severit y when 
administered in combination with [COMPANY_004]3174998.
2017N327572_07 CONFIDENTIA L
204686
423.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reasonabl y expected AEs of [COMPANY_004]1795091 , [COMPANY_004]3174998 , and [COMPANY_004]3359609 may be 
found in the respective IBs [ [COMPANY_004] Document Number 2015N239078_0 4,[COMPANY_004] Document 
Number 2014N212091_0 5, and [COMPANY_004] Document Number 2017N319717_02 ].Information 
for pembrolizumab is found in the KEYTRUDA Prescribing Information. The following 
section outlines the risk assessment and mitigati on strategy  for this protocol.
2017N3 27572_07 CONFIDENTIA L
204686
433.3.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Products [[COMPANY_004]1795091, [COMPANY_004] 3174998, [COMPANY_004]3359609, and pembrolizumab ]
Cytokine release syndrome (CRS) and/or 
cytokine -associated symptoms (flu -like 
symptoms, fever, tachycardia, hypotension , etc.).TLR agonists are known to increase serum 
cytokine levels based upon extensive preclinical 
and clinical data [ Kanzler , 2007; Astiz , 1995; 
Dillingh , 2014; Isambert , 2013].[COMPANY_004]1795091 starting dose selected as a 
minimally active dose based on clinical and 
pharmacodynamic data from the 
[COMPANY_004]1795091 FTIH study [[COMPANY_004] Document 
Number 2015N236402_03 ].  No further 
modification appears indicated given 
available in vivo and in vitro combination 
data for [COMPANY_004]1795091 and clinical data for 
the mAbs.
The first [ADDRESS_99828] 3 days apart 
Evaluation of [COMPANY_004]1795091 tolerability during 
a 2-week run -in period before administration 
as a combination.
Conservative and progressively smaller 
relative dose increases of [COMPANY_004]1795091 
between cohorts (Section 5.1.1 )
Adverse event management with supportive 
care and paracetamol.  In the event of 
unexpectedly severe cases, AE 
management with fluids, oxygen, 
vasopressor support, etc. Refer to 
Section 7.2.
2017N3 27572_07 CONFIDENTIA L
204686
44Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Vagal reactions Rare cases of severe vagal reactions, 
bradycardia and asystole have been described in 
healthy participants receiving LPS. Risks for 
these events may include prior history of 
syncope and inadequate hydration [ van Eijk , 
2004].Hydration of participants before and after 
study product administration.
Frequent vital sign and electrocardiogram 
(ECG) measurements in the immediate post -
dose time frame.
Adverse event management with fluids and, 
if neces sary, vasopressor support (Section 
7.2.1).
Infusion reactions and hypersensitivity Risk for infusion reactions and hypersensitivity is 
inherent to many mAbs [ Brennan , 201 0].Exclusion of participants with history of 
severe hypersensitivity to another mAb.  
Refer to Section 6.2for exclusions.
[COMPANY_004]3174998, [COMPANY_004]3359609, and 
pembrolizumab administration to be 
completed with no res idual infusion -
associated events before [COMPANY_004]1795091 
administration. 
Refer to Section 7.2.1 for management of 
infusion reactions.
2017N3 27572_07 CONFIDENTIA L
204686
45Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Immune -related AEs Monoclonal antibodies which affect the adaptive 
immune -system and promote the killing of tumor 
cells (e.g., ipi[INVESTIGATOR_125], pembrolizumab and 
nivolumab) have been associated with 
inflammatory AEs such as diarrhea/colitis, 
pneumonitis, nephritis, hypophysitis, adrenalitis, 
thyroiditis, severe skin reactions, uveitis, 
myocarditis and hepatotoxicity.  These are well 
established after treatment with checkpoint 
modulators, and are consistent with the immune -
stimulatory mechanism of action of these agents.  
Data are insufficient at this time to fully 
appreciate the characteris tics of [COMPANY_004]3174998 or 
[COMPANY_004]3359609 in this regard; however, 
surveillance for events of this nature is 
warranted.  Risks of irAEs are well -described for 
pembrolizumab [ KEYTRUDA PI, 2019].Exclusion of participants with:
Toxicity ( Grade 3) related to prior 
immunotherapy leading to study 
treatment discontinuation
Refer to Section 6.2.
2017N3 27572_07 CONFIDENTIA L
204686
46Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Liver toxicity One (1) participant with a history of transaminase 
and bilirubin elevations expe rienced a mild 
increase in ALT at study day 7 (>1.5 -fold) and a 
significant increase in ALT ([ADDRESS_99829]), AST 
(5-fold ULN) and total bilirubin (1.[ADDRESS_99830]) 35 
days following a single dose of [COMPANY_004]1795091.  Exclusion of participants with ALT or bilirubin 
1.5-times ULN or greater at screening.
Administration of [COMPANY_004]1795091 monotherapy 
during a [ADDRESS_99831] not attributable to another cause 
during the run -in will discontinue study 
treatment and not receive [COMPANY_004]1795091 and 
mAbs in combination.
Criteria for stoppi[INVESTIGATOR_90524], monitoring and 
managing transaminase elevations, and 
rechallenging participants that experience a 
transaminase elevation ( Appendix 7).
Embryofetal harm Based on the mechanism of action, 
pembrolizumab can cause fetal harm 
[KEYTRUDA PI, 2019]. The risks of 
[COMPANY_004]1795091, [COMPANY_004]3174998 and [COMPANY_004]3359609 
are unknown. Based on the therapeutic targets 
for [COMPANY_004]1795 091, [COMPANY_004]3359609, and 
[COMPANY_004]3174998, they have the potential to 
modulate maternal tolerance to the fetus and can 
therefore cause fetal harm. ( Riella , 2013; Clark ,
2004; Heikkinen , 2004).Exclude pregnant woman from participation 
in the study and require highly effective 
contraceptive measures for WOCBP.
Immune complex disease Immune complex formation and deposition were 
findings in nonclinica l safety studies for 
[COMPANY_004]3359609 (refer to the [COMPANY_004]3359609 IB)Clinical laboratory safety assessments and 
immunogenicity testing
2017N327572_0 7 CONFIDENTIA L
204686
473.3.2. Overall Benefit: Risk Conclusion
This is an open -label, dose escalation study  and the first study  of the combination of 
[COMPANY_004]179 5091 with [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab conducted in 
humans; this study  will enroll participants with advanced solid tumors.  There is biologic 
rationale to study  these combination sfor the treatment of cancer based on complementary  
modes of act ion on the immune sy stem, and antitumor activity  of the combination sthat 
exceeds activity of the monotherapi[INVESTIGATOR_90525]. However, it is unknown if 
the combination swill have clinical activit y for patients with cancer. 
Based on nonclinical in vivo and ex vivo combination evaluations and clinical experience 
to date, and the conservative starting dose of [COMPANY_004]1795091, the safet y profile sof the 
combination sarenot expected to exceed that of the monotherapi[INVESTIGATOR_90526] .  
In contrast to experience to date with [COMPANY_004]3174998 and [COMPANY_004]3359609 , it is expected that 
increasing the dose of [COMPANY_004]1795091 past a certain threshold will be associated with DLTs 
given the T LR4 agonist mechanism of action and experience with other TLR agonists 
including L PS.  As a checkpoint inhibitor, rather than a direct immune -stimulator, 
pembrolizumab is not expected to substantially  increase the potential for DLTs with 
[COMPANY_004]1795091 , but the potential for specific sy nergies cannot be excluded a priori.   
Consistent with oth er Phase 1 trials for the treatment of cancer, a target DLT frequency  
has been set as 16 -33%, and a Bay esian adaptive dose escalation design for [COMPANY_004]1795091 
is employ ed to efficiently  determine the dose(s) associated with this DL T frequency .  In 
addition, i t is possible that infrequent events unrelated to [COMPANY_004]1795091 dose, such as 
increases in hepatic laboratory  values, might be observed. This risk will, in part, be 
mitigated b y a run -in period for [COMPANY_004]1795091 prior to the initiation of combination study  
treatment. The run -inprovides an evaluation of monotherap y [COMPANY_004]1795091 safet y and 
tolerability  in participants with cancer and prevents the administration of combination 
therap y to participants that experience, with [COMPANY_004]1795091 alone, a DLT, unacceptable 
tolera bility , or an increase in ALT to 1.5x UL N and 1.5x baseline. Overall, the benefit: 
risk is ty pi[INVESTIGATOR_12340] a Phase I stud y of participants with advanced cancer.
2017N327572_0 7 CONFIDENTIA L
204686
484. OBJECTIVES A ND ENDPOINTS
Objectives Endpoints
Primary
 To evaluate the safety and tolerability of 
[COMPANY_004]1795091 when administered in combination 
with either [COMPANY_004]3174998, [COMPANY_004]3359609, or
pembrolizumab . AEs, SAEs , DLT s, withdrawals due to AEs, dose 
reductions or delays, and changes in safety 
assessments (e.g., laboratory parameters, vital 
signs, and cardiac p arameters).
Secondary
 To evaluate the antitumor activity of [COMPANY_004]1795091 
when administered in combination with either
[COMPANY_004]3174998, [COMPANY_004]3359609, orpembrolizumab Objective response rate (ORR) and disease control 
rate (DCR) (complete response [CR]+ partial 
response [PR]+ stable disease [SD] ≥12 weeks), 
time to response, duration of response, 
progression -free survival (PFS), and overall survival 
(OS).
 To characterize the pharmacokinetics (PK) of 
[COMPANY_004]1795091 when administered in combination 
with either [COMPANY_004]3174998 , [COMPANY_004]3359609, or 
pembrolizumab. [COMPANY_004]1795091 , concentrations in plasma and 
assessment of PK parameters ( e.g., Cmax, AUC (0-
τ)andCtrough )if data permit.
 To evaluate the immunogenicity of [COMPANY_004]3174998 , 
[COMPANY_004]3359609, and pembrolizumab when 
administered in combi nation with [COMPANY_004]1795091 .   Number and percentage of participant s who 
develop detectable ADA against [COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab .
Exploratory
 To evaluate the immunologic effects of 
[COMPANY_004]1795091 when administered in combination 
with either [COMPANY_004]317 4998 ,[COMPANY_004]3359609, or
pembrolizumab .   Assessments of OX40 or ICOS receptor expression 
and occupancy of [COMPANY_004]3174998 or [COMPANY_004]3359609 on 
immune cells in the peripheral blood.  
Assessment of the phenotype, quantity, and 
activation state of T cells and other immu ne cells in 
peripheral blood.
Assessment of tumor biopsies by 
[CONTACT_90601] -infiltrating lymphocytes and other cells 
expressing key phenotypic markers.
 To explore the association between treatment with 
[COMPANY_004]1795091 when administered in combination 
with either [COMPANY_004]3174998 ,[COMPANY_004]3359609, or 
pembrolizumab and measures of gene expression 
and immune function.   Assessment of gene expression and immune 
function from study part icipants tumor tissue and/or 
blood samples may include but is not limited to 
immune related gene expression (RNA expression 
or RNAseq), gene signatures, and T -cell receptor 
DNA sequences. 
Assessment of soluble factors from study 
participants blood samples and/or tumor may 
include but is not limited to cytokines and stress -
related proteins, cell free DNA (cfDNA), and 
exosomes. 
2017N327572_0 7 CONFIDENTIA L
204686
49Objectives Endpoints
 To explore the association between treatment with 
[COMPANY_004]1795091 when administered in combination 
with either [COMPANY_004]3174998 ,[COMPANY_004]3359609, or 
pembrolizumab and biomarkers which may be 
associated with response . To explore the utility of 
these measures to enrich for clinical efficacy and/or 
development of a diagnostic test. Comparison between antitumor activity and 
baseline biomarker samples fr om study participants 
blood and/or tumor which may include but are not 
limited to DNA, gene expression (RNA), proteins, 
immune cell phenotypes, and immune response 
markers. 
Analysis of the data to identify potential selection 
biomarkers for participant en richment.
 To characterize the PK of [COMPANY_004]3174998, 
[COMPANY_004]3359609, or pembrolizumab when 
administered in combination with [COMPANY_004]1795091.   [COMPANY_004]3174998, [COMPANY_004]3359609, or pembrolizumab 
concentrations in plasma /serum and assessment of 
PK parameters (e.g., maximum observe d 
concentration [C max], AUC (0-τ)and trough 
concentration [C trough ]) if data permit.
 To explore PK -Pharmacodynamic relationships, 
such between PK parameters and antitumor 
activity, safety or pharmacodynamic markers after 
treatment with [COMPANY_004]1795091 when administered in 
combination with either [COMPANY_004]3174998 ,
[COMPANY_004]3359609, or pembrolizumab . Evaluation of the relationship of antitumor activity 
as assessed by [CONTACT_3168], DCR, safety and/or 
pharmacodynamic markers with PK parameters 
(e.g., C max). 
 Pharmacogenetics (PGx): To evaluate the 
association of g enetic variations in the host DNA 
and response to therapy. Germline genetic evaluations may be conducted to 
test for association with:
Response to treatment , including [COMPANY_004]1795091 
when administered in combination with either 
[COMPANY_004]3174998, [COMPANY_004]3359609, or pembr olizumab.
Disease susceptibility, severity, and progression 
and related conditions.
 To explore the gut microbiome composition and 
relationship to treatment response. Sequencing of the microbiome from stool samples.  
Analysis of the data to identify potent ial selection 
biomarkers for participant enrichment
Evaluation of the relationship between 
antibiotic/probiotic use prior to treatment and 
antitumor activity
 To evaluate disease and treatment related 
symptoms and impact on function and health -
related qual ity-of-life. Qualitative telephone interview.
2017N327572_0 7 CONFIDENTIA L
204686
505. STUDY DESIGN
5.1. Overall Design
This is a Phase I, open -label, non -randomized, multicentre, multi -country study  designed 
to evaluate the safet y, tolerability, PK, pharmacody namic, and preliminary  clinical 
activity of [COMPANY_004]1795091 administered in combination with other immunotherapi[INVESTIGATOR_90527].  
With the implementation of amendment 06, the study  is closed to enrolment and Part 2 
will not be opened.
Figure 7 Study  Design
Part 1 is divided into 3 treatment arms based on the [COMPANY_004]1795091 combination partner ;
Part 1a , Part 1b, or Part 1c .  Each of the three treatment arms may  have up to 5 dose 
escalation cohorts to investigate the safet y and tolerability of escalating doses of 
[COMPANY_004]1795091 with a single dose level of the combination partner .[COMPANY_004]1795091 
combination partners are:
2017N327572_0 7 CONFIDENTIA L
204686
51[COMPANY_004]3174998 24 mg (Part 1a)
[COMPANY_004]3359609 80mg (Part 1b)
Pembrolizum ab 200 mg (Part 1c)
Part 1 will include a [COMPANY_004]1795091 run -in period of 2 weeks (i.e. ,[COMPANY_004]1795091 
administration on day s1 and 8) prior to administration of the combination sbeginning on 
day15(Week 3). Following protocol amendment, [COMPANY_004]1795091 may  also be evaluated 
by [CONTACT_90602]. Safety  data will be evaluated according to a 
Neuenschwander -Continual Reassessment Method (N -CRM) design [ Neuenschwander , 
2008].
With the implemention of ame ndment 06, enrolment into the study  is no wclosed and 
Part 2 of the study  will not open.
For each combination of [COMPANY_004]1795091 in Part 1, PK/Pharmacod ynamic c ohort swill be 
opened at cleared dose levels for that combination (i.e. the most recent investigated dose 
level that supported dose escalation) to explore the potential relationships between dose, 
biological effects in the tumor microe nvironment, and tumor response.  A particular 
emphasis in the PK/ Pharmacod ynamic cohort is placed on evaluating the possib le effects 
of the combination on the immune cells and immune status within the tumor 
microenvironment.  Thus ,to be eligible for the PK/Pharmacod ynamic cohort, participants 
must consent to mandatory  fresh biops y collection at baseline and on treatment ( see
Section 2,SoA). An additional radi ographic disease assessment (s ee Section 2,SoA)will 
support exploratory  investigation of tumor growth kinetics in this cohort.   Note that while 
consent to fresh tumor biopsy  is not required for participation in the dose escalation 
cohorts in Part 1, it is strongl y encouraged. Up to 6participants per dose level may  be 
enrolled into the PK/ Pharmacod ynamic cohort for each combination and a maximum of 
approximately [ADDRESS_99832] has completed/discontinued study  treatment , comple ted the Treatment 
Discontinuation Visit (TDV) assessments, and the OS FU visit is completed (as
applicable) .Following protocol amendment (s), additional participants may be enrolled to 
evaluate additional routes of study  treatment admini stration (e.g., int ratumoral 
administration), additional agents to be used in combination with [COMPANY_004]1795091 , or 
additional indications, based on emerging nonclinical and/orclinical data .
2017N327572_0 7 CONFIDENTIA L
204686
525.1.1. Part 1: Dose E scalation of [COMPANY_004]1795091 administered in 
combination with either [COMPANY_004]3174998 ,[COMPANY_004]3359609, or 
pembrolizumab
In Part 1,dose escalation will be performed to identify  combination dose levels 
comprising [COMPANY_004]1795091 with either 24mg [COMPANY_004]3174998 (Part 1a) , 80mg[COMPANY_004]3359609
(Part 1b) , or 200 mg pembrolizumab (Part 1c) .  One (1) dose level of [COMPANY_004] 3174998 , 
[COMPANY_004]3359609, orpembrolizumab with up to 5 dose levels of [COMPANY_004]1795091 are planned 
for evaluation, pending emerging safet y and tolerability  information as dose escalation 
proceeds . 
Part 1 will include a run -in period of 2 weeks in which [COMPANY_004]179 5091 is administered 
once -weekl y[i.e.,administration on day  1(Week 1) andday8(Week 2)]prior to 
initiation of combination treatment with either [COMPANY_004]3174998 , [COMPANY_004]3359609, or 
pembrolizumab beginning on day 15(Week 3) .  During the run -in period, particip ants
that experience a DLT , unacceptable toxicity ,or an increase in ALT (1.5x ULN and 1.5x 
baseline )and not attributable to another cause will be discontinued from the study  and
will not receive [COMPANY_004]1795091 in combination . (See Section 5.1.3 ).
Guidance for the management of toxicity , including dose modification algorithms, is 
provided in Section 7.2.
The starting schedule for [COMPANY_004]1795091 will be at every  1-week intervals (Q1W) from 
Week 1 through Week 12 including the 2-week monotherapy  run in period (Week 1 and 
Week 2) (see So A Table 1). Subsequently ,[COMPANY_004]1795091 will be administered at every  3-
week intervals (Q3W) to coincide with [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab
dosing .  Thus, beginning with Week 12 for Part 1 and Week 13 for Part 2 , both 
[COMPANY_004]1795091 and combination partners will be administered on the same study  day at a 
frequency  of Q3W . 
Cohorts will be opened beginning with 50 ng [COMPANY_004]1795091 admin istered in combination 
with either 24mg [COMPANY_004]3174998 , 80mg[COMPANY_004]3359609, or 200 mg pembrolizumab .Three
(3)or more participant s will be enrolled in each cohort .The t otal number of participant s 
enrolled into each cohort and dose assignments will be guided by[CONTACT_45308] y information
(Section 5.1.3 )from participant s receiving the study  treatment combination s according to 
N-CRM modelling (Section [IP_ADDRESS] , [Neuenschwander , 2008] ).  
Sequential groups of 3 -4 participants will be enrolled and dose escalation (or de -
escalation) will proceed guided b yan N -CRM design .  Dose escal ation for each co hort
will proceed independently  of the other co horts, e.g. dose escalat ion for Part 1a is not 
required prior to dose escalation for Part 1b or Part 1c . The first [ADDRESS_99833] 3 day s apart (e.g., if the participant in a 
cohort were dosed on Monday , the earliest the ne xt participant could be dosed is 
Thursday ). Once the 6-week DLT evaluation period has been completed for at least 3 
subjects in each group (Section 5.1.3 ), N-CRM analy sis will be performed to guide the 
dose level to which the next 3 -4participant s willbe assigned based on DLT frequency  
(Section [IP_ADDRESS] ). The number of participants allocated to any cohort is an estimate; 
participants may also be allocated to PK/ Pharmacody namic cohor tsat aprevious dose 
level that supported dose escalation .
2017N327572_0 7 CONFIDENTIA L
204686
53Dose level s-1 areavailable for [COMPANY_004]3174998 (8 mg +50 ng [COMPANY_004]1795091) and 
[COMPANY_004]3359609 (24 mg + 50 ng [COMPANY_004]1795091) if the target toxicity  level is exceeded in 
Cohort 1 and a dose reduction is needed b elow planned doses .  No dose reductions for 
pembrolizumab will be implemented.
[IP_ADDRESS]. Description of the Continual Reassessment Method
The N -CRM model -based design is a Bay esian adaptive dose escalation scheme that 
assumes a 2-parameter logistic model for the to xicity  rate as a function of dose. I t is a 
modified version of the original Continual Reassessment Method proposed by  
[O’Quigley , 1990]. The N -CRM method is fully  adaptive and makes use of all DLT 
information, there foreis expected to locate the target dose level efficientl y.In this case, 
the model will be applied to the dose escalation decision for [COMPANY_004]1795091, which will be 
performed independentl y for each combination.
Dose escalatio n decisions will be held after participants within any  given cohort have 
been observed for at least 6 weeks after starting the study  treatment (per Section 5.1.3 ). 
At the time of each dose escalation decision, the Fixed and Adaptive Clinical Trial 
Simulator (FACTS [Tessella ,Abington, [LOCATION_008]]) will be used to obtain the 
posterior probabilities forthe DLT rate . The N -CRM estimates for each potential dose
willprovide the posterior probabilities that the DLT rate lies in each of four toxicity  
ranges :
[0%, 16% ]Underdosing
[16%, 33% ]Target toxicity
[33%, 60% ]Excessive toxicity
[60%, 100% ]Unacceptable toxicity
The recommended dose for dose escalation , based on the N -CRM model ,will be the dose 
with the highest posterior probability  of lying in the tar get toxicity  interval with the 
additional requirement that the sum of the posterior probabilities of the DLT rate l ying in 
the excessive toxicity  or unacceptable toxicity range is less than 25%. An updated 
estimate of the toxicity  curve will be provided at the time of each dose escalation 
meeting.  Note that de -escalation as well as escalation is possible using this method. 
Dose escalation will continue until conditions for either scenario (i) or (ii) are met:
i) Six participant shave been treated at the current target dose 
AND
For the current dose level, the posterior probabilities of the DLT rate l ying within the 
excessive toxicity  interval or within the unacceptable toxicity  interval sum to less 
than 25% 
AND
For the next higher dose, the posterior pro babilities of the DLT rate ly ing within the 
excessive toxicity  interval or within the unacceptable toxicity  interval sum to greater 
than 25%.
2017N327572_0 7 CONFIDENTIA L
204686
54ii)No doses are usable (i.e. ,forall doses, the posterior probabilities of the DLT rate 
lying within the excess ive toxicity  interval or within the unacceptable toxicity  interval 
sum to more than 25%) 
AND 
At least [ADDRESS_99834] been observed.
Dose recommendations based on the N -CRM analy sis will be used as guidance. To 
ensure safet y of participants, additional parti cipants may  be enrolled at a current dose 
level at the discretion of the study  investigators and sponsor , even though a higher dose is 
recommended b y N-CRM analy sis.
[IP_ADDRESS]. Logistic Model for N -CRM
A two -parameter logistic model will be used forN-CRM analy sis for dose level selection
during the dose escalation phase . This model will estimate the probability  of observing a 
DLT at each dose level in the study  as DLT information becomes available.
The logistic model that used for describing the dose -toxicity  relati onship is: 
,
where p dis the probability  of DLT at dose d, and dmis a reference dose, and α and β are 
Bayesian priors.
5.1.2. PK/Pharmacody namic Cohort(s)
Characterizing the effects of treatment on the tumor microenvironment is essential to the 
understanding the mechanism of action of [COMPANY_004]1795091 and its combination partners at 
the site of action. Thus, f or each combination of [COMPANY_004]1795091 in Part 1, 
PK/Pharmacod ynamic cohort swill be opened to characterize the biological effects in the 
tumor microenvironment and explore the potential relationships be tween dose and tumor 
respons e.  PK/Pharmacody namic cohorts , with up to 6participants per dose level , will be 
opened for [COMPANY_004]1795091 dose levels previousl y cleared fordose escalation.
Pre-and on -treatment t umor biopsies arerequired for enrol lment to this cohort .PK, 
pharmacod ynamic markers , and safety samples will be drawn according to Section 2to 
obtain additional PK and pharmacod ynamic data.  Following the selection of a 
recommended combination dose for Part 2 , participants in the Part 1 
PK/Pharmacod ynamic cohort may have the dose escalated to a higher completed dose 
level (not exceeding the target toxicity  level )after Week9once the necessary  
PK/Pharmacod ynamic procedures and tissue biopsies have been completed. See 
Section 5.1.7 for further instructions on intra -participant dose escalation.
5.1.3. Dose -Limiting Toxicity
All toxicities will be graded using National Cancer I nstitute -Common Toxicity  Criteria 
for AEs (NCI -CTCAE), version 4.0.  
An AE is consider ed to be a DLT if it is considered by  [CONTACT_90603] (definitely , probabl y, or possibly ) to the study  treatment and meets 
2017N327572_0 [ADDRESS_99835] 1 of the criteria listed in Table 3.  Ifan AE is considered related to the underl ying 
disease ,it is not a DLT .
Table 3 Dose -Limiting Toxicity  Criteria
Toxicity DLT Definition
Hematologic Grade 4 neutropenia of >7 days’ duration or febrile neutropenia 
Grade 4 anemia 
Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding
Non-
hematologic Grade 4 toxicity
Grade 3 toxicity that does not resolve to Grade 1 or baseline within 14 days despi[INVESTIGATOR_90528] 
Immune -related toxicity requiring >10 mg pred nisone (or equivalent) per day after [ADDRESS_99836] dose of study treatment
Cardiopulmonary or hemodynamic toxicity starti ng within 24 hours of study treatment injection 
that requires >40% fraction inspi[INVESTIGATOR_1401] (FiO2), vasopressor administration , antiarrhythmic 
agent or other significant medical intervention.
ECG changes showing asystole or bradycardia that is symptomatic and requires medical 
intervention.
Liver toxicity (see Appendix 7) including 
oALT 5xUL N
oALT 3xULN persists for 4 weeks
oALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) 
oALT 3xULN and INR >1.5, if INR measured
oALT 3xULN associated with symptoms (new or worsening) believed to be related to 
liver injury or hypersensitivit y
Following events are notconsidered DLTs
oChanges in leukocyte parameters within 48 hours of [COMPANY_004]1795091 administration
oGrade 1 changes in ALT 
o≥ Grade 3 electrolyte abnormalities that are corrected within 24 hours without clinical 
sequelae
oGrade 3 tumor flare (defined as local pain, irritation, or rash localized at sites of known or 
suspected tumor)
o Grade 3 fatigue
Other (not 
addressed 
above) Toxicity that results in permanent discontinuation or dose reduction of [COMPANY_004]1795091 during 
the first 6 weeks of treatment
Any other event which in the judgment of the investigator and [COMPANY_004] Medical Monitor is 
considered to be a DLT
For participants to be cons idered evaluable for dose escalation decisions, missed study  
treatments m ust be limited during the first 6 weeks of dosing . Participants may  not miss 
any study  treatment administered Q3W and may  not miss more than 1 study  treatment 
administered Q1W .
Partic ipants who withdraw from study  treatment before completing 6 weeks of treatment 
for reasons other than DLT or who are not evaluable for dose escalation decisions may be 
replaced .  If a participan t experiences a DLT during this period , the participant will be 
discontinued from the study .  
Guidance for the management of toxicity , including dose modification al gorithms, is 
provided in Section 7.2.
2017N327572_0 7 CONFIDENTIA L
204686
565.1.4. Part 2: Expansion C ohort
With the implementation of amendment 06, th e study  is closed to enrolment and Part 2 
will not be opened.
5.1.5. Oversight
The active study  investigators, [COMPANY_004] medical monitor, [COMPANY_004] pharmacovigilance phy sician, 
[COMPANY_004] statistician , [COMPANY_004] phy sician (s)independent of the study  team and contract 
organization phy sicians will be responsible fordecisions to escalate doses.  Prior to the 
dose escalation decision, the attendees will review critical safety  information defined in 
Section 5.1.3 , and in the Dose Escalation Plan. Decisions will be based on safet y 
information and other available data from ongoing and prior cohorts.
The dose -determination decision and rationale for each cohort will be discussed with 
investigators during teleconference(s) and documented in writing, wi th copi[INVESTIGATOR_90529] y site and in the study master file.
Although the N -CRM will be used to recommend the next dosing level, clinical judgment 
by [CONTACT_90604].
5.1.6. Tumor Types Enrolled D uring Parts [ADDRESS_99837] 6 weeks of study  treatment without the occurrence of a 
SAE or ≥Grade 2 drug -related toxicity .  Approval by [CONTACT_90605] -
participant dose escalation .
5.1.8. Study Treatment
Study Part Study Treatment: [COMPANY_004]1795091 in combination with [COMPANY_004]3174998, [COMPANY_004]3359609, 
or pembrolizu mab
Part 1: Dose Escalation
1a [COMPANY_004]3174998 24 mg IV and [COMPANY_004]1795091 IV 
1b [COMPANY_004]3359609 80 mg IV and [COMPANY_004]1795091 IV
1c pembrolizumab 200 mg IV and [COMPANY_004]1795091 IV
2017N327572_0 7 CONFIDENTIA L
204686
575.2. Number of Participants
Approximately  72participants will be enrolled into Part 1 (dose -escala tion) of the study
with approximately  24participants in each combination .  .  
Additionally , for each combination, up to 6 participants in each dose cohort and a 
maximum of approximately  45participants in total may  be enrolled into the 
PK/Pharmacod ynamic cohort sof Part 1 . Additional cohorts (up to a maximum of 12total 
participants) may be enrolled in Part [ADDRESS_99838] 1 stud y treatment and experience a DLT or 
complete the 6-week DLT observation period, and the treatment discontinuation visit 
(TDV) .
Cause of death must be documented in the case report form ( CRF )/electronic CRF
(eCRF) .A participant will be considered to have withdrawn from the study  if the 
participant has not died and is lost to follow -up, has withdrawn consent, at the 
investigator’s discretion is no longer being followed or if the study  is closed/terminated.
Disease progression and AEs, are not b y themselves reasons for withdrawal from the 
study .The end of the stu dy is defined as the last participan thas completed/discontinued 
study  treatment and completed the TDV assessments , andthe OS follow -up visit is 
completed (asapplicable) .See SoA (Section 2).
5.4. Scientific Rationale for Study  Design
The combination of [COMPANY_004]1795091 with either [COMPANY_004]3174998 , [COMPANY_004]3359069, or
pembrolizumab was selected based on complementary mechanisms of action and robust 
antitumor activity  in preclinical models. 
Eligibility  criteria requ ire that participan ts have progressed after standard therapi[INVESTIGATOR_90530], and the criteria are intende d to minimize the 
risk of adverse reactions to treatment with immunotherapi[INVESTIGATOR_014].
In Part 1, dose escalation of [COMPANY_004]1795091 ,with a fixed dose of the combination partners ,
will be performed using a nN-CRM model to optimi ze the allocation of participan ts to 
dose levels with a 16 -33% DLT frequency .TheDLT criteria are based on ty pi[INVESTIGATOR_90531] s.
2017N327572_0 [ADDRESS_99839] been previousl y administered as 
monotherapi[INVESTIGATOR_90532] 204685 ([COMPANY_004] Document Number 2015N236402_03 ), 201212
([COMPANY_004] Document Number 2014N225045_02 ), and 204691 ([COMPANY_004] Document Number 
2015N238345_03 ),respectively .  
Theselection of starting combination dose shas taken into consi deration all available 
data, including the safety, tolerability , and pharmacology  data of monotherapy  
[COMPANY_004]1795091 ,monotherapy  [COMPANY_004]3174998 , and monotherapy  [COMPANY_004]3359609 observed in 
the respective FTIH studies [ [COMPANY_004] Document Number 2015N236402_03 ,[COMPANY_004] Document 
Number 2014N225045_02 , and [COMPANY_004] Document Number 2015N238345_03 ]and for 
pembrolizumab as summarized in the Prescribing Information [ KEYTRUDA PI, 2019 ], 
together with pharmacology  and safet y data from animal models and human ex vivo 
(peripheral blood mononuclear cell [ PBMC ]) assays, conducted under monotherap y and 
combination conditions.   
[IP_ADDRESS]. Starting dose for TLR4 agonist [COMPANY_004]1795091
The starting dose of [COMPANY_004]1795091 is 50 ngadministered once -weekl yIV. Previously  
[COMPANY_004]1795091 was administered at doses up to 100 ng IV to healthy  participants in the 
FTIH Stud y (204685).  Base d on data from the FTIH study , the starting dose in th e 
current stud y (50 ng) is expected to produce low level pharmacological effects consistent 
with TL R4 agonism based on data from the FTIH study  (Section [IP_ADDRESS] ).  
Because robust TLR receptor saturation assay s are not available, target engagement by 
[CONTACT_23983]1795091 in the FTIH study  (204685) was monitored using representative 
inflammatory  cytokine biomarkers. Based on review of a vailable preliminary data (dose 
levels up to 100ng), post -dose elevations of cy tokines following administration of
[COMPANY_004]1795091 in the FTIH study  were of a low magnitude compared to historical clinical 
studies of TLR agonists administered to cancer patients .  For example, thepeak levels of 
inflammatory  cytokines at 2h , such as TNF (median: 12pg/ml ; min: 6pg/ml ; max: 23
pg/ml) and IL -6 (median: 132pg/ml; min: 81pg/ml; max: 184pg/ml pg/ml , 
respectivel y), associated with administration of 100 ng [COMPANY_004]1795091 are below levels 
reported in previous studies of TL R agonists in cancer patients ( >1000 pg/ml) [Chow , 
2017; Engelhardt , 1991 ]. These differences are likely  not a function of differences in 
study  populations, given that prior comparisons of TL R agonists in health y participants 
and cancer participants have shown similar cy tokine responses between populations 
[Schmidt , 2015; Dietsch , 201 4]. Even acknowledging possible differences in 
pharmacod ynamic assay  performance, the greater than 10–100 fold margin between 
2017N327572_0 7 CONFIDENTIA L
204686
59cytokine concentrations associated with 100ng doses of [COMPANY_004]1795091 v ersus
concentrations reported in other studies of cancer patients provides reassurance that a 
significant margin separates the starting dose of [COMPANY_004]1795091 and maximum tolerated 
dose of other TLR agonists .  
Consistent with the mechanism of action of [COMPANY_004]1795091, body  temperature and heart 
rate increased with dose in Study  204685 ([COMPANY_004] Document Number 2015N236402_03 ). 
Mean maximum change with 95% CI in body  temperature in the participant sthat 
received placebo was 0.4 0.2oC. For [COMPANY_004]1795091 dose levels, 7 ng, 21 ng, 60 ng, and 
100 ng, mean maximum change with 95% CI in body  temperature was 0.50.3, 0.6 
0.4, 0.8 .5, and 1.3 0.3oC, respectivel y. Mean maximum change with 95% CI  in heart 
rate in the participant s that received placebo was 6 5beats per minute.  For 
[COMPANY_004]1795091 dose levels, 7 ng, 21 ng, 60 ng, and 100 ng, mean maximum cha nge with 
95% CI  in heart rate was 8 9, 10 18, 18 15, 21 5beats per minute , respectively .  
Thus, a [ADDRESS_99840] changes in body  
temperature and heart rate. 
Based on preliminary , unblinded safet y data (described in Section [IP_ADDRESS] ), the most 
common clinical findings were influenza -like s ymptoms and increased body temperature. 
Predominantly  mild AEs were reported when doses up to 60 ng were administered .  
Three (3) participants experienced moderate AEs following administration of [ADDRESS_99841] increase in total bilirubin on day  35.  As 
only 1 event was observed and the dose administered was below the maximum 
administered, 100 ng, the data are too limited to relate elevation sin hepatic laboratories
todose. Because of the possible risk of infrequent or idiosy ncratic transaminase 
elevations, a 2 -week [COMPANY_004]1795091 run -in period will be performed in Part 1 ,including 
monitoring and study  treatment discontinuation criteria for ALT elevations , before 
[COMPANY_004]179 5091 and combination partners are administered .
In summary , at the [COMPANY_004]1795091 starting dose of 50 ng, minimal pharmacody namic 
effects and dose -related cytokine -associated clinical effects are expected. The risk of 
infrequent events of uncertain relationshi p to [COMPANY_004]1795091 dose will be mitigated b y a 2-
week monotherap y run -in period.
[IP_ADDRESS]. Dose for OX -[ADDRESS_99842] [COMPANY_004]3174998
The starting dose of [COMPANY_004]3174998 is 24 mg (~0.3 mg/kg) IV administered every  3 weeks
(Q3W ).  No DLTs were observed over a range from 0.003 mg/ kg (~0.24 mg) to 10 mg/kg 
(~800mg)in cancer patients receiving [COMPANY_004]3174998 monotherap y in [COMPANY_004] Document 
Number 2014N225045_02 , Study  201212 .  Thu s, the starting dose of 24 mg is 1/33 of the 
top dose of [COMPANY_004]3174998 that was eval uated and produced no DLTs in Study 201212 .
OX40 receptor occupancy  (RO) in the central circulation is expected to be near maximal
over the whole 3-week dosing interval with 24 mg [COMPANY_004]3174998 based on measured RO 
2017N327572_0 7 CONFIDENTIA L
204686
60in Study  201212 (seethe0.3 mg/kg dose levelin Figure 8).Efficacy  responses to OX40 
agonism have been observed at widel y var ying dose levels , including 0.3 mg/kg .
Figure 8 Median Receptor Occupancy  Profiles for Varying Doses of 
[COMPANY_004]3174998
Preliminary measured RO data from Study 201212 ([COMPANY_004] Document Number 2014N225045_02 )Part 1A 
([COMPANY_004]3174998 monotherapy) .
Based on the totality  of available data, including receptor occupancy , efficacy and safet y, 
a 24 mg dose level was selected for [COMPANY_004]3174998. Based on emerging safety , exposure 
and/or pharmacod ynamic data, the dose for [COMPANY_004]3174998 may be adjusted lower, to 8 
mg, if agreed b y the study investigators and [COMPANY_004] study  team.
[IP_ADDRESS]. Dose for ICOS ago nist [COMPANY_004]3359609
The starting dose of [COMPANY_004]3359609 is 80mg (~1 mg/kg ) IV administered Q3W . In the 
FTIH stud y (Study  204691) of [COMPANY_004]3359609, doses up to 3mg/kg (~240 mg) Q3W were 
evaluated as monotherapy or in combination with pembrolizumab 200 mg Q3W .Based
on the available clinical exposure and safet y data from Study  204691 as listed in the IB 
[[COMPANY_004] Document Number 2017N319717_02 ], [COMPANY_004]3359609 can be dosed up to 3 mg/kg 
(~240 mg) . One DLT was reported in one out of 10 participan ts treated at this dose (see 
Section [IP_ADDRESS] ).  The planned dose of [COMPANY_004]3359609 for evaluation in the present stud y is 
80mg,or approximately  1/[ADDRESS_99843] been simulated with a 
population pharmacokinetic model developed with available clinical data.
2017N327572_0 7 CONFIDENTIA L
204686
61ICOS receptor occupancy (RO) in the central circulation has been estimated based on 
predicted [COMPANY_004]3359609 systemic exposures and potency  values for the functional effect s
of [COMPANY_004]3359609 characterized from in vitro binding/activation assay s.  Potency  values 
generated from three different binding/activation assay s (Kd, T -cell binding, IFN -
release) were in the range of 0. 09 to 4.14 µg/mL. The correspo nding ICOS RO levels 
with predicted [COMPANY_004]3359609 sy stemic exposures at different dose levels are listed in 
Table 4. The predicted RO demonstrates that the 80 mg dose (~1 mg/kg) provides 
adequate level of target engag ement across all three approaches.  The currently  planned 
80mg [COMPANY_004]3359609 dose may  be adjusted lower to 24mg based on emerging safet y, 
exposure and/or pharmacody namic data if agreed by  [CONTACT_90606] . 
Table 4 Projected CD4+ receptor occupancy  in central circulation from 
population PK predicted median steady -state peak and trough 
exposures of [COMPANY_004]3359609 (Q3W regimen) base d on in vitro potency  
estimates
Dose
(mg)Cmax
(g/mL)C
(g/mL)RO based on K d
[0.09 g/mL] (%)RO based on T -
cell binding 
[0.989 g/mL] 
(%)RO based on 
IFNrelease 
(bound) [4.14 
g/mL] (%)
At C max At C At C max At C At C max At C 
8 3.47 0.919 97.5 91.1 77.8 48.2 45.6 18.2
24 10.3 2.73 99.1 96.8 91.3 73.4 71.4 39.8
80 34.7 9.23 99.7 99.0 97.2 90.3 89.3 69.0
240 103.6 27.3 99.9 99.7 99.1 96.5 96.2 86.8
Note :  8 (~0.01mg/kg) to 240mg (~3mg/kg) Q3W regimen evaluated as monotherapy and in 
combination with pembrolizumab 200mg Q3W in Clinical study 206491
[IP_ADDRESS]. Pembrolizumab dose
The dose regimen for pembrolizumab, 200 mg IV Q3W , is the approved dosing scheme 
as described in the Prescribing Information [ KEYTRUDA PI, 201 9].  No reduction in 
dose is planned given that pembrolizumab has been administered in combination wit h 
other TL R agonists to subjects with advanced cancers without causing a notable change 
in the safet y and tolerability profile [Flowers , 2017; Leung , 2017; Milhem , 2018] .  
Moreover, the safety  and efficacy  profile of the approved dose regimen for 
pembrolizumab is well established, whereas the efficacy  of lower doses is not fully  
characterized. 
[IP_ADDRESS]. Combination considerations
At the 50 ng starting dose of [COMPANY_004]1795 091, onl y minimal clinical and pharmacod ynamic
effects are expected. Therefore, at the starting dose, [COMPANY_004]1795091 is not expected to 
significantl yalter the safety  and tole rability  profile of [COMPANY_004]3174998 , [COMPANY_004]3359609, or
pembrolizumab .Conversely , these mAb combination partners are not expected to 
significantl yalter the safety  and tolerability  profile of[COMPANY_004]1795091 based on available in 
vitro data, in vivo data, clinical data for [COMPANY_004]1795091, and reported clinical data for other 
TLR agonists.
2017N327572_0 7 CONFIDENTIA L
204686
[IP_ADDRESS].1. Combination of [COMPANY_004]1795091 and [COMPANY_004]3174998
Collectively , in vitro, in vivo, and preliminary  clinical data suggest that [COMPANY_004]3174998 is 
unlikely  to significantly  alter the safet y profile of [COMPANY_004]1795091.  
In vitro studies of [COMPANY_004]1795091 and [COMPANY_004]3174998 in PBMCs produced incre ases inIL-6, 
IL-10 or TNF -for6 of 10 healthy  donors treated with [COMPANY_004]3174998 ( ≥0.1 pg/mL) in 
combination with [COMPANY_004]1795091 ( ≥100 pg/mL) compared to either [COMPANY_004]3174998 or 
[COMPANY_004]1795091 alone. No effect of [COMPANY_004]3174998 at concentrations up to 10 pg/mL was 
observed o n cytokine responses at 10 pg/mL [COMPANY_004]1795091. There was high donor -to-
donor variability  in cy tokine responses, and individual donors had inconsistent 
concentration -responses of the various testconditions. Therefore, the potential for 
enhanced cy tokine re lease when these agents are administered in combination in patients 
cannot be eliminated due to the high amount of data variability .
[COMPANY_004]3174998 did not enhance cy tokine induction by  [CONTACT_23983]1795091 in cynomolgus 
monkey s. Overall, when [COMPANY_004]1795091 was evaluated alone or in combination with 
[COMPANY_004]3174998, cy tokine values were variable and the distributions were generall y 
overlappi[INVESTIGATOR_007]. Based on these nonclinical data, [COMPANY_004]3174998 is not expected to
significantl yalter the safety  and tolerability  profile of [COMPANY_004]1795091.
As of the cut -off date of [ADDRESS_99844] on [COMPANY_004]1795091 -induced cy tokines in vitro .  However, 
variability  in response is significant and the potential for enhanced cy tokine release when 
these agents are administered in combination in patients cannot be eliminated.  This risk 
is mitigated by  [CONTACT_941] 2 -week [COMPANY_004]1795091 monotherapy  run-in perio d that prevents 
administration of combination therap y to participants that do not tolerate [COMPANY_004]1795091 
monotherap y (See Section 5.1.3 ). Preliminary  clinical data reaffirm that the combination 
of [COMPANY_004]1795091 with [COMPANY_004]3174998 is to lerated at the starting doses .
[IP_ADDRESS].2. Combination of[COMPANY_004]1795091 and[COMPANY_004]3359609
Collectively , in vitro andin vivo data suggest that [COMPANY_004] 3359609 is unlikely  to 
significantl y alter the safety profile of [COMPANY_004]1795091.  
In vitro studies of [COMPANY_004]1795091 and [COMPANY_004]3359609 i n PBMCs were performed. No 
increases in IL -2, IL -6, IL -10, IFN -, or TNF -were detected in PBMCs treated with 
[COMPANY_004]3359609 in combination with [COMPANY_004]1795091 (at concentrations up to 1000 pg/mL 
and 10 pg/mL, respectively ) compared to [COMPANY_004]3359609 alone, either i nthe presence or 
absence of sub -optimal anti -CD3 stimulation.
In vivo, the anti -ICOS 7E.17G9 clone was evaluated in the CT26 murine syngeneic 
tumor model in co mbination with the TL R4 agonist [COMPANY_004]1795091 in two separate in vivo 
studies.  Female BALB/c mice bearing CT26 mouse colon carcinoma tumors 
2017N327572_0 7 CONFIDENTIA L
204686
63(n=10/group) were given twice weekly  IP doses of 7E.17G9 at 10 or 100 g/mouse for 
3weeks alone and in combination with [COMPANY_004]1795091 at 5, 10 or 25 g/mouse.   The 
treatments were well -tolerated with no significant loss of body  weight .
Overall, the nonclinical data for [COMPANY_004]1795091 and [COMPANY_004] 3359609 administered as 
monotherapi[INVESTIGATOR_90533]1795091 and 
[COMPANY_004] 3359609 .
[IP_ADDRESS].3. Combination of [COMPANY_004]1795091 andpembrolizumab 
Collectively , in vitro , in vivo, and clinical data reported for TLR agonists and 
pembrolizumab suggest that pembrolizumab is unlikely  to significantl y alter the safet y 
profile of [COMPANY_004]1795091.  
In vitro, w hen pembrolizumab ( ≥0.1 μg/mL) was combined with [COMPANY_004]179 5091 (10, 100 
or 10 00 pg/mL) in rested PBMCs, there was an increase in the anti-inflammatory
cytokine, IL-10 [median increase 3.1 -fold (range 0.01 -to 119 -fold)], in up to 5 of 10 
donors compared to the respective concentrations of [COMPANY_004]1795091 plus human IgG4 
isoty pe control.   Enhanced responses were also observed in rested PBMCs of one to three 
donors (out of 10) for inflammatory  cytokines IL-2 [1.5 -fold (0.01 -to 4.5 -fold)], IL -6 
[1.8-fold (1.1 -to 8.2 -fold)], or TNF -α[1.7-fold (0.2 -to 7.8 -fold)]. There was high 
donor -to-donor variability  in cy tokine responses, and individual donors had inconsistent 
concentration -response curves amongst the various testconditions.  Given that a subset of 
the donors had increases in one or more of the pro -inflammatory  cytokines, IL -2, IL -6, 
and TNF -, the potential for enhanced cy tokine release when [COMPANY_004]1795091 and 
pembrolizumab are administered in combination in patients cannot be eliminated .
The a nti-PD-1 RMP1 -14 clone was evaluat ed in the EMT6 murine s yngeneic tumor 
model in combination with [COMPANY_004]1795091.  BALB/c mice were given twice weekl y IP 
doses of RMP1 -14 at 200 µg/mouse for 3 weeks alone and in combination with 
[COMPANY_004]1795091 at 2.5 or 25 µg/mouse . The treatments were well -tolerated with no 
significant loss of bod y weight .
Clinical trials of other TLR agonists at doses associated with systemic cy tokine -related 
AEs have not demonstrated unexpected toxicities when administered in combination with 
pembrolizumab [Flowers , 2017; Leung , 2017; Milhem , 2018] .  Flowers et al. evaluated 
the AE profile of G100 , a TL R4 agonist, alone and in combination with pembrolizumab 
and reported that all AEs considered possibl y related to G100 were grade [ADDRESS_99845] concluded that the 
combination theTLR agonists, at doses associated with sy stemic cytokine -related effects, 
didnot result in a diminish ed safet y profile forpembrolizumab [KEYTRUDA PI, 201 9].
See Section [IP_ADDRESS] for further details.
In summary , in vitro data for [COMPANY_004]1795091 and pembrolizumab along with clinical data 
for other TLR agonists and pembrolizumab support the combination of these agents.  On 
average, pembrolizumab has a minimal effect on [COMPANY_004]1795091 -induced inflammatory  
2017N327572_0 7 CONFIDENTIA L
204686
64cytokines in vitro , with high donor -to-donor variability  noted .  However, the potential for 
enhanced cytokine release when these agents are administered in combination in patients 
cannot be eliminated .  This risk is mitigated by  [CONTACT_941] 2 -week [COMPANY_004]1795091 monotherap y 
run-in period that prevents administration of combination therapy  to participants that do 
not tolerate [COMPANY_004]1795091 monotherap y (See Section 5.1.3 ).Clinical re ports for multiple 
TLR agonists administered at doses associated with sy stemic cy tokine related AEs do not 
indicate a heightened risk of combining with pembrolizumab (Section [IP_ADDRESS] ). In 
general , the nonclinical data for [COMPANY_004]1795091 and pembrolizumab and clinical data 
reported for other TLR agonists with pembrolizumab support the starting combination of 
low doses of [COMPANY_004]1795091 with pembrolizumab .  
Overall, the clinical and nonclinical data for [COMPANY_004]1795091 ,[COMPANY_004]3174998 , [COMPANY_004]3359609, 
and pembrolizumab administered as monotherapi[INVESTIGATOR_90534]1795091 with either [COMPANY_004]3174998 , 
[COMPANY_004]3359609, orpembrolizumab .
5.5.2. Dose Escalation and Top Dose
Based on available clinical data, the tolerability  of [COMPANY_004]1795091 approximates that of 
LPS.  Therefore, the top dose of [COMPANY_004]1795091 for study  participants with cancer is 
expected to be similar to doses of L PS studied in similar populations , namely 2to 4 ng/kg 
(i.e.,160 to 320 ng).  Thetop dose of [COMPANY_004]1795091 will not exceed approximately  250 
ng, which would represent a less than 3 -fold escalation bey ond the 100 ng dose which has 
been studied in the FTIH healthy  volunteer study .  The dose escalation step size of 50 ng 
increments results in a dose escalation scheme with progressivel y more conservative
relative increases (e.g., 50 ng to 100 ng = 100% increase; 100 to 150 ng = 50% increase; 
150 ng to 200 ng = 33% increase; 200 ng to 250 ng = 25% increase).
6. STUDY POPU LATION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
Specific information regarding warnings, precautions, contraindications, AEs, and other 
pertinent inf ormation on the [COMPANY_004] investigational product or other study  treatment that 
may impact participant eligibility  is provided in the IB s/IB supplements.  Deviations 
from inclusion and exclusion criteria are not allowed because they  can potentially  
jeopardize th e scientific integrit y of the study, regulatory acceptability, or participan t 
safet y.  Therefore, adherence to the criteria as specified in the protocol is essential.
2017N327572_0 7 CONFIDENTIA L
204686
656.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of t he following criteria 
apply :
Age
1.Participant must be 18 years of at the time of signing the informed consent.
Type of Participant and Disease Characteristics
2.Histological documentation of advanced solid tumor.
3.Archival tumor tissue obtained at any time from the initial diagnosis to study  
entry . Although a fresh biopsy  obtained during screening is preferred, archival 
tumor specimen is acceptable if it is not feasible to obtain a fresh biops y.  
Note: Participants enrolled in a PK/Pharmacod ynamic Cohort must provide a 
fresh biops y of a tumour lesion not previously irradiated during the screening 
period and must agree to provide at least one additional on -treatment biopsy .
4.Disease that has progressed after standard therapi[INVESTIGATOR_90535] y is ot herwise unsuitable ( e.g., intolerance). 
5.Measurable disease, i .e.,presenting with at least 1 measurable lesion per 
Response Evaluation Criteria in Solid Tumors (RECI STversion 1.1).  See 
Appendix 9for definition of a measurable lesion.
6.Eastern Cooperative Oncology  Group (ECOG) performance status (PS) [ADDRESS_99846] 12 weeks.  
8.Adequate organ function (see Table 5):
9.In [LOCATION_009], a participant will be eligible for inclusion in this study  only if either 
affiliated to or a beneficiary  of a social security  category .
2017N327572_0 7 CONFIDENTIA L
204686
66Table 5 Organ Function
System Laboratory Values
Hematologic
ANC ≥1.5x10 9/L
Hemoglobina≥9 g/dL
Plateletsa≥100x109/L
PT/INR and PTT (unless participant is receiving anticoagulant) <1.5xULN
Hepatic
Total bilirubin
For participant s with Gilbert’s Syndrome (only if direct bilirubin ≤35%)≤1.5xULN
≤3.0xULN
ALT ≤1.5x ULN
Renal
Calculated CrCl b> 50 mL/min
Endocrine
TSHcWNL
Cardiac
Ejection fraction ≥ 50% by [CONTACT_6751] d
ANC = Absolute neutrophil count; ALT = alanine aminotransferase; CrCl = creatinine clearance; INR = 
International Normalized Ratio ;TSH = thyroid -stimulating hormone; ULN = upper limit of normal; WNL = 
within normal limits ; PT = prothrombin time; PTT = partial thromboplastin time
a. Participants must maintain h emoglobin and/or platelet values for at least 2 weeks without transfusion or 
growth factor support.
b. Estimated CrCl should be calculated using the Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD -
EPI) formula (se eAppendix 10)
c. If TSH is not within normal limits at baseline, the participant may still be eligibl e if total T3 or free T3 and free 
T4 are within the normal limits
d. Multigated acquisition scan (MUGA) is acceptable if echocardiography is not available
Sex
10. Male or female
a.Female participants: 
A female participant is eligible to participate if she is not p regnant (see 
Appendix 5), not breastfeeding, and at least 1 of the following conditions 
applies:
i.Not a woman of childbearing potential (WOCBP) as defined in 
Appendix [ADDRESS_99847] dose of study  treatment.
Informed Consent
11.Capable of giving signed informed consent as described in Appendix 3which 
includes compliance with the requirements and restrictions listed in the I CF 
and in this protocol.
2017N327572_0 7 CONFIDENTIA L
204686
67Additional Inclusion Criteria for Pa rticipants in Part 2 a ([COMPANY_004]3174998 expansion ) 
and Part 2b ([COMPANY_004]3359609 expansion)
12.Histological or cy tological documentation of SCCHN (oral cavit y, 
orophary nx, hy pophary nx, or lary nx) that is recurrent, locall y advanced, or 
metastatic and is not amenable to curative treatment options, surgery  or 
definitive chemoradiation therap y.
13.Received ,ineligible for,orotherwise unsuitable for platinum -based therapy  
and anti-PD-1/PD -L1 therap y.
14.Received n o more than 3 prior lines of s ystemic t herap y for metastatic disease.
Additional Inclusion Criteria for Participants in Part 2c (pembrolizumab 
expansion)
15. Histological or cy tological documentation of SCCHN (oral cavit y, 
orophary nx, hy pophary nx, or lary nx) that is recurrent, locall y advanced, or 
metastatic and is not amenable to curative treatment options, surgery  or 
definitive chemoradiation therap y.
16.Received nomore tha n 2prior lines of s ystemic therapy  for metastatic disease.
6.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Malignancy  other than disease under study  with the exception of those from 
which the participan t has been disease -free for more than [ADDRESS_99848] the safety  of the participan t or the endpoints of the trial.  
2.Symptomatic central nervous sy stem (CNS) metastases or as ymptomatic CNS 
meta stases that have required steroids within [ADDRESS_99849] 2 y ears.
Note: Replacement therapy  (e.g., thy roxine or physiologic cortico steroid
replacement therap y for adrenal or pi[INVESTIGATOR_90536] , etc.) is permitted .
4.Concurrent medical condition requiring the use of sy stemic 
immunosuppressive treatment within [ADDRESS_99850] dose of study  
treatment.  
5.Known human immunodefi ciency  virus infection.
6.Current unstable liver or biliary  disease per investigator assessment d efined by  
[CONTACT_31816], encephalopath y, coagulopathy , hypoalbuminaemia, 
oesophageal or gastric varices, persistent jaundice, or cirrhosis. 
NOTE: Stab le chronic liver disease (including Gilbert’s sy ndrome or 
asymptomatic gallstones) or hepatobiliary  involvement of malignancy  is 
acceptable if participant otherwise meets entry  criteria .
2017N327572_0 7 CONFIDENTIA L
204686
687.Presence of Hepatitis B surface antigen (HBsAg) at screening or withi n [ADDRESS_99851] 
dose of study  treatment. 
NOTE: Participants with positive Hepatitis C antibody  due to prior resolved 
disease can be enrolled, only if a confirmatory  negative Hepatitis C RNA test 
is obtained. Participants with negative Hepatitis C antibody  test are not 
required to also undergo Hepatitis C RNA testing 
9.QTcF>450 msec or QTc F>480 msec for participants with bundle branch 
block
TheQTcF is the QT interval corrected for heart rate according to Fridericia’s 
formula, machine -read or manually  over -read.
10.Recent history  (within the past 6 months) of acute diverticulitis, inflammatory  
bowel disease, intra -abdominal abscess, or gastrointest inal obstruction .
11.Recent history  of allergen desensitization therapy  within 4 weeks of starting 
study  treatment.  
12.History  of severe hy persensitivity  to mAbs.  
13.History  or evidence of cardiovascular (CV) risk including any  of the 
following:
Recent (within the past 6 months) history  of serious uncontrolled cardiac 
arrhythmia or clinically  significant ECG abnormalities including second 
degree (T ype II) or third degree atrioventricular block.  
Cardiomy opath y, myocardial infarction, acute coronary s yndromes 
(including unstable angina pectoris), coronary  angioplasty , stenting, or 
by[CONTACT_90607] 6 months before enrollment.  
Congestive heart failure (Class II, III, or IV) as defined by [CONTACT_90608] s ystem [NYHA , 1994 ].  
Recent (within the past 6 months) history  of symptomatic pericarditis.  
14.History  of idiopathic pulmonary  fibrosis, pneumonitis, interstitial lung 
disease, or organizing pneumonia, or evidence of acti ve, non -infectious 
pneumonitis.  Note: post -radiation changes in the lung related to prior 
radiotherap y and/or as ymptomatic radiation -induced pneumonitis not 
requiring treatment may  be permitted if agreed b y the investigator and 
Sponsor.
15.Recent history  (within 6 months) of uncontrolled sy mptomatic ascites or 
pleural effusions .
16.Any serious and/or unstable pre -existing medical, psy chiatric disorder, or 
other condition that could interfere with the participant ’s safet y, obtaining 
informed consent, or complianc e to the study  procedures.  
2017N327572_0 7 CONFIDENTIA L
[PHONE_2131].Is or has an immediate family  member (e.g., spouse, parent/legal guardian, 
sibling or child) who is investigational site or sponsor staff directly  involved 
with this trial, unless prospective Institutional Review Board (IRB) approval 
(by [CONTACT_66870]) is given allowing exception to this criterion for a 
specific participant .
Prior/Concomitant Therapy
18.Prior treatment with the following agents: 
OX40, ICOSagonist atany time.
Prior sy stemic or intra tumoral therap y with TLR ag onist .
Anticancer therap y or investigational therap y within 30 days or 5 half -lives of 
the drug, whichever is shorter.
Prior radiation therap y:  permissible if at least [ADDRESS_99852], brain, or visceral organs is required.
19.Prior allogeneic or autologous bone marrow transplantation or another solid 
organ transplantation.  
20.Toxicity  from previous treatment including:
Toxicity  Grade ≥3 related to prior immunotherapy  and tha t lead to study  
treatment discontinuation.   
Toxicity  related to prior treatment has not resolved to Grade 1 (except 
alopecia, or endocrinopathy  managed with replacement therap y).  
21.Received transfusion of blood products (including platelets or red blood cells) 
or administration of colony  stimulating factors (including G -CSF, 
granulocy te-macrophage colony -stimulating factor, and recombinant 
erythropoietin) within [ADDRESS_99853] dose of study  treatment.   
Other Exclusions
22.Major surgery  [ADDRESS_99854] also fully  recovered from any  surgery  (major or minor) and/or its 
complications before initiating study  treatment.  
23.Known drug or alcohol abuse.  
24.Receipt of an y live vaccine within 4 weeks. 
Additional Exclusion Criteria for Participants in Part 2c
25.Received prior anti-PD-1/PD -L1 therapy .
2017N327572_0 [ADDRESS_99855] yle Restrictions
6.3.1. Meals and Dietary  Restrictions
No dietary  restrictions are required. Note that p articipants should be well -hydrated before 
receiving study  treatment (see Section 7.1)
6.3.2. Caffeine, Alcohol , and Tobacco
Participants who use products containing caffeine, alcohol, or tobacco are not required to
change their habits of using these products during the study  treatment .
6.3.3. Activity
Participants may  experience orthostatic dizziness following administration of 
[COMPANY_004]1795091. Precautions should be taken to avoid falls after rising from a ly ing or 
seated position for several hours after administration of study  treatment.  In addi tion, 
participants will abstain from strenuous exercise for 8 hours before each blood collection 
for clinical laboratory  tests. Participants may  participate in light recreational activities 
during studies (e .g., watching television, reading).
6.4. Screen Failur es
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl yentered in the stud y. A minimal set of screen failure information 
is required to ensure transparent reporting of screen failure partici pants to meet the 
Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queries from regulatory  authorities. Minimal information includes demography , screen 
failure details, eligibility  criteria, and any  SAEs .
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened once .  This includes retesting specific vital sign measurements, 
laboratory  assessments, etc. that may  not have met eligibility  criteria.
7. TREATMENTS
Study  treatmen t is defined as an y investigational treatment(s), marketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  participant according 
to the study  protocol. The term ‘study  treatment’ is used throughout the protocol to 
describe any combination of products received b y the participan t as per the protocol 
design.  
7.1. Treatments A dministered
Participant s receiving study  treatment should be well -hydrated (TLR agonists have rarel y 
been associated with severe brad ycardia or as ystole in cl inical trials, attributed to poor 
hydration and/or history  of sy ncope )[van Eijk , 2004 ]. Oral hy dration should be 
encouraged in the day s prior to study  treatment and /orIV fluids (e.g., 1 L or as clinicall y 
indicated ) administered before [COMPANY_004]1795091. Participant s with a history  of sy ncope
2017N327572_0 7 CONFIDENTIA L
204686
71and/or uncertain compliance with h ydration recommendations should receive additional 
pre-dose and/or post -dose fluids at the discretion of the investigator. 
Treatment with [COMPANY_004]1795091 was suspended as of Protocol amendment 05. Participants 
may continue to receive either [COMPANY_004] 3174998, [COMPANY_004]3359609 or pembrolizumab as 
monotherap y. 
Following administration of [COMPANY_004]1795091, assessments must be performed as noted in 
the S oA. Cytokine -related AEsincluding changes in vital signs commonly  beginwithin 
several hours of administration of [COMPANY_004]1795091.  Participants must be monitored for [ADDRESS_99856] 
the duration of observation with subsequent study treatment reduced to 2hours, provided 
the dose and schedule has not been changed. Guidelines for monitoring cytokine -related 
AEs are summarized in Section [IP_ADDRESS] .
[COMPANY_004]1795091 and mAb comb ination partners [COMPANY_004]3174998 , [COMPANY_004]3359609, or 
pembrolizumab will be administered to participan ts at each stud y site under medical 
supervision of an investigator or designee.  [COMPANY_004]3174998 , [COMPANY_004]3359609, or 
pembrolizumab will be administered first, and [COMPANY_004]1795091 will be administered at least 
1 hour after the completion of themAb infusion .  The date and time of administration 
will be recorded in the source documents and reported in the eCRF.  
If a participant experiences an infusion reaction with the administrat ion of the mAb
combination partner , associated AEsshould resolve before [COMPANY_004]1795091 is ad ministered.  
If AE sassociated with the mAb are slow to resolve, it is acceptable to administer 
[COMPANY_004]1795091 on the following day .Should further delay  be required, the participant will 
be discontinued from study  treatment .Anyparticipant who experience san infusion 
reaction attributable to the mAb may receive [COMPANY_004]1795091 on the following dayfor all 
subsequent study  treatments.
The specific time of study treatment admini stration (e.g. ,time of the week for first 
administration; time of the day  for each administration) should take into consideration PK
sampling time points and study  visit procedures.  See Section 2for dosing timepoints and 
visit windows and Section 7.9for additional details regarding dosing delay s.
The Study  Reference Manual (SRM) contains specific instructions for the preparation of 
[COMPANY_004]1795091 , [COMPANY_004]3174998, [COMPANY_004]3359609, and pembrolizumab and the uni t dose 
strength of each formulation .  
2017N327572_0 [ADDRESS_99857] Dosage/A dministration
Study 
Treatment 
Name:[CONTACT_23983]1795091 [COMPANY_004]3174998 [COMPANY_004]3359609 Pembrolizumab
Dosage 
formulation:Solution for 
injectionLyophilized powder for
solution (reconstitution) 
for infusionSolution for 
infusionSolution for 
infusion or 
lyophilized 
powder for 
reconstitution b
Dosage 
level(s):Dose Level: 
50-250 ngDose level: 24mgDose Level:
80mgDose Level:
200 mg every 3 
weeks
Route of 
Administration:IV injection IV infusion –30minaIV infusion -
30minaIV infusion -
30mina
Packaging and 
LabelingStudy 
Treatment 
will be 
provided in 
container. 
Each 
container will 
be labeled as 
required per 
country 
requirement.Study Treatment will be 
provided in c ontainer. 
Each container will be 
labeled as required per 
country requirement.Study 
Treatment 
will be 
provided in 
container. 
Each 
container will 
be labeled as 
required per 
country 
requirement.Commercial 
Supply
Labeled as 
required per 
country 
requirement
Manufacturer: [COMPANY_004] [COMPANY_004] [COMPANY_004] [COMPANY_006]
Note:   Refer to the SRM for detailed information on the investigational products
a.  Infusions may be prolonged in the event of an infusion reaction.  If multiple participants experience clinically 
significant infusion reac tions, the infusion rate may be slowed for all future administrations of study treatment(s) 
for all participants. Should this global change in infusion rate be required, it will be communicated to the sites in 
writing .
b.  The dosage form of pembrolizumab wi ll be either solution or lyophilized powder for all subjects/doses. This 
will be dependent on country or site formulary requirements .
7.2. Dose Modification
Safety  management guidelines, including dose modification algorithms, are provided
below . Please note, in case swhere the investigator is directed to permanently  discontinue 
study  treatment, these instructions are mandatory  as described in Section 7and Section 8.
An overview of the d ose modification guidelines is presented in Table 7.
2017N327572_0 7 CONFIDENTIA L
204686
73All AEs are to be graded according to NCI -CTCAE, version 4.0 (http://ctep.cancer.gov )
and unless otherwise specified (e.g., S ection [IP_ADDRESS] ).  All dose modifications and the 
reason(s) for the dose modification must be documented in the eCRF. 
The major classes of toxicity  described in Section 7include “cytokine -related AE s and 
infusion reac tions” (Section 7.2.1 ) and “immune -related AE s” (irAE) (Section 7.2.2 ).  
Even though both cy tokine production and immune activity  play  roles in both categories 
of events, the nomencl ature is intended to describe d istinct classes of AE s, as described 
below. 
Investigators should refer to the IB sfor [COMPANY_004]1795091 [ [COMPANY_004] Document Number 
2015N239078_0 4],[COMPANY_004]3174998 [ [COMPANY_004] Document Number 2014N212091_0 5], and 
[COMPANY_004]3359609 [[COMPANY_004] Document Number 2017N319717_02 ]for additional information 
regarding the background of each drug and the management of other AEs or pot ential 
safet y-related issues.  Refer to the approve d labelling for pembrolizumab -related 
background information and management of AEs [KEYTRUDA SPC, 2019; 
KEYTRUDA PI, 2019 ].
In case a dose reduction is necessary , the dose level of [COMPANY_004]1795091, the mAb or both 
may be changed as determined by  [CONTACT_86206].   If either study  treatment 
is deemed intolerable and requires discontinuation despi[INVESTIGATOR_3064], as 
described below, the participant must be discontinued from both study  treatments.  I f one 
study  treatment is not continued for reasons beside safet y or tolerability, the other stud y 
treatment may  be continued following approval b y the sponsor and investigator.  Refer to 
Appendix 13 and SO A(Section 2)for instructions regarding participant activity  if onl y 
mAb monotherap y is administered .
[COMPANY_004]1795091 may  be restarted at the next lower dose level, and /orthe mAb 
([COMPANY_004]3174 998 or [COMPANY_004]3359609) at the next lower dose l evel described in Section 5.1.[ADDRESS_99858] s be administered at the fixed 200 mg dose level.
2017N327572_0 7 CONFIDENTIA L
204686
74Table 7 General Dose Modification and Management Guidelines for Drug -
Related No n-Hematologic A dverse Events Not Otherwise Specified
Severity Management Follow -up
Grade 1Administer symptomatic 
treatment as appropriate
Continue study treatmentSymptoms resolve to baseline within 7 days:
Provide close follow -up to evaluate for increas ed severity
Symptoms ongoing >7 days :
Consider following algorithm for Grade 2 events
Grade 2Administer symptomatic 
treatment
Investigate etiology
Consider consulting 
subspecialist, biopsy, and/or 
diagnostic procedure
Discuss with Sponsor/Medical 
Monito rSymptoms ongoing >7 days or worsening
Consider interruption of study treatment
oResume study treatment at the same dose if 
symptoms have improved to Grade 1 and steroid 
dose is 10 mg prednisone/day or less
For immune -related events, consider starting mode rate 
dose systemic corticosteroids (e.g., 0.5 mg/kg/day of 
prednisone or equivalent)
oContinue steroids until improvement to Grade 1 or 
resolution; taper steroids as medically appropriate
If symptoms continue or worsen to Grade 3-4, follow 
algorithm for Gra de 3-4 events
Grade 3 -4Interrupt or discontinue study 
treatment
Consult subspecialist
For possible immune -related 
events, administer 1 -
2mg/kg/day IV 
methylprednisolone 
Discuss with Sponsor/Medical 
MonitorSymptoms improve to Grade 2:
For possible imm une-related events, continue steroids 
until improvement to Grade ≤1 or baseline; taper 
steroids over at least [ADDRESS_99859] 
improved to Grade 1 and steroid dose is 10 mg 
prednisone/day or less, consider resumption of study 
treatment at the next lower dose level of [COMPANY_004]1795091 
and/or mAb
Symptoms ongoing : 
Discuss further management with consultant and 
Sponsor/Medical Monitor
Consider alternative immunosuppressive therapy
7.2.1. General Guidelines for Cytokine -Related A dverse Events and 
Infusion Reactions
Cytokine -related AE s and infusion reactions aretoxicit ies with sometimes similar 
underly ing pathology . However, for the purposes of this protocol, the 2 terms should not 
be used interchangeably . “Cytokine -related AEs” describe the common and expected 
spectrum of flu -like s ymptoms that are associated with admi nistration of TLR agonists, 
such as [COMPANY_004]1795091, and are attributable to cy tokine induction. The AEs may  be related 
to the dose level of study treatments.  “Cytokine release s yndrome ”describes a severe 
form of a cy tokine -related AE. “Infusion reactions ” describe theless common and 
typi[INVESTIGATOR_1306] y idiosyncratic reactions to mAbs and other proteins that can occur by  [CONTACT_90609], in some circumstances, IgE. The AEs are not necessarily  related 
to the dose level of study treatments. The verbatim term s used to report “cy tokine -related 
2017N327572_0 7 CONFIDENTIA L
204686
75AEs” or “infusion reactions” should describe the specific clinical signs or symptoms 
experienced b y the stud y participant (e.g. chills, hypotension, rash, etc.) rather than non -
descriptive , high -level terms (e.g. cy tokine release sy ndrome, infusion reaction, etc.).  
The management recommendations for both cy tokine -related AEs and for infusion 
reactions are summarized below .
[IP_ADDRESS]. Management of Cy tokine Related A dverse Events and Cy tokine 
Release Sy ndrome
The TLR agonists (includ ing TLR4 agonists) are known to increase serum cy tokine 
levels based upon evaluations in laboratory  animals, healthy  participant s and patients 
[Kanzler ,2007; Astiz ,1995; Dillingh ,2014; Isambert , 2013 ]. Drugs in this class have 
generall y caused mild to moderate toxicities associated with systemic cy tokine 
production such as flu -like sy mptoms, fever , tachy cardia, headache, nausea, and 
vomiting. The severity  of cy tokine -related AEs associated with TL R agonists generall y 
peaks within several hours and subsides within a day . In a case report of a participant that 
self-administered a very  high dose (1 mg) of LPS, supportive care was provided in an 
Intensive Care Unit (I CU). Reported treatment included fluids and vasopressors to 
maintain hemody namic stability  and diuresis for pulmonary  edema [Taveira da Silva ,
1993 ].
Recent experiences of CRS with cell therapi[INVESTIGATOR_90537].  Guidelines for managing CRS associated 
with cell th erapi[INVESTIGATOR_90538] [Lee, 2014 ]. Patients with mild or moderate AEs 
have been managed with supportive care, including fluids, vasopressors, and/or ox ygen. 
Patients with high grade CRS have been managed in an intensive care unit and received 
immunosuppressive treatment. Anecdotall y, tocilizumab (anti -IL-6 receptor antibody ) 
has produced rapid and complete correction of CRS associated with cellular therapi[INVESTIGATOR_014] 
[Maude , 2014 ].  Tocilizumab was recentl y approved by [CONTACT_90610] (CAR) T cell -induced severe or life -threatening cy tokine 
release sy ndrome (8 mg/kg given as a 60 -minute intravenous infusion for patients at or 
above 30 kg, with doses not to exceed 800 mg per infusion) . 
The attribution of signs and sy mptoms to cytokine production should be influenced b y 
the timing with respect to administration of study  treatment. The grading of cytokine -
related AEsaccording to NCI -CTCAE criteria and according to Lee et al [Lee, 201 4] is 
based on the requirement for intervention and the responsiveness to treatment.   
Recommenda tions for managing AE s are provided in Table 8.
2017N327572_0 7 CONFIDENTIA L
204686
76Table 8 Cytokine Related A dverse Event Dose Modification and Treatment 
Guidelines
Treatm ent Prem edication at 
Subsequent Dosing
Grade s1or 2
Mild reaction ; intervention may be 
indicated
Grade 1: e.g., fever, constitutional 
symptoms
Grade 2 :e.g., hypotension 
responsive to fluids, hypoxia 
responsive to <40% FiO2 orother 
cytokine -related AEs responsive to 
intervention.Monitor vital signs until any 
changes in body temperature, 
heart rate, and blood pressure 
attributable to cytokine 
production are resolving.  In 
some circumstances, 
monitoring overnight may be 
require d.  
Provide 
symptomatic/supportive care, 
including paracetamol, fluids, 
supplemental oxygen, etc., as 
required. Prem edication may be 
considered w ith subsequent 
study treatment.
Participants that tolerate 
initial study treatment may 
have the duration of 
observation with subsequent 
study treatments reduced at 
the discretion of the 
investigator
Grade s3 or 4
Grade 3: AEs requiring aggressive 
intervention such as vasopressor 
administration, > 40% FiO2 or 
other cytokine -related AEs 
unresponsive to interventi on.
Grade 4: life threatening symptoms 
or severe organ toxicities with 
interventions including mechanical 
ventilationMonitor vital signs until any 
changes in body temperature, 
heart rate, and blood pressure 
attributable to cytokine 
production are resolvi ng.  In 
some circumstances, 
monitoring overnight may be 
required.
Perform ECG and/or 
echocardiographic monitoring 
as indicated based on medical 
history and cardiac function. 
Provide 
symptomatic/supportive care, 
including paracetamol, fluids, 
supplemental oxygen, 
vasopressor administration, 
diuresis etc. as indicated. 
Consider tocilizumab if 
conventional supportive 
measures are inadequate to 
control a declining clinical 
course or potentially life -
threatening toxicities. 
Obtain serum for C -reactive 
protein (CRP), tryptase, ferritin, 
and plasma for the cytokine 
panel (see Table 9and SRM) 
within 3 hours of the event.  Should the c ytokine-related 
event be attributed to 
[COMPANY_004]1795091 and further 
study treatment administered, 
the dose of [COMPANY_004]1795091 w ill 
be reduced to the next lower 
dose level.
2017N327572_0 7 CONFIDENTIA L
204686
77Treatm ent Prem edication at 
Subsequent Dosing
Do not administer further study 
treatment, unless approved by 
[CONTACT_2728]/Medical Monitor.
Appropriate resuscitation equipment and a physician should be readily available during the pe riod of drug 
administration.
Table 9 Biomarker Panel
Biomarker Relationship to Adverse Event
Serum try ptasea IgE-related infusion reaction (Allergic/anaph ylaxis) 
[Schwartz , 2006]
Serum C RPaElevated in CRS [ Lee, 2014]
Serum ferritinaElevated in CRS [ Lee, 2014]
Plasma cy tokine panelb
(IFN -γ*^, TNF -α*^, IL -2*, 
IL-4, IL -5*, IL -6*^, IL-8*, 
IL-10*, IL -12p70, IL -1, IL-
1Ra, GCSF, I P-10, MCP -1, 
RANTES )*Reported to be elevated in CRS [ Lee, 2014]
^consistently  reported as elevated in CRS [ Lee, 2014]
CRP=C -reactive protein; CRS= Cytokine release syndr ome; IFN -= Interferon gamma; TNF -= Tumor necrosis factor 
alpha; IL = Interleukin. 
a. Performed by [CONTACT_976] [INVESTIGATOR_90539]
b. Performed by [CONTACT_90611]: Serum and plasma to be drawn within 3 hours of aGrade 3 or 4 cytokine 
related AE, as per Table 8
[IP_ADDRESS]. Management of Infusion Reactions
Infusion reactions are a well -documented AE associated with the administration of mAbs
and other therapeutic proteins . The incidence of infusion reactions varies by [CONTACT_90612], 
and there are multiple mechanisms known to lead to infusion -related reactions including 
both IgE -dependant anaphy lactic and non -IgE dependent anaph ylactoid 
hypersensitivities. 
Clinically  infusion reaction may  present asflushing, itching, u rticaria, and/or 
angioedema, repetitive cough, sudden nasal congestion, shortness of breath, chest 
tightness, wheeze, sensation of throat closure or choking, and/or change in voice quality , 
faintness, tach ycardia (or less often brad ycardia), hy potension, h ypertension and/or loss 
of consciousness, nausea, vomiting, abdominal crampi[INVESTIGATOR_007], and/or diarrhea, sense of 
impending doom, tunnel vision, dizziness, and/or seizure, severe back, chest, and pelvic 
pain.
2017N327572_0 [ADDRESS_99860] ion to resolve, the 
participant will be discontinued from study  treatment .If a participant experienced an 
infusion reaction attributable to [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab with 
prior administration, it is acceptable to administer [COMPANY_004]1795091 on t he following day .
Guidelines for the management of infusion reactions are provided in Table 10.
Table 10 Infusion Reaction Dose Modification and Treatment Guidelines
NCI CTCAE Grade Treatm ent Prem edication at 
Subsequent Dosing
Grade 1
Mild reaction; requires infusion 
rate to be decreased; intervention 
may be indicated Decrease the rate of the mAb 
infusion to 25% or less of the 
original infusion rate until 
recovery from symptoms.  
The participant must be 
closely monitored until 
resolution of symptoms. 
Diphenhydramine 50 mg may 
be administered at the 
discretion of the treating 
physician.  
When symptoms resolve, 
resume the infusion at 50% of 
the original infusion rate; if no 
further complications ensue 
after 30minutes, the rate may 
be increased to 100% of the 
original infusion rate. 
[COMPANY_004]1795091 may be 
administered following 
complete resolution of 
symptoms.
The amount of mAb infused 
must be recorded.  Diphenhydramine 50 mg (or 
equivalent) and/or 
paracetamol (acetaminophen) 
325mg to [ADDRESS_99861] 30 
minutes before additional 
study treatment 
administration. Study 
treatments may continue to be 
administered on the same 
day.
Grade 2
Moderate reaction such as 
generalized pruritus, flush ing, rash, 
dyspnea, or hypotension with 
systolic blood pressure > 80 mmHgStop Infusion.
Begin an IV infusion of 
norm al saline .  
Administer diphenhydramine 
50mg IV (or equivalent) 
and/or paracetamol 
(acetaminophen) 325 mg to 
1000 mg.
The participant must be 
closely monitored until 
resolution of symptoms. 
Corticosteroid therapy may be 
administered at the discreti on 
of the treating physician.
When symptoms resolve, 
restart the infusion at 50% of 
the original infusion rate; if no Diphenhydramine 50 mg (or 
equivalent) and/or 
paracetamol (acetaminophen) 
325mg to [ADDRESS_99862] 30 
minutes before additional 
study treatment 
administration.  [COMPANY_004]1795091 
may be administered the 
following day.
2017N327572_0 7 CONFIDENTIA L
204686
79NCI CTCAE Grade Treatm ent Prem edication at 
Subsequent Dosing
further complications ensue 
after 30 minutes, the rate may 
be increased to 100% of the 
original infusion rate. 
Monitor participant closely.  If 
symptoms recur, immediately 
discontinue the infusion; no 
further study treatment will be 
administered at that visit.  
Administer diphenhydr amine 
50mg IV and continue to 
monitor the participant closely 
until resolution of symptoms.  
Participants who develop 
Grade [ADDRESS_99863] 
be permanently discontinued 
from further study treatment 
administration. 
The amoun t of mAb infused 
must be recorded.
Grades 3 or 4
Severe reaction [e.g., 
bronchospasm, generalized 
urticaria, systolic blood pressure < 
80mm Hg, hypoxemia, or 
angioedema]
Grade 3: prolonged [i.e., requiring 
6 or more hours to respond to 
symptomatic medication and/or 
discon tinuation of infusion]; 
recurrence of symptoms following 
initial improvement; 
hospi[INVESTIGATOR_38195] [e.g., renal 
impairm ent, pulmonary infiltrates].  
Grade 4: life-threatening; pressor 
or ventilatory support indicatedImmed iately discontinue the 
mAb infusion .  No further 
study treatment will be 
administered, unless approved 
by [CONTACT_2728]/Medical Monitor 
(criteria for rechallenge 
include but are not limited to 
participants who are receiving 
compelling benefit with study 
treatmen t that exceeds risk, 
and no effective alternative 
therapy is available).
The amount of mAb infused 
must be recorded on the eCRF.  
Investigators should follow 
their institutional guidelines 
for the treatment of 
anaphylaxis (e.g., epi[INVESTIGATOR_238] 
0.2mg to 1.0 mg of a 1: 1,000 
solution for subcutaneous 
administration or 0.1 mg to 
0.25 mg of a 1: 10,000 
solution injected slowly for IV 
administration, and/or 
diphenhydramine 50 mg IV 
with methylprednisolone 
100mg IV (or equivalent), as 
needed.) 
Consider additiona l 
intervention in consultation 
with the Sponsor (e.g., Diphenhydramine 50 mg (or 
equivalent) and/or 
paracetamol (acetaminophen) 
325mg to [ADDRESS_99864] 30 
minutes before additional 
study treatment 
administration.   [COMPANY_004]1795091 
may be administered the 
following day.
2017N327572_0 7 CONFIDENTIA L
204686
80NCI CTCAE Grade Treatm ent Prem edication at 
Subsequent Dosing
tocilizumab).  
Obtain serum for CRP, 
tryptase, ferritin, and plasma 
for the cytokine panel (see 
Table 9and SRM) w ithin 3 
hours of the event.  
The participan t must be 
closely monitored until 
resolution of symptoms.
Appropriate resuscitation equipment and a physician should be readily available during the period of drug 
administration.
For further information, please refer to the Common Terminology Criteria for Adverse Events v4. 0 
(CTCAE) at http://ctep.cancer.gov
7.2.2. General Guidelines for Immune -Related A dverse Events
An “immune -related AE ”(irAE) is defined as a clinically  significant AE of any  organ 
that is associated with study  treatment exposure, is of unknown etiology , and is consistent 
with an immune -related mechanism. The classification refers to the traditional spectrum 
of AEs associated with checkpoint modulators ( e.g., colitis, pneumonitis, etc.)  The term 
is not intended to describe the acute cy tokine -related AEs or infu sion reactions described 
in Section 7.2.[ADDRESS_99865] dose of treatment.
Early recognition of irAEs and initiation of treatment are critical to reduce the risk of 
complications, since the majority  of irAEs are reversible with the use of steroids and 
other immune suppressants [ Pardoll , 2012 ; Weber , 2012].  I f an irAE is suspected, the 
participant must return to the study  site as soon as possible instead of waiting for his/her 
next scheduled visit.  Participants who experience a new or worsening irAE must be 
contact[CONTACT_21116]/or evaluated at the study  site more frequently .  
If an irAE is suspected, a thorough evaluation must be conducted in an effort to possibly  
rule out neoplastic, infectious, metabolic, toxin, or other etiologic causes before 
diagnosing an irAE.  Serological, immunological, and histological (biops y) data should 
be considered to support the diagnosis of an immune -related toxicity .  Consultation with 
the appropriate medical specialist should be considered when investigating a possible 
irAE.  
Organs most frequently  affected by  [CONTACT_90613]. Less frequently  affected tissues are lung, liver, and the pi[INVESTIGATOR_90540].  Mild irAEs are usually  treated sy mptomaticall y and do not require 
dosing delay s or discontinuation.  Higher grade and persistent lower grade irAEs 
typi[INVESTIGATOR_1306] y necessitate interrupting or discontinuing treatment and administration of 
systemic steroids or other immunosuppressive agents (such as TNF blockers) when 
systemic steroids are not effective.  
2017N327572_0 7 CONFIDENTIA L
204686
[IP_ADDRESS]. General Principles of Immune -Related A dverse Events Identification 
and Evaluation
Before administration of study  treatment, investigators are to review a participant 's AEs, 
concomitant medications, and clinical evaluati on results e.g., vital signs, lab results, 
ECGs, ECOG PS, phy sical exam findings, responses, etc. as outli ned in the Schedule of 
Activities (SoA) (Section 2)to monitor for new or worsening irAEs and ensure continued 
dosing is a ppropriate.  
Adverse events of special interest (AESIs) are defined as events of potential immunologic 
etiology . Such events reported after treatment with other immune modulatory  therapy  
include Grade 2 colitis, uveitis, hepatitis, pneumonitis, Grade 3 diarrhea, endocrine 
disorders, and specific cutaneous toxicities, as well as other events that may be immune 
mediated, including but not limited to demy elinating pol yneuropath y, myasthenia gravis -
like sy ndrome, non -infectious my ocarditis, or non -infectious pericarditis [see
Appendix 11for a listing of AESI s].  
For participant s who experience signs or s ymptoms that may  be consistent with an AESI , 
sites must notify  the Sponsor of the event within 24 hours via email and /or phone.  
Documentation of events potentially  qualify ing for AESI must occur after discussion 
between the investigator and the Sponsor.  
[IP_ADDRESS]. General Guidelines for Clinically  Significant Toxicities Not Otherwise 
Specified
While specific guidance is provided for AESI, it is possible that other clinically  
significant drug -related toxicities that are not specifically  described may  occur and 
warrant dose modification.  Table 7provides general guidance for the management of 
clinically  significant toxicities that are not otherwise specifically  described in this section.  
Investig ators must contact [CONTACT_90614] 24 hours of being notified of the event for 
all Grade [ADDRESS_99866] infusion /injection , study  treatment must be permanently  discontinued after 
consultation with the Sponsor. With investigator and Sponsor agreement, participant s 
with a laboratory  AE still at Grade 2 after 12 weeks may  continue treatment in the trial 
only if as ymptomatic and controlled.  
For participant s who experience a recurrence of the same AE(s) at the sam e grade or 
greater with rechallenge of study  treatment, a consultation between the Sponsor and 
investigator willoccur to determine whether the participant should continue in the study .  
Recurrence of an SAE at the same grade or greater with rechallenge of study  treatment 
must result in permanent discontinuation of the study  treatment.  
2017N327572_0 7 CONFIDENTIA L
204686
[IP_ADDRESS]. Management of Hepatotoxicity
In the event of treatment -emergent hepatotoxicity , potential contributing factors such as 
concomitant medications, viral hepatitis and other in fectious causes, choledocholithiasis, 
and hepatic metastases, and my ositis should be investigated. Concomitant medications 
known to be hepatotoxic which may  be contributing to liver d ysfunction should be 
discontinued or replaced with alternative medication s to allow for recovery of liver 
function. As generally  understood, AST or ALT >[ADDRESS_99867] and concomitant bilirubin 
≥2.0x ULN (>35% direct bilirubin), in the absence of elevated alkaline phosphatase or 
biliary  injury , suggests significant liver injury . Record alcohol use on the liver event 
alcohol intake form in the eCRF. Liver d ysfunction mus t be fully  evaluated even if 
clinical signs and s ymptoms indicate progression of liver tumor lesions. I maging studies 
must be obtained to document potential progression of malignancy . Guidelines for 
management of emergent hepatotoxicity  are shown in Sectio n 8.1.1 and Appendix 7.
Report hepatotoxicity  events to [COMPANY_004] within 24 hours.  Complete liver event eCRF forms 
and SAE forms if the event also meets the criteria for SAE repo rting.  
If treatment is held or discontinued do not restart/rechallenge the participant with study  
treatment unless all of the requirements described in Section [IP_ADDRESS] have been met. Liver 
chemistry  stoppi[INVESTIGATOR_007] c riteria are provided in Section 8.1.1 .
In Canada, if liver chemistry stoppi[INVESTIGATOR_23893], participants will not be 
allowed to restart study drugs or be rechallenged.
[IP_ADDRESS]. Management of Gastrointestinal Events ( Diarrhea or Colitis)
Signs/sy mptoms may  include, but are not limited to: diarrhea, constipation, abdominal 
pain, crampi[INVESTIGATOR_6926]/or bloating, nausea and/or vomiting, blood and/or mucus in stool with 
or without fever, rectal bleeding, peritoneal signs consiste nt with bowel perforation, and 
ileus.
Differential diagnosis: All attempts should be made to rule out other causes such as 
metastatic disease, bacterial or parasitic infection, viral gastroenteritis, or the first 
manifestation of an inflammatory  bowel dise ase by  [CONTACT_90615], 
stool cultures, and a Clostridium difficile titer.  Dose modification guidelines for 
gastrointestinal events are provided in Table 11.
2017N327572_0 7 CONFIDENTIA L
204686
83Table 11 Guid elines for Dose Modification and Management of 
Gastrointestinal Events (Diarrhea or Colitis)
Severity Management Follow -up
Grade 1Administer anti -diarrheal and 
symptomatic treatment as 
appropriateSymptoms resolve to baseline within 7 days:
Provide close follow -up to evaluate for increased severity.
Symptoms ongoing > 7 days :
Consider following algorithm for Grade 2 events
Grade 2Interrupt study treatment
Administer antidiarrheal and 
symptomatic treatment
Discuss with Sponsor/Medical 
MonitorSymptoms re solve to Grade ≤1 or baseline within 3 days : 
resume study treatment
Symptoms ongoing >3 days, blood or mucus in stool, or 
ulceration/bleeding on endoscopy :
consider GI consultation and endoscopy to confirm or 
rule out colitis 
Start systemic corticosteroids ( e.g., 0.5mg/kg/day of 
prednisone or equivalent)
Continue steroids until improvement to Grade 1 or 
resolution; taper steroids as medically appropriate
Resume study treatment if symptoms have improved to 
Grade 1 and steroid dose is 10 mg prednisone/day or 
less
If sym ptoms continue or worsen to Grade 3 -4, follow 
algorithm for Grade 3 -4 events
Grade 3Interrupt study treatment
Assess for bowel perforation; 
do not administer 
corticosteroids if present
Consult gastrointestinal (GI) 
service, perform endoscopy 
with biopsy
Administer 1 -2mg/kg/day IV 
methylprednisolone 
Discuss with Sponsor/Medical 
Monitor When symptoms improve to Grade ≤1, taper steroids 
over at least 1 month.  
If corticosteroid therapy does not reduce initial 
symptoms within 48 to 72 hours, treat with add itional 
anti-inflammatory measures. Discontinue additional anti -
inflammatory measures upon symptom relief and initiate 
a prolonged steroid taper over 45 -60days.  
If symptoms worsen during steroid taper, retaper starting 
at a higher dose followed by a mor e prolonged taper.  
Resume study treatment (s) if toxicity has resolved to 
Grade 1 and steroid dose is [ADDRESS_99868] dose was administered >12 weeks, study 
treatment (s) must be permanently discontinued.
Recurrence after rechallenge:
Discontinue study treatment permanently unless 
otherwise agreed upon by [CONTACT_1034]/Medical 
Monitor and Investigators
Grade 4Permanently d iscontinue 
study treatment
Immediately inform 
Sponsor/Medical MonitorManagement as per Grade 3
2017N327572_0 7 CONFIDENTIA L
204686
[IP_ADDRESS]. Management of Skin Toxicity
Differential diagnosis: All attempts should be made to rule out other causes such as 
metastatic disease, infection, or allergic dermatitis. Dose modification guidelines for skin 
toxicity  are provided i n Table 12.
Table 12 Guidelines for Dose Modification and Management of Skin Toxicity
Severity Management Follow -up
Grade 1 Symptomatic 
managementProvide close follow -up
Grade 2Interru pt study 
treatment
Discuss with 
Sponsor/Medical 
Monitor
Consider dermatology 
consultation and biopsySymptoms resolve to baseline within 7 days : 
resume study treatment
Symptoms ongoing > 7 days :
Start topi[INVESTIGATOR_90541] ( e.g., 0.5-
1mg/k g/day of prednisone or equivalent)
Continue steroids until improvement to Grade 1 or 
resolution; taper steroids as medically appropriate
Resume study treatment if symptoms have improved 
to Grade 1 and steroid dose is 10 mg 
prednisone/day or less
If symptom s continue or worsen, follow algorithm for 
Grade ≤3 events
Grade 3 or greater 
or Stevens -Johnson 
syndrome, toxic 
epi[INVESTIGATOR_7387], or rash 
complicated by [CONTACT_90616], or 
necrotic, bullous, or 
hemorrhagic 
manifestations Permanently 
discontinue study 
treatment
Administer 1 -
2mg/kg /day IV 
methylprednisolone 
Discuss with 
Sponsor/Medical 
Monitor
Consider dermatology 
consultation and biopsyWhen dermatitis is controlled, taper steroids over at 
least 1 month 
IV = Intravenous
[IP_ADDRESS]. Management of Endocrine Events
Signs/sy mptoms may  include , but are not limited to: fatigue, weakness, headache, mental 
status and/or behavior changes, fever, vision disturbances, cold intolerance, abdominal 
pain, unusual bowel habits, loss of appetite, nausea and/or vomiting, and hypotension.  
Endocrine events m ay include the following AE terms: adrenal insufficiency , 
hyperthy roidism, hy pophy sitis, hy popi[INVESTIGATOR_297], hy pothy roidism, thy roid disorder, and 
thyroiditis. Hypophy sitis with clinically  significant adrenal insufficiency  and 
hypotension, deh ydration, and/or electroly te abnormalities (such as hy ponatremia and 
hyperkalemia) constitutes an adrenal crisis and must be considered a medical emergency .
2017N327572_0 7 CONFIDENTIA L
204686
85Dose modification guidelines for endocrine events are provided in Table 13.
Table 13 Guidelines for Dose Modification and Management of Endocrine 
Events
Severity Management Follow -up
Grade 1 or 2
Signs and/or 
symptoms of 
dysfunction
Endocrinopathies 
requiring hormone 
replacement or 
medical 
interventionConsider interruption of study 
treatment if symptomatic
Assess endocrine function
Consider pi[INVESTIGATOR_90542]
Administer up to 1 -2mg/kg/day 
IV methylprednisolone if clinically 
indicated
Initiate appropriate hormone -
replacement therapy
Consider consultatio n with 
endocrinology
Discuss with Sponsor/Medical 
MonitorConsider resuming study agent(s) when:
Participant is stable (on hormone -
replacement therapy if indicated) and 
symptoms have resolved or return to 
baseline
Participant is receiving ≤10 mg 
prednisone or equivalent per day
Grade 3 or greater
Adrenal crisis or 
other adverse 
reactions requiring 
hospi[INVESTIGATOR_059], 
urgent medical 
intervention.Consider interruption of study 
treatment
Discuss with Sponsor/Medical 
Monitor
Consider immediate initiation of 
1-2mg/kg/day IV 
methylprednisolone
Consult endocrinology
Other management as aboveConsider resuming study agent(s) when:
Participant is stable (on hormone -
replacement therapy if indicated) and 
symptoms have resolved or return to 
baseline
Participant is rece iving ≤10mg 
prednisone or equivalent per day
[IP_ADDRESS]. Management of Pneumonitis
Signs/sy mptoms may  include, but are not limited to: dy spnea, dry  cough, hemopty sis, 
fever, chest pain and/or tightness, abnormal breath sounds, and fatigue.  If symptoms 
indicate pos sible new or worsening cardiac abnormalities additional testing and/or a 
cardiology  consultation should be considered.  Pneumonitis events may  include the 
following AE terms: pneumonitis, interstitial lung disease, and acute interstitial 
pneumonitis. 
If symptoms indicate possible new or worsening cardiac abnormalities additional testing 
and/or a cardiology  consultation should be considered.
Differential diagnosis: All attempts should be made to rule out other causes such as 
metastatic disease, and bacteria l or viral infection. I t is important that participant s with a 
suspected diagnosis of pneumonitis be managed as per the guidance below until 
treatment -related pneumonitis is excluded.  Treatment of both a potential infectious 
etiology  and pneumonitis in pa rallel may  be warranted.  Management of the treatment of 
2017N327572_0 7 CONFIDENTIA L
204686
86suspected pneumonitis with steroid treatment should not be delay ed for a therapeutic trial 
of antibiotics.  If an alternative diagnosis is established, the participant does not require 
management as below; however, the AE should be reported regardless of etiology . Dose 
modification guidelines for pneumonitis are provided in Table 14.
Table 14 Guidelines for Dose Modification and Managem ent of Pneumonitis
Severity Management Follow -up
Grade 1
(asymptomatic with 
radiographic findings 
only)Discuss continued 
treatment with study 
treatment with 
Sponsor/Medical Monitor
Consider pulmonary 
consultation and/or 
bronchoscopy if clinically 
indicat edSerial imaging
Grade 2First epi[INVESTIGATOR_1865] :
Interrupt study treatment
Consider pulmonary 
consultation with
bronchoscopy and 
bronchoalveolar lavage 
(BAL) 
Administer 1 -2mg/kg/day IV 
methylprednisolone 
Discuss with 
Sponsor/Medical Monitor
Second epi[INVESTIGATOR_1865] :
Permanently discontinue 
study treatmentWhen symptoms improve to ≤ Grade 1, taper 
steroids over at least 1 month. Permanently 
discontinue study treatment if unable to 
reduce corticosteroid dose to ≤10mg 
prednisone or equivalent daily.  
Rechallenge with study treatment at the 
same dose(s) may b e considered if a first 
event improves to Grade [ADDRESS_99869] imaging 
monthly as clinically indicated.  
Grade 3 and 4Permanently discontinue study 
treatment
Bronchoscopy with biopsy and 
BAL is recommended
Administ er 1-2mg/kg/day IV 
methylprednisolone 
Discuss with Sponsor/Medical 
Monitor When symptoms improve to ≤Grade 1, taper 
steroids over at least 1 month.  
If corticosteroid therapy does not reduce 
initial symptoms within 48 to 72 hours, treat 
with additional anti -inflammatory measures. 
Discontinue additional anti -inflammatory 
measures upon symptom relief and initiate a 
prolonged steroid taper over 45 -60days.  
If symptoms worsen during steroid taper, 
retaper starting at a higher dose followed by 
a more prolonged taper.  
Add anti -infective prophylaxis as appropriate.
2017N327572_0 7 CONFIDENTIA L
204686
[IP_ADDRESS]. Management of H ematologic Events
Dose modification guidelines for hematologic events are provided in Table 15.
Table 15 Guidelines for Dose Modification and Management of Hematologic 
Events
Severity Manage ment Follow -up
Grade 1 -2 As clinically indicatedProvide close follow -up to evaluate for increased 
severity
Grade 3 Consider interruption of study 
treatment
Discuss with Medical Monitor
Obtain flow cytometry study of 
T and B lymphocytes
Consult hematolog y
Further management as 
clinically indicatedAs clinically indicated
Grade 4 Consider discontinuation of
study treatment for any 
severe or life-threatening
event 
Consult hematology
Obtain flow cytometry study of 
T and B lymphocytes.
Discuss with Sponsor /Medical 
MonitorAs clinically indicated
[IP_ADDRESS]. Uveitis/Iritis
All attempts should be made to rule out other causes such as metastatic disease, infection 
or other ocular disease ( e.g., glaucoma or cataracts). However, the AE should be reported 
regardless of et iology . Dose modification guidelines for uveitis/iritis are provided in 
Table 16.
2017N327572_0 7 CONFIDENTIA L
204686
88Table 16 Guidelines for Dose Modification and Management of Uveitis/Iritisa
Severity Management Follow -up
Grade 1 Symptomatic treatment as appropriateSymptoms resolve to baseline within 7 days:
Provide close follow -up to evaluate for increased 
severity.
Symptoms ongoing > 7 days :
Consider following algorithm for Grade 2 events
Grade 2Interrupt study treatm ent
Consultation with ophthalmologist is 
strongly recommended
Treat with topi[INVESTIGATOR_90543] 
1% prednisolone acetate 
suspension and iridocyclitics
Discuss with Sponsor/Medical 
MonitorSymptoms resolve to baseline within 7 days : 
resume study treatment
Symptoms ongoing > 7 days :
Discontinue study treatment s
If symptoms continue or worsen to Grade 3 -4, 
follow algorithm for Grade 3 -4 events
Grade 3 Interrupt study treatment
Administer 1 -2 mg/kg/day IV 
methylprednisolone (local 
administration of 
cortico steroids may be 
considered after consultation 
with an ophthalmologist)
Consultation with 
ophthalmologist is strongly 
recommended
Discuss with Sponsor/Medical 
MonitorSymptoms improve to Grade ≤2:
continue steroids until improvement to Grade ≤1 or 
baseline; taper steroids over at least 1 month
Symptoms ongoing ≥12 weeks
permanently discontinue study treatment s
Grade 4Permanently d iscontinue study 
treatment
Immediately inform 
Sponsor/Medical MonitorManagement as per Grade 3
a. If multiple study treatment s are administered per pro tocol, guidance may apply to 1 or more study agents; 
discuss management on a case -by-case basis with the Sponsor/Medical Monitor.  
[IP_ADDRESS]. Management of Left Ventricular Dy sfunction
Echocardiograph y (ECHO) or MUGA must be performed at Screening, and if clinically  
indicated as outlined in the SoA (Section 2).
Participant s with Grade 3 or Grade 4 (s ymptomatic) left ventricular (LV) s ystolic 
dysfunction that includes left ventricular ejection fraction (LVEF) decrease of >10% 
from baseline should interrupt study  treatment and have repeat echocardiogram 
performed. LVEF should be monitored every  4 weeks for a total of 16 weeks or until 
resolution. If recovery  occurs (LVEF >institutional lower limit of normal [LLN] and 
symptom resolution) within [ADDRESS_99870] a full evaluation performed as 
appropriate (e.g., cardiology  consult, additional workup for swelling/shortness of breath) 
and sy mptoms should resolve to <Grade 2 prior to discussion of restarting study  
treatment at the same or reduced dose with the Sponsor.
Copi[INVESTIGATOR_90544] s who 
experience a >10% decrease in LVEF from baseline and whose cardiac ejection fraction 
is <institution’s LL N will be required b y the Sponsor for review. Instructions for 
submitting qualify ing ECHOs are provided in the SRM.
[IP_ADDRESS]. Management of Valvular Toxicity
Participant s with a Grade 3 or Grade 4 (s ymptomatic, severe regurgitation/stenosis by  
[CONTACT_90617]) valvular toxicity  must 
interrupt study  treatment. Valvular toxicity  should continue to be monitored every  4 
weeks for 16 weeks or until resolution.  I f recovery  occurs (return to baseline via imaging 
AND s ymptom resoluti on) within 4 weeks, the participant may restart study  treatment at 
a reduced dose in consultation with and after approval of the Sponsor.
Copi[INVESTIGATOR_90544] s who 
experience valvular toxicity  will be req uired by  [CONTACT_90618].  Instructions for 
submitting qualify ing ECHOs are provided in the SRM.
7.3. Method of Treatment A ssignment
All screened participants will be identified by  a unique participant number that will 
remain consistent for the duration of the study .  Upon completion of all the required 
screening assessments, eligible participant s will be registered into the study by [CONTACT_90619]. See SRM for additional information on screening and 
enrollment procedures.
7.4. Blind ing
This is an open label study; there is no blinding.
7.5. Preparation/Handling/Storage/A ccountability
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  treatments 
must be stored in a se cure, environmentall y controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.
2017N327572_0 7 CONFIDENTIA L
204686
90The investigator, institution, or the head of the medical instit ution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance ( i.e., receipt, reconciliation, and final disposition records).
Further guidance and information for the final disposition of unused study  treatment 
are provided in the SRM . 
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet y risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_90620] a erosols or mists. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or 
[COMPANY_004] study  contact.
A Material Safety  Data Sheet/equivalent document describing occupational hazards 
and recommended handling precautions either will be provided to the investigator, 
where this is required b y local laws, or is available upon request from [COMPANY_004].
7.6. Treatment Compliance
[COMPANY_004]1795091 in combination with either [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab
will be intravenously  administered to par ticipants at the site.  When participants are dosed 
at the site, they  will receive study  treatment directly  from the investigator or designee, 
under medical supervision. Administration will be documented in the source documents 
and reported in the CRF.
7.7. Concomitant Therapy
Participant s will be instructed to inform the investigator before starting any  new 
medications from the time of first dose of stud y treatment until the end of the study  (Final 
Study  Visit).  Any  concomitant medication(s), including antibio tic and probiotic use 
within [ADDRESS_99871] dose, non-prescription medication(s) and herbal product(s), 
taken during the stud y will be recorded in the eCRF. The minimum requirement is that 
drug name, dose, and the dates of administration are to be recorded.  Additionally , a 
complete list of all prior anticancer therapi[INVESTIGATOR_42214].  
Questions regarding concomitant medications should be directed to the [COMPANY_004] Medical 
Monitor for clarification.  
If future changes are made to the perm itted/prohibited medications, formal 
documentation will be provided by  [CONTACT_90621].  An y such changes 
will be communicated to the investigative sites in the form of a letter.  
7.8. Treatment after the End of the Study
The investigator is r esponsible for ensuring that consideration has been given to the post -
study  care of the participant ’s medical condition.
2017N327572_0 7 CONFIDENTIA L
204686
917.9. Dose Delay
[COMPANY_004]1795091 in combination with either [COMPANY_004]3174998, [COMPANY_004]3359609, or pembrolizumab 
may be interrupted for treatment -related AEs or other reasons such as medical / surgical 
events or logistical reasons not related to study  therapy .
During the first 12 weeks (Part 1) of stud y participation ([COMPANY_004]1795091 Q1W dosing), i f 
there is a dose delay  between 1 and 3 day s, the procedures at the o riginal scheduled visit 
(including dosing) should be performed as soon as possible .  If the delay is >3 day s, the 
visit and dose (s) will be considered missed and t he procedures at the next scheduled visit 
should be performed.   After Week 12 (Part 1) of stu dy participation (Q3W dosing), if 
there is a dose delay  between 1 and 7 day s, the procedures at the original scheduled visit 
(including dosing) should be performed as soon as possible. I f the delay  is >7 day s, the 
visit and dose(s) will be considered misse d and the procedures at the next scheduled visit 
should be performed.
If a biops y sample collection is missed, it may  be collected at the next possible visit.  
Participant s with infusion delay s equivalent to [ADDRESS_99872] udy treatment (s) unless the treating investigator and Sponsor agree there is 
strong evidence sup porting continued treatment. Administration of [COMPANY_004]1795091 the day  
following the treatment mAb infusion is not considered a dose delay .
8. DISCONTINUA TION CRIT ERIA
Participant s will receive study  treatment for the s cheduled time period, unless 1 of the 
following occurs earlier: disease progression (as determined b y immune -related RECI ST 
[irRECI ST]), death, unacceptable toxicity  or stoppi[INVESTIGATOR_23893], includin g meeting 
criteria for liver chemistry defined in Section 8.1.1 .
8.1. Discontinuation of Study  Treatment
In addition to the above, study  treatment might be permanentl y discontinued for an y of 
the following reasons:
Deviation(s) from the protocol
Withdrawal of consent by  [CONTACT_90622] y
Discretion of the investigator 
Participant loss to follow -up by  [CONTACT_3878]
Closure or termination of the study  
Criteria described in Section 7.9(Dose Delay )
Female participant who becomes pregnant while on study  treatment
Criteria for discontinuation of study  treatment (s) as described in Section 7.2
(Dose Modification Guidelines) have been met
Criteria described in Section 8.1.2 (QTcF) Stoppi[INVESTIGATOR_2121]) have been met
2017N327572_0 7 CONFIDENTIA L
204686
92Criteria described in Section 8.1.3 (Stoppi[INVESTIGATOR_90545]) 
have been met
Note: Participants who require permanent discontinuation of one of the study  treatments 
due to toxicity  in a given treatment combination must permanentl y discontinue both 
treatments in that combination and the reason for discontinuation must be recorded. . The 
TDV must be conducted within [ADDRESS_99873] dose of study  treatment (s).
The primary  reason for discontinuation must be documented in the participant ’s medical 
records and eCRF . If the participant voluntarily  discontinues from tr eatment due to 
toxicity , ‘AE’ will be recorded as the primary  reason for permanent discontinuation on 
the eCRF. 
Once a participant has permanently  discontinued from study  treatment (s), the participant 
will not be allowed to be retreated. 
The assessments required at the TDV must be completed within [ADDRESS_99874] dose 
ofstudy  treatment (s).
Partic ipants who permanently  discontinue from study  treatment(s) will no longer be 
followed for for PFS FU . One Survival FU visit will be performed 12wks after the last 
dose of study  treatment or prior to the start of the next anti -cancer therap y, whichever 
occurs first.   If a new anti -cancer therap y is started before the TDV, the OS visit is not 
required.   The study  will conclude when the last subject has completed /discontinued 
study  treatment , completed the Treatment Discontinuation Visit (TDV) assessments, and 
the OS FU visit is completed (asapplicable) .
All participant s who discontinue from study  treatment will undergo safet y assessments at 
the time of disconti nuation and during post -study  treatment follow -up as specified in the 
SoA (Section 2).
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_90546] .
Discontinuation of study  treatment for abnormal liver tests is required when a participant 
meets the conditions outlined inFigure 9.
2017N327572_0 7 CONFIDENTIA L
204686
93Figure 9 Liver Chemistry  Stoppi[INVESTIGATOR_90547] 7for required Liver Safet y Actions and Follow up Assessments .
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
In Canada, if liver chemistry  stoppi[INVESTIGATOR_90548] t, participants will not be allowed to
restart stud y drugs or be rechallenged.
If a participant meets liver chemistry  stoppi[INVESTIGATOR_90549]/rechallenge the 
participant with study  treatment unless:
[COMPANY_004] Medical Governance approval is granted
Ethic s and/or I RB approval is obtained, if required, and
Separate consent for treatment restart/rechallenge is signed b y the participant
Refer to Appendix 7for full guid ance.
8.1.2. QTcFStoppi[INVESTIGATOR_2121]
The QTcF correction form ula must be used for each individual participant to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the participant has been enrolled.
The QTcF should be based on single or averaged QTcF va lues of triplicate ECGs 
obtained over a brief (e.g., 5 -10 minute s) recording period (i.e. ,single QTcF is 
2017N327572_0 7 CONFIDENTIA L
204686
94used when a single ECG is performed, and averaged QTcF is used when triplicate 
ECGs are performed) .
Withdrawal of subjects is to be based on an averag e QTcF value of triplicate 
ECGs. If asingle ECG demonstrates a prolonged QTcF interval, then obtain 2 
more ECGs over a brief period of time (e.g., 5 -10 minute s)and then use the 
averaged QTcF values of the [ADDRESS_99875] be discontinued from 
study  treatment .  
QTcF >500 msec
OR
Change from baseline of QTcF >60 msec
For participant s with underly ing bundle branch block , proceed with the following 
discontinuation criteria:
Baseline QTcF with Bundle Branch Block Discontinuation QTcF with Bundle Branch Block
<450msec 500msec
450 –480msec 530msec
QTcF = QT duration corrected for heart rate by [CONTACT_6550]’s formula
See the SoA (Section 2)for data to be collected at the time of treatment discontinuation 
and follow -up and for any  further evaluations that need to be completed.
8.1.3. Stoppi[INVESTIGATOR_90550] 9.1, in order to adequatel y assess the antitumor effect of 
immunotherapeutic agents ,participant s experiencing apparent progression as defined b y 
RECI ST version 1.[ADDRESS_99876] 
guidelines. These considerations should be balanced by  [CONTACT_90623]. 
In cases where deterioration was assessed in the investigator’s opi[INVESTIGATOR_90551] a clinical event and is attributable to disease progression ,is unlikely  to reverse with 
continued study  treatment or m anaged b y supportive care (e.g., bisphosphonates and/or 
bone directed radiotherapy , thoracentesis, or paracentesis for accumulating effusions), 
study  treatment should be discontinued. The decision to stop treatment should be 
discussed with the Sponsor’s Me dical Monitor.  Examples of events that may , in the 
investigator’s opi[INVESTIGATOR_1649], indicate a lack of clinical benefit include, but are not limited to, 
the following:
ECOG PS decrease of at least 2 points from baseline
Skeletal related events defined by  [CONTACT_90624]:
2017N327572_0 7 CONFIDENTIA L
204686
95pathologic bone fracture in the region of cancer involvement
cancer related surgery  to bone, and/or
spi[INVESTIGATOR_90552]
Development of new CNS metastases
Any setting where the initiation of new antineoplastic therapy  has been deemed
beneficial to the participant even in the absence of any  such documented clinical 
event.
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or 
may be withdrawn at any time at the discretion of the inves tigator for safety , 
behavioral, compliance or administrative reasons.
If the participant withdraws consent for disclosure of future information, the 
sponsor may  retain and continue to use any  data collected before such a 
withdrawal of consent.
If a partici pant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records.
Refer to the SoA (Section 2) for data to be c ollected at the time of study  
discontinuation and follow -up  for any  further evaluations that need to be 
completed.
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is una ble to be contact[INVESTIGATOR_530] b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_90625]/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 
telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_19425]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
2017N327572_0 7 CONFIDENTIA L
204686
969. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and their tim ing are summarized in the SoA (Section 2). 
Protocol waivers or exemptions are not allowed 
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA 
(Section 2), is essential and required for study  conduct.
All scr eening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reaso ns for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management ( e.g., 
blood count) and obtained before signing of ICF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA (Section 2).
If assessments are scheduled for the same nominal time, it is recommended that the 
assessments should occur in the following order: [ADDRESS_99877] 
nominal time.  
The timing and number of planned study  assessments may  be altered during the course of 
the stu dy based on newl y available data (e.g., to obtain data closer to the time of peak 
plasma concentrations) to ensure appropriate monitoring for the following assessments: 
safet y, PK, pharmacod ynamic s/biomarker, or other assessments (not applicable for 
partic ipants in Canada) .  
The change in timing or addition of time points for any  planned stud y assessments 
must be approved b y the relevant [COMPANY_004] stud y team member and then archived in 
the study  Sponsor and site study  files, but this will not co nstitute a protoc ol 
amendment.
The IRB/IECwill be informed of an y safety issues that require alteration of the safet y 
monitoring scheme or amendment of the informed consent form.
No more than 550mLof blood for the purposes of this study , will be collected over the 
first12 weeks of the study . The total volume will depend on how long the participant
remains on treatment.  There may  be additional blood collection performed for non -study  
reasons.
Protocol waivers or exemptions are not allowed with the exception of immediat e safety  
concerns.  Therefore, adherence to the stud y design requirements, including those 
specified in the SoA (Section 2), are essential a nd required for study  conduct.
This section lists the procedures and pa rameters of each planned study  assessment.  The 
exact timing of each assessment is listed in the SoA (Section 2).
2017N327572_0 7 CONFIDENTIA L
204686
979.1. Efficacy  Assessments
Lesion assessment method and timing, evaluation of disease, disease progres sion and 
response criteria will be conducted according to Response Evaluation Criteria in 
Solid Tumors (RECI ST1.1) [ Eisenhauer , 2009] as outlined below and in Appendix 9
of this protocol.
Disease assessment modalities may  include imaging (e.g., computed tomography  
[CT] scan, magnetic resonance imaging [MRI ], bone scan, plain radiography ) and 
physical examination (as indicated for palpable/superficial lesions). Scans will be 
collected centrall y during the study and may be reviewed or anal yzed by [CONTACT_90626]. De tails will be provided in the SR M.
The baseline disease assessment will be completed up to [ADDRESS_99878] 
dose of study  treatment .  See the Schedule of Activities Table s(Section 2) for the 
schedule of assessments of anti -cancer activity subsequent to the baseline disease 
assessment . 
Assessments must be performed on a calendar schedule and should not be affected 
by [CONTACT_90627]/delay s. 
For post -baseline assessments, a window of [7 day s]is permitted to allow for 
flexible scheduling.  If the last radiographic assessment was 6 weeks or more prior to 
the participant’s withdrawal from study  treatment and PDhas not been documented, 
a disease assessment should be obtained at the time of withdrawal from study
treatment .
To ensure comparabilit y between the baseline and subsequent assessments, the same 
method of assessment and the same technique wil l be used when assessing response.
9.1.1. Evaluation of Anti-Cancer A ctivity
RECI ST version 1.[ADDRESS_99879] target and non -target lesions, and in the disease assessments 
throughout the duration of the study  [Eisenhauer , 2009] as further outlined in 
Appendix 9of this protocol . irRECI ST assessments will be evaluated as well. 
Treatment decisions according to irRECI ST are encouraged ,including confirmatory  
disease assessments at least [ADDRESS_99880] guidelines.   
Lym ph nodes that have a short axis of <10 mm are considered non -pathological and 
should not be recorded or followed.
Pathological l ymph nodes with <15 mm and but 10mm short axis are considered 
non-measurable .
Pathological l ymph nodes wi th 15mm short axis are considered measurable and 
can be selected as target lesions, however l ymph nodes should not be selected as 
target lesions when other suitable target lesions are available.  
Measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, 
representative of all involved organs, should be identified as target lesions, and 
2017N327572_0 7 CONFIDENTIA L
204686
98recorded and measured at baseline. These lesions should be selected on the basis of 
their size (lesions with the longest diameter) and their suitabi lity for accurate 
repeated measurements (either b y imaging techniques or clinicall y). 
Note: Cystic lesions thought to represent cy stic metastases should not be selected as 
target lesions when other suitable target lesions are available.
Note : Measurable l esions that have been previously  irradiated and have not been shown 
to be progressing following irradiation should not be considered as target lesions. 
Lytic bone lesions or mixed ly tic-blastic lesions, with identifiable soft tissue 
components, that can b e evaluated b y CT or MRI can be considered measurable.   
Bone scans, fluorodeoxyglucose (FDG) -positron -emission tomograph y(PET)scans 
or X-rays are not considered adequate imaging techniques to measure bone lesions.
All other lesions (or sites of disease) should be identified as non -target and should 
also be recorded at baseline. Non -target lesions will be group edby [CONTACT_90628]. 
Measurements of these lesions are not required, but the presence or absence of each 
should be noted throughout follow -up.
The followin g are required at baseline (up to [ADDRESS_99881] dose , see 
Section 2): CT scan with contrast of the chest, abdomen, and pelvis is required . For 
participant s with SCCHN, a scan of the head and neck area is required. Other areas 
should be evaluated as indicated b y the participant ’s underl ying disease prior to 
screening, including clinical disease assessment for palpable/visible lesions. 
Although CT scan is preferred, MRI may  be used as an alternative method o f 
baseline disease assessment, especiall y for those participant s where a CT scan is 
contraindicated due to allergy  to contrast, provided that the method used to document 
baseline status is used consistently  throughout study  treatment to facilitate direct 
comparison. At each post baseline assessment, evaluations of the sites of disease 
identified by  [CONTACT_90629].  Refer to RECI ST version 1.1 guidelines for 
use of FDG -PET/CT [ Eisenhauer , 2009].  
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 4.
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remai n responsible for 
following up AE sthat are serious, considered related to the study  treatment or the study , 
or that caused the participant to discontinue [COMPANY_004]1795091 and combination partners (see 
Section 8). 
2017N327572_0 7 CONFIDENTIA L
204686
999.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAE swill be collected from the start of study  treatment until the follo w-up
visit at the time points specified in the SoA (Section 2).  (However , any  SAEs 
assessed as related to study  participation [ e.g., study  treatment, protocol -mandated 
procedures, invasive tests, or change in existing the rapy]or related to a [COMPANY_004] 
product will be recorded from the time a participant consents to participate in t he 
study ).
All AE swill be collected from the start of treatment until the follow -up visit at
the time points specified in the SoA (Section 2).  
Medical occurrences that begin before the start of study  treatme nt but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the CRF not the AE section.
Any AESI  and SAEs assessed as related to study  participation (e.g., protocol -
mandated procedures, invasive tes ts, or change in existing therapy ) or related to a 
[COMPANY_004] product will be recorded from the time a participant consents to participate 
in the study  up to [ADDRESS_99882] dose of study  treatment (s)or until the start 
of another anti -cancer therap y, whic hever is first . SAEs must be reported within 
24 hours to the Sponsor either by  [CONTACT_26365].
All SAE swill be recorded and reported to the sponsor or designee immediately  
and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 4. The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Investigators are not obligated to activel y seek AEs or SAEs in former study  
participants. However, if the investigator learns of any  SAE, including a death, at 
any time after a participant has been discharged from the study , and he/she 
considers the event to be reasonabl y related to the study  treatment or study  
participation, the investigator must promptl y notify the sponsor.
The method of recording, evaluating, and assessing causality  of AEs and SAEs
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 4.
9.2.2. Method of Detecting A Es an d SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence. Appropriate questions include:
“How are you feeling?”
“Have you had an y (other) medical problems since y our last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?”
2017N327572_0 7 CONFIDENTIA L
[PHONE_2132].2.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, [and non-serious AESI s(as defined in 
Section 9.2.8 )], will be followed until the event is resolved, stabilized, otherw ise
explained, or the participant is lost to follow -up (as defined in Section 8.3). Further 
information on follow -up procedures is given in Appendix 4.
9.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and 
the safet y of a study treatment under clinical investigation a re met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  
and other regulatory  agencies about the safet y of a study treatment under clinical 
investigation. The sponsor will comply  with country -specific regulatory  
require ments relating to safet y reporting to the regulatory authority, IRB/IEC , and 
investigators.
Investigator safety  reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor polic y and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information (e.g., summary  or listing of SAE s) from the 
sponsor will review and then file it along with the IBand will notify  the IRB/IEC, 
if appropriate according to local requirements.
9.2.5. Cardiovascular and Death Events
For an y CV events detailed in Appendix 4and all deaths, whether or not they are 
considered SAEs, specifi c CVand Death sections of the CRF will be required to be 
completed. These sections inclu de questions regarding CV (including sudden cardi ac 
death) and non -CVdeath. 
The CV CRFs are presented as queries in response to reporting of certain CV Medical 
Dictionary  for Regulatory  Activities ( MedDRA )terms. The CV information should be 
recorde d in the specific CV section of the CRF within 1week of receipt of a CV Event 
data query  prompting its completion. 
The Death CRF is provided immediately  after the occu rrence or outcome of death is 
reported. Initial and follow -up reports regarding de ath must be completed within 1week 
of when the death is reported.
2017N327572_0 7 CONFIDENTIA L
[PHONE_2133].2.5.1. Cardiovascular and Death Events
A CV event is defined as:
Myocardial infarction/unstable angina
Congestive heart failure
Arrhythmias
Valvulopathy
Pulmonary hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary embolism
Revascularization
9.2.6. Disease -Related Events and/or Disea se-Related Outcomes Not 
Qualify ing as SA Es
An event which is part of the natural course of the disease under stud y (i.e., disease 
progression or hospi[INVESTIGATOR_44814]) does not need to be reporte d as 
aSAE.
Death due to disease under s tudy is to be recorded on the death eCRF form.
However, if the underly ing disease (i.e., progression) is greater than that which would 
normally  be expected for the participant , or if the investigator considers that there was a 
causal relationship between t reatment with stud y treatment(s) or protocol 
design/procedures and the disease progression, then this must be reported as a SAE.
NOTE: If either of the following conditions apply , then the event mus t be recorded and 
reported as a SAE (instead of a disease -related event):
The event is, in the investigator’s opi[INVESTIGATOR_1649], of greater intensity , frequency , or 
duration than expected for the individual participant , or
The investigator considers that there is a reasonable possibility  that the event 
was related to treat ment with study  treatment(s).
9.2.7. Pregnancy
Details of all pregnancies in female participants will be collected after the start of 
study  treatment and until [ADDRESS_99883] dose of study  medication .
If a pregnancy  is reported, the investigator should inform GS Kwithin 24hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 5.
Abnormal pregnancy  outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE s.
2017N327572_0 7 CONFIDENTIA L
[PHONE_2134].2.8. Guidelines for Events of Special Interest
The severit y of AEs will be graded utilizing the NCI -CTCAE, version 4.0 . Guidelines for 
dose modifications and interruptions for management of common toxicities associated 
with the study  treatment(s) are provided in Section 7.  
9.3. Treatment of Overdose
For this study , any  dose of [COMPANY_004]1795091 orcombination partners greater than 50% of the 
intended dose within a 24 -hour time period will be considered an overdose.
There is no specific antidote for overdose with [COMPANY_004]1795091 ,[COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab .  In the event of a suspected overdose, it is 
recommended that the appropriate supportive clinical care should be instituted, as 
dictated b y the participant ’s clinical status. 
In the event of an overdose, the investigator should:
1.Contact [CONTACT_27465] .
2.Closely  monitor the participant for AE/SAE and laboratory  abnormalities for 
at least [ADDRESS_99884] dose of study  treatment if requested by  [CONTACT_1689] (determined 
on a case -by-case basis).
4.Document the quantit y of the excess dose as well as the duration of the 
overdosing in the eCRF.
Decisions regar ding dose interruptions or modifications will be made by  [CONTACT_43208].
9.4. Safet y Assessments
Planned time points for all safety  assessments are lis ted in the SoA (Section 2).
9.4.1. Physical Examinations
A complete ph ysical examination will be done at screening and TDV and will 
include assessments of the CV, Respi[INVESTIGATOR_696] , Gastrointestinal and Neurological
systems. Height and wei ght will also be measured and recorded.
A brief ph ysical examinat ion will be done at all other timepoints and will include 
assessments of the skin, lungs, CV system, and abdomen (liver and spleen).
Investigators should pay  special attention to clinical si gns related to previous 
serious illnesses.
For melanoma participant s, a full body  dermatological examination will be 
performed b y a dermatologist (or suitabl y qualified physician) to identify 
2017N327572_0 7 CONFIDENTIA L
204686
103abnormal skin lesions within the 28 -day screening period.  All f indings will be 
photographed and identified during screening.  Brief skin examinations will be 
performed as indicated in the SoA (Section 2)or more frequently  as necessitated.  
Wherever possible, the same ph ysician should perform these examinations.  
Follow -up skin examinations by  a referral dermatologist should be conducted if 
clinically  indicated by [CONTACT_90630] .  
The PS will be assessed using the ECOG scale (Appendix 12) as specified in the 
SoA (Section 2).
9.4.2. Vital Signs
Vital sign measurements to be measured in semi -supi[INVESTIGATOR_55848] [ADDRESS_99885] will include temperature, s ystolic and diastolic blood pressure, and pulse rate . 
Vital signs will be measured more frequently  if warranted by  [CONTACT_90631] .  On day s where vital signs are measured multiple times, 
temperature does not need to be repeated unless clinically  indicated.  
If a participant develops a fever, refe r to Section [IP_ADDRESS] for fever management 
guidelines.
9.4.3. Electrocardiograms
Twelve -lead ECGs will be obtained at each planned ECG assessment during the study  
using an ECG machine that automatically  calculates the h eart rate and measures PR, 
QRS, QT, and QTcF intervals.  Refer to Section 8.1.[ADDRESS_99886] for approximately  10 minutes. The 
participant should be in the semi -recumbent or supi[INVESTIGATOR_2547]; the same position must be 
used for all subsequent ECG tests.
For Part 1 of the study , ECG measurements will be performed in triplicate at specified 
times (see SoA [Section 2]including footnotes). All other measurements may  be 
performed as single ECG measurements.
At each time point at which triplicate ECG are required, 3 individual ECG tracings 
should be obtai ned as closely  as possible in succession, but no more than 2 minutes apart. 
The full set of triplicates should be completed in less than 4 minutes .
ECGs will be collected centrally  during the study  and may  be reviewed or anal yzed. 
Details will be provided in the S RM.
9.4.4. Clinical Safety  Laboratory  Assessments
Refer to Appendix 2for the list of local clinical laboratory  tests to be performed 
and to the SoA for all protocol -required laboratory assessments ,including timing 
and frequency . 
2017N327572_0 7 CONFIDENTIA L
204686
104The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be more severe than expected for the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within 30days after the last dose of study  
treatment must be repeated until the values return to normal or baseline or are no 
longer considered significantly  abnormal by  [CONTACT_90632]. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology must be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA (Section 2).
Laboratory  requisition forms must be completed and samples must be clearly  labeled 
with the participant number, protocol number, site/center number, and visit date. Details 
for the preparation and shipment of samples will be provided b y the laboratory and are 
detailed in the SRM. Reference ranges for all safety  parameters will be provided to the 
site by  [CONTACT_90633].
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in participant management or are 
considered clini cally  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF.
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate 
and/or additional blood draws.  
All study -requi red laboratory  assessments will be performed b y a central laboratory , apart 
from:
Hematology
Clinical Chemistry
Hepatitis B and C
Pregnancy  Test
Urinaly sis, calculated creatinine clearance (CrCl)
Thyroid Function Tests
Lipid Panel
The results of applicable tests must be entered into the eCRF as required .
Hematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Appendix 2.
2017N327572_0 7 CONFIDENTIA L
[PHONE_2135].5. Pharmacokinetics
With the implementation of Amendmen ts 05 a nd06, PK will no longer be collected.
However, even t-driven collections (e.g. in response to hy persensitivity  including infusion 
reactions) will be performed per Table 2(footnote h and i) and Section [IP_ADDRESS] .
9.5.1. Blood Sample Collection
Blood samples for PKanaly sis of [COMPANY_004] 1795091, [COMPANY_004] 3174998 , [COMPANY_004]3359609 , and 
pembrolizumab will be collected at the time points described in the SoA (Section 2). The 
actual date an d time of each blood sample collection will be recorded in the eCRF .  The 
timing of PK samples may  be altered and/or PK samples may  be obtained at additional 
time point s to ensure thorough PK monitor ing.  Any change to the number and timing of 
PK samples i s not applicable for participants enrolled in Canada .  Details on PK blood 
sample collection, processing, storage, and shippi[INVESTIGATOR_42232].  
Processing, storage and shippi[INVESTIGATOR_42232].
9.5.2. Blood Sample A nalysis
Concentrations of [COMPANY_004]1795091 , [COMPANY_004]31 [ZIP_CODE], [COMPANY_004]3359609 , and pembrolizumab will 
be determined in blood samples using the currently  approved bioanaly tical methodology .
Raw data will be archived at the bioanal ytical site .  Once the sample has been anal yzed 
for study  drugs any remaining sample may be analy zed for other compound -related 
metabolites and the results reported under a separate PTS -DMPK/Scinovo or [COMPANY_004] 
protocol.  
9.6. Pharmacody namics
See Section 9.8below .  
9.7. Genetics
Information regarding genetic research is include d in Appendix [ADDRESS_99887] 
consented to participate in the genetics analy sis component of the study . 
In the event of DNA extraction failure, a replacement genetic blood sample may  be 
requeste d from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.
Details on processes for collection and shipment and destruction of these samples can be 
found in the SRM.
2017N327572_0 7 CONFIDENTIA L
[PHONE_2136].8. Bioma rkers/Pharmacody namic Markers
With the implementation of Amendment s05 and 06, samples for biomarkers will no 
longer be collected.
9.8.1. Blood Biomarkers
Blood samples will be collected and analy zed by  [CONTACT_90634] s of al l treatments onvarious immune cell populations.  I n 
addition, the binding of [COMPANY_004]3174998 to the OX40 receptor and[COMPANY_004]3359609 to the 
ICOS receptor may be measured in blood b y flow cytometry analysisasdescribed in 
Table 2.
Blood samples will also be collected for the isolation of PBMCs, plasma and serum. 
Plasma and serum samples may be used for an analy sis of circulating soluble factors and 
soluble OX40 , soluble I COS, soluble OX40 -drug complex , and soluble I COS -drug 
complex depending on the availability  of the assays . Plasma samples may  also be 
analyzed for cell -free DNA (cfDNA) ,orexosomes or for novel biomarkers of immune 
activation or response to treatment.  Additional f actors to be anal yzed from plasma and 
serum may include but are not limited to several cytokines, as well as antibodies against 
tumor, self, or viral antigens.  
Based on the availability  of sample, PBMCs will be isolated from whole blood . Isolated 
PBMCs will be preserved and stored for other re levant experiment s, which may  include 
but arenot limited to flow cy tometry  of additional immune cell ty pes, subsequent 
functional anal ysis or assessment of the diversit y of the T -cell repertoire by [CONTACT_90635] , its relationship to clinical responses, a nd changes in response to treatment 
with [COMPANY_004]1795091 when administered in combination with either [COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab .  The functional state of PBMCs may  be analy zed for 
expression of cytokines .  PBMCs may  also be evaluated for genomic (DNA) , gene 
signature [CONTACT_90668] (RNA) alterations to determine treatment -related 
changes in immune -related signatures.  
Other biomarkers may  be evaluated as determined by  [CONTACT_90636]. If 
predictive biomarkers are identi fied in samples ,they may beused for the development of 
a diagnostic test. Details for sample collection, processing, storage, and shipment will be 
provided in the SRM.
9.8.2. Tumor Tissue
Based on the availability  of sample, tumor biopsies and/or archival tis suewill be 
evaluated b y IHC or related technologies for expression of phenoty pic and functional 
immune cell markers on tumor infiltrating l ymphocy tes and other immune cells as well as 
immune signaling markers (on both the surface and internal) of tumor ce lls, to understand 
antitumor immune responses. In addition, when possible, similar analy ses will be 
performed on tumor tissue samples obtained upon progression. Additionally, tumor tissue 
DNA may be sequenced to assess mutational burden and/or TCR diversit y, and RNA 
expression analy sis may  be performed by  [CONTACT_90637].  Further 
2017N327572_0 7 CONFIDENTIA L
204686
107research may  also evaluate changes in an yDNA/RNA/protein correlating inresponse to 
treatment with [COMPANY_004]1795091 when administered in combination with either
[COMPANY_004]31749 98, [COMPANY_004]3359609, or pembrolizumab .  
Other biomarkers may  be evaluated as determined by  [CONTACT_90636]. If 
predictive biomarkers are identified in samples ,they may beused for the development of 
a diagnostic test.  Details for sample collecti on, processing, storage, and shipment will be 
provided in the SRM.
9.8.3. Stool Collection for Microbiome A nalysis
Stool specimens offer accessible means of evaluating the gut microbial community .  
Association of the stool microbiome composition with phy siologica l and medical 
conditions and response to treatments has been reported in patients with various diseases, 
including cancer .Stool samples may be evaluated for changes in the gut microbial 
community  as a response to treatment, and may  also assess the relatio nship between 
antibiotic /probiotic use prior to treatment and antitumor response .
Details for sample collection, processing, storage, and shipment will be provided in the 
SRM.
9.9. Medical Resource Utilization and Health Economics
Medical Resource Utilization a nd Health Economics parameters are not evaluated in this 
study .
9.10. Qualitative Telephone Interview
To further evaluate disease and treatment related symptoms and associated impacts on 
function and health -related quality  of life, participants will have the opt ion to participate 
in a qualitative interview via telephone.  The interview will be conducted by a trained 
interviewer in the participant ’s native language and will be audio recorded for 
transcription and analy sis.
The telephone interview is to be complete d within [ADDRESS_99888] the TDV within 30 days of the Day 64 
interview are not required to repeat the interview.
Additional details on the optional qualitative telephone interview can be found in the 
SRM.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE]. STATISTICA L CONSIDER ATIONS AND DA TA 
ANALYSES
Part 1: Dose Escalation
With respect to the primary  objectives and endpoints, no specific statistical hy potheses 
are being tested.  The dose escalation part of the study  will be focu sed on the
determin ation of the recommended dose for dose expansion and further exploration, the 
safet y profile, and antitumor activity  of the combination of [COMPANY_004]1795091 with 
[COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab .
Part 2: Cohort Expansion
With the implementation o f amendment 06, the study  is closed to enrolment and Part 2 
will not be opened .
10.1. Sample Size Determination
The planned sample size for the stud y was chosen to allow adequate characterization
of safet y, clinical activity, PK, and PD profile based on the stu dy objectives.   For dose 
escalation, the total sample size depend son the number needed to adequately  characterize 
the DLT profile and determine the recomendend Part 2 dose .
With the implementation of amendment 06, the study  is closed to enrolment and Par t 2 
will not be opened .
10.2. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
All Enrolled All participants who sign the ICF to participate in the clinical trial .
All Treated All participant swho recei ve at least 1 dose of [COMPANY_004]1795091, [COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab .
Pharmacokinetic All participants from the All Treated population for whom a PK sample is obtained ,
analysed , measureable, and valid .  
PharmacodynamicAll participants from the All Treated population for whom a 
pharmacodynamic /biomarker sample is obtained ,analysed , and measureable.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].3. Statistical A nalyses
Data will be listed and summarized according to the [COMPANY_004] reporting standards, where 
applicable.  Complete details wil l be documented in the Reporting and Analysis Plan 
(RAP).  Any  deviations from, or additions to, the original anal ysis plan described in this 
protocol will be documented in the RAP and final study  report.
As it is anticipated that accrual will be spread th inly across centers and summaries of data 
by [CONTACT_90638] , data from all participating centers will be 
pooled prior to anal ysis.
All data up to the time of study  completion/withdrawal from study  will be included in the 
analysis, regardless of duration of treatment.
As the duration of treatment for a given participant will depend on efficacy  and 
tolerability , the duration of follow -up will vary  between participants. Consequently ,there 
will be no imputation for missing data. 
Demographic and baseline characteristics will be summarized.
10.3.1. Primary Analyses
[IP_ADDRESS]. Safety  Analyses
The All Treated Population will be used for the analy sis of safet y data.  All serially 
collected safet y endpoints (e.g., laboratory  tests, vital signs, ECGs) will b e summarized 
according to the scheduled, nominal visit at which they  were collected and across all on -
treatment time points using a “worst -case” analy sis.  Complete details of the safet y 
analyses will be provided in the RAP.
[IP_ADDRESS]. Extent of Exposure
The number o f participant s administered study  treatment will be summarized according 
to the duration of therap y.
2017N327572_0 [ADDRESS_99889] MedDRA and grouped by  [CONTACT_70244].  A dverse event s will be graded by  [CONTACT_90639] -CTCAE 
(version 4.0).  
Events will be summarized by  [CONTACT_90640] s, by  [CONTACT_53428].  Separate summaries will be given for all AEs, treatment -
related AEs, SAEs and AEs leading t o discontinuation of study  treatment.  Adverse 
events , if listed in the NCI -CTCAE (version 4.0) will be summarized by  [CONTACT_90641].  Otherwise, the AEs will be summarized by  [CONTACT_11196] .  
Characteristics (e.g., number of occurrences, action tak en, grade, etc) of AESI  (see 
Section [IP_ADDRESS] and Appendix 12will be summarized separatel y.  
The incidence of deaths and the primary  cause of death will be summarized.
[IP_ADDRESS]. Clinical Laboratory Evaluations
Change of hema tology  and clinical chemistry  will be descriptivel y summarized by 
[CONTACT_9084] . These summaries will include sample size, mean, median, standard deviation, 
minimum, and maximum.
The toxicity  grades and the worst -case to xicity  grade of h ematology  and clinical 
chemistry  data will be summarized using frequencies and proportions according to NCI -
CTCAE (version 4.0) .  Laboratory  test results outside the reference ranges that do not 
have an associated NCI -CTCAE criteria will b e summarized using proportions.  Further 
details will be provided in the RAP.  
[IP_ADDRESS]. Other Safety  Measures
Vital signs (body temperature and pulse rate) and ECGs (QT and QTcF) measurements 
change from baseline will be descriptivel y summarized by [CONTACT_9084] . These s ummaries will 
include sample size, mean, median, standard deviation, minimum, and maximum.
Vital signs and ECGs will also be tabulated according to the categories specified below. 
Thesummaries will include frequencies and corresponding percentages. Furthe r details 
will be provided in the RAP.  
Vital Signs:
-Increased bod y temperature to: ≤38.0, 38.1 -38.5, 38.6 -39.0, ≥39.1 oC
-Change in bod y temperature from baseline b y: ≤1.0, 1.1 -1.5, 1.6 -2.0, ≥2.1 oC
-Increased pulse rate to: ≤100, 101 -115, 116 -130, ≥131 bpm
-Change in pulse rate from baseline by : ≤20, 21 -35, 36 -50, ≥51 bpm
-Decreased pulse rate to: <45 bpm
-Increased s ystolic blood pressure to: ≤140, 141 -160, 161 -180, ≥181 mmHg
-Decreased s ystolic blood pressure to: <80 mmHg
-Increased diastolic blood pressure to: ≤90, 91 -100, 101 -110, ≥111 mmHg
-Decreased diastolic blood pressure to: <50 mmHg
2017N327572_0 7 CONFIDENTIA L
204686
111ECGs:
-PR interval: >200 msec
-QRS interval: >120 msec
-QT interval: ≤450, 451 -480, 481 -500, ≥501 msec
-QTcF interval: ≤450, 451 -480, 481 -500, ≥501 msec
-Change in QT from baseline by : ≤30, 31 -60, ≥61 msec
-Change in QTcF from baseline by : ≤30, 31 -60, ≥61 msec
10.3.2. Secondary Analyses
[IP_ADDRESS]. Anticancer A ctivity  Analyses
The All Treated Population will be used for anticancer activity  anal yses. Anticancer 
activity  will be evaluated based on clinical evidence and response criteria as assessed b y 
RECI ST v1.1 andspecified in Appendix 9.  Immune related response criteria (irRECI ST) 
will be evaluated as an exp loratory  endpoint.  If data warrant, the response data will be 
summarized by  [CONTACT_9084] .  
If the data warrant, PFS ,time to response, duration of response and overall survival will 
be calculated and listed for each participant , and be summarized by  [CONTACT_9084] .  PFS is 
defined as time from the date of first dose to the date of disease progression according to 
clinical or radiological assessment o r death due to any  causes, whichever occurs earliest.  
Time to response is defined as the time from the date of first dose to the date of the first 
documented evidence of response (PR or CR). Duration of response is defined as the time 
from first documente d evidence of CR or PR until disease progression or death due to 
any cause among participants who achieve an overall response (i.e., unconfirmed or 
confirmed CR or PR). If the participant does not have a documented date of event, PFS 
will be censored at th e date of the last adequate assessment.  Further details on rules of 
censoring will be provided in the RAP.  PFS will be summarized using the Kaplan -Meier 
method if the data warrant. Overall survival is defined as time from the date of first dose 
to the da te of death due to any  cause. For participant s who do not die, time of death will 
be censored at the date of last contact.
Objective response rate ( ORR ) and disease control rate (DCR) will be summarized by  
[CONTACT_9084] .ORR is defined as percentage of participan ts with complete response or partial 
response. DCR is defined as percentage of participants with complete response or partial 
response or at least 12 weeks of stable disease .If data warrant, t he corresponding 95% CI 
for ORR and DCR will also be provided. Participants with unknown or missing responses 
will be treated as non -responders, i.e., these participants will be included in the 
denominator when calculating percentages of response.
[IP_ADDRESS]. Pharmacokinetic A nalyses
[IP_ADDRESS].1. Pharmacokinetic Parameters
Pharmacokinetic ana lysis of study  treatments willbe the responsibility  of the Clinical 
Pharmacology  Modeling and Simulation (CPMS) Department.
2017N327572_0 [ADDRESS_99890] ion of CPMS, Quantitative 
Sciences, [COMPANY_004] .  PK parameters including but not limited the following will be 
determined if data permit:
Maximum observed concentrations ( Cmax)
Trough plasma concentrations(C trough )
AUC (0-τ)(repeat dosing)
[IP_ADDRESS].2. Statistical A nalysis of Pharmacokinetic Data
Statistical analy ses of the PKparameters data will be the responsibility  of Clinical 
Statistics and Programming .
Drug concentration -time data will be listed for each participant and summarized by  
[CONTACT_90642] p oint by  [CONTACT_9084]. PK parameter data will be listed for 
each participant and summarized by  [CONTACT_90643]. 
Ifdata warrant s, the data from this study  may  be combined with the data from other 
studies for a population PK analysis, which will be reported separatel y.A nonlinear 
mixed effects model will be used to determine population pharmacokinetic parameters 
and identify  relevant covariates (e.g., age, weight, or disease related covariates).
[IP_ADDRESS]. Immunogenicity  Analyses
Serum samples to assess the presence of anti -drug antibodies (ADA) will be collected as 
described in the SoA (Section 2). All sample swill be assessed for anti -[COMPANY_004]3174998 and
anti-[COMPANY_004]3359609 antibodies using validated immun oassay s. Anal ysis for the pres ence 
of anti -pembrolizumab antibodies will be performed contingent on availability  of a 
validated assay , and ifconsidered clinicall y relevant .  The actual date and time of each 
blood sample collection will be recorded. Details of blood sample collection (including 
volume to be collected), processing, storage, and shippi[INVESTIGATOR_90553].  
The timing and number of planned immunogenicity  samples may  be altered during the 
course of the stud y, based on newly available data to ensure appr opriate safety  
monitoring (any change to the number and timing of immunogenicit ysamples is not 
applicable for participants enrolled in Canada) .In the event of a h ypersensitivity  reaction 
that is either 1) clinicall y-significant in the opi[INVESTIGATOR_90554], or 2) leads to the 
participant withdrawing from study treatment , blood samples should be taken from the 
participant for immunogenicity  testing at the time of the event and again [ADDRESS_99891] dose.  
Serum will be tested for the presence of ADA using a tiered testing schema: screening, 
confirmation and titration ste ps.The presence of treatment emergent ADA will be 
determined using a drug-specific bridging st yle ADA assay  with a bio -analy ticall y 
determined cut -point determined during assay  validation. Samples taken after dosing 
2017N327572_0 [ADDRESS_99892] a value at or above the cut -point will 
be considered treatment -emergent ADA -positive. These ADA positive samples will be 
further evaluated in a confirmatory  assay , and confirmed positive samples will be further 
characterized b y assessment of titer. A neutralizing ADA assay  may  be developed for 
characterization of selected, stored samples. Results of ADA testing will be reported at 
the end of the stud y and will include incidence and titer.
10.3.3. Other A nalyses
[IP_ADDRESS]. Translational Research A nalyses
The r esults of translational research investigations may  be reported in the main clinical 
study  report (CSR) or in a separate CSR .  All endpoints of interest from all comparisons 
will be descriptivel y and/or graphically summarized as appropriate to the data.
Further details on the translational research anal yses will be addressed in the RAP. 
[IP_ADDRESS].1. PK/Pharmacodynamic/ Analyses
Observed or predicted concentrations or summary  exposure measure (e .g.,Cmax, Ctrough , 
and AUC ) may  be combined with safet y, efficacy ,orpharm acody namic measures of 
interest to examine potential exposure -response relationships.  Descriptive and g raphical 
evaluation will first be performed. 
Where evidence of relationship is seen, statistical models may  be fitted to further explore 
PK/Pharmacod ynamic relationship. Further model details will be provided in the R AP.
[IP_ADDRESS].2. Biomarker(s) Analyses
The results of biomarker investigations, which may  include but is not limited to immune 
cell phenot ypes in blood and tumor , abundance of soluble factors such as cyt okines and 
stress -related proteins, DNA sequence alterations , gene expression (RNA) in immune 
cells and tumor , tumor mutational burden, and microbiome analysis may be reported 
separately  from the main CSR.  All analy ses will be descriptivel y and/or graphic ally 
summarized as appropria te to the data.  
Performance of these investigations may be conditional on the results of the clinical trial 
principally , but not exclusively , on the primary  measures of the clinical trial outcome and 
samples may be selected fo r anal ysis on the basis of the clinical outcome.
OR
These investigations may be performed irrespective of whether a response to
[COMPANY_004]1795091 when administered in combination with either [COMPANY_004]3174998 , 
[COMPANY_004]3359609, or pembrolizumab is observed .
Additionally , comparative examination of post -dosing profiles in conjunction with pre -
dosing profiles may  yield known and novel candidate biomarkers/profiles and new 
insights which relate to the action of [COMPANY_004]1795091 when administered in combination 
with either [COMPANY_004]3174998 , [COMPANY_004]3359609, or pembrolizumab.
2017N327572_0 [ADDRESS_99893] participant completes the trial.
Where evidence of association between anticancer activity or immunologic effects and 
biomarkers is seen, a dditional exploratory  anal yses may  be performed to further 
characterize the biomarker (s). Full details will be addressed in the RAP.
[IP_ADDRESS]. Pharmacogenetic A nalyses
Further details on PGx analy ses will be addressed in Appendix 6and the PGx RAP.  
[IP_ADDRESS]. Qualitative Telephone Interviews
The results of these qualitative telephone interviews will be descriptivel y summarized 
and may be reported separatel y from the main CSR .  
10.3.4. Interim Analyses
No formal interim analysis is planned for this study .
10.4. N-CRM A nalysis for Dose Escalation
10.4.1. Implementation of N-CRM
The N-CRM model implementation will be performed using the FACTS (Version 4.0or 
higher) .
10.4.2. Bayesian Prior for the Logistic Model
The N -CRM methodology  requires th at a Bay esian prior distribution for the dose -toxicity  
curve be pre -specified.  The Bay esian prior used for this design was determined using the 
quantile method.  For each dose, the most likely  (median) presumed probability  of DLT 
was specified, along with a 95% credible interval –an interval within which the team is 
95% a priori certain the probability  of a DLT lies.  The 95% credible intervals are 
intentionally  wide due to limited information about the toxicity  profile of [COMPANY_004]1795091
in humans and to allo w the accumulating data to have more influence on dose 
recommendations than the prior.  
The Bayesian prior (, ln()) is assumed to follow bivariate normal distribution. The 
Bayesian prior means (standard deviations) for dosing scheme shown in Table 17are 
determined to be: E[ ]=-1.889 (1.0079 ), E[ln( )]=0.1807 (0.6682 ), with correlation 
between and ln( ) as ρ= -0.3644 , and use 100 ng as the reference dose. 
Table 17and Figure 10shows the median prior probability  of experiencing a DLT at the 
given dose along with a 95% credible interval a round the median:
2017N327572_0 7 CONFIDENTIA L
204686
115Table 17 Table of Specified Prior Probability  of DLT (with 95% Credible 
Interval)
Anticipated Dose for 
[COMPANY_004]1795091 (ng)Median Probability 
of Toxicity2.5% Quantile for 
Probability of Toxicity97.5% Quantile for 
Probability of Toxicity
50 0.075 0.005 0.4
100 0.15 0.01 0.5
150 0.225 0.02 0.65
200 0.30 0.04 0.75
250 0.375 0.05 0.85
Figure 10 Graphical Display  of the Prior Distribution for the Probability  of DLT 
Given Dose (Median wi th 95% Credible Interval)
Note: x -axis is natural log (dose/reference dose).
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE]. REFERENCES
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced liver injury : the 
attractive hazard.  Expert Opin Drug Saf. 2009;8:[ADDRESS_99894], Cato A, Von Eschen KB, et al. Pretreatment 
of normal humans with monophosphory l lipid A induces tolerance to endotoxin: a 
prospective, double -blind, randomized, controlled trial. Crit Care Med. 1995 Jan;23(1):9 -
17.
Bahador M, Cross AS. Fr om therap y to experimental model: a hundred years of 
endotoxin administration to human subjects. J Endotoxin Res. 2007;13(5):251 -79. 
Review.
Brennan FR, Morton LD, Spi[INVESTIGATOR_90555] S, Kiessling A, Allenspach R, Hey A, et al. 
Safety  and immunotoxicity  assessme nt of immunomodulatory  monoclonal antibodies. 
mAbs. 2010;2:233 -255.  
Chen DS, Mellman I . Elements of cancer immunity  and the cancer -immune set point. 
Nature. 2017;541(7637):321 -330.
Chen DS, Mellman I . Oncology  meets immunology : The cancer -immunity  cycle.
Immunity .2013;39:[ADDRESS_99895], Motolimod (VTX -2337), Combined with Cetuximab in 
Patients with Recurrent or Metastatic SCCHN. Clin Cancer Re s. 2017 May  
15;23(10):2442 -2450.
Clark, D.A., J. Manuel, L. L ee, G. Chaouat, R.M. Gorczy nski, and G.A. Levy . 2004. 
Ecology  of danger -dependent cy tokine -boosted spontaneous abortion in the CBA x 
DBA/[ADDRESS_99896] of LPS and (TNF -alpha + IFN -gamma) on 
pregnancy  loss. American journal of reproductive immunology  ([LOCATION_001], N.Y. : 1989) 
52:370 -378.
Cohen E, Milhem M, Ribas A, et al. Phase 1b/2, Open -Label, Multicenter Study  of 
Intratumoral SD -101 in Combination with Pembrolizumab in Anti -PD-1 Treatment -
Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. 
Presented at: 2018 American Association for Cancer Research (AACR) Annual Meeting; 
April 14 -18, 2018; Chicago, IL. Abstract CT098
de Bono JS, Dalgleish AG, Car michael J, Diffley  J, Lofts FJ, Fy ffe D, et al. Phase I study  
of ONO -4007, a s ynthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. 
Clin Cancer Res.  2000 Feb;6(2):[ADDRESS_99897] vtx -2337 (motolimod) in cancer 
patients and health y volunteers. Journal for ImmunoTherapy  of Cancer. 2014;2(Suppl 
3):P165.
2017N327572_0 [ADDRESS_99898] E, Malone K, Kemper E, Stroes E, Moerland M, et al. 
Characterization of inflammation and immune cell modulation induced by  [CONTACT_6398]-dose L PS 
administration to healthy volunteers. Journal of Inflammation. 2014;11(1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumors: Revised RECI ST guidelines (version 1.1). 
Eur J Cancer. 2009;45:228 -247.  
Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenousl y administered 
endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 1991 May  
15;51(10):2524 -30.
Flowers CR, Panizo C, I sufi I , Herrera AF, Okada C, Cull EH, et.al. Intratumoral G100 
Induces S ystemic Immunity  and Abscopal Tumor Regression in Patients with Follicular 
Lym phoma: Results of a Phase 1/2 Study  Examining G10 0 Alone and in Combination 
with Pembro lizumab [Abstract # 2771] ASH December 10, 2017 ; Atlanta, Georgia.
[COMPANY_004] Document Number 2014N212091_0 5. Investigator’s Brochure for [COMPANY_004]3174998. 
Version 0 4. 201 8
[COMPANY_004] Document Number 2014N225045_02 Study  201212. A Phase I , Open -Label Study 
of [COMPANY_004]3174998 Administered Alone and in Combination with Anticancer Agents 
including Pembrolizumab in Subjects with Selected Advanced Solid Tumors. 2016.
[COMPANY_004] Document Number 2015N236402_03 Study  204685. A 2 -part randomized, double -
blind (sponsor -unblinded), placebo -controlled, ascending dose and parallel group study  
of TL R4 agonist ([COMPANY_004]1795091) administered to healthy  subjects. 2017.
[COMPANY_004] Document Number 2015N238345_03 .Study 204691. A Phase I Open L abel study  
of [COMPANY_004]3359609 administered al one and in combination with anticancer agents in 
subjects with selected advanced solid tumors . 2017.
[COMPANY_004] Document Number 2015N239078_0 4, Investigator’s Brochure for [COMPANY_004]1795091. 
Version 03. 201 8
[COMPANY_004] Document Number 2017N319717_02 , Investigator’s Brochure fo r [COMPANY_004] 3359609 . 
Version 0 4. 201 9. 
Guha M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov. 2012 Jun 
29;11(7):503 -5. doi: 10.1038/nrd3775.
Heikkinen, J., M. Mottonen, A. Alanen, and O. Lassila. 2004. Phenoty pic 
characterization of regulatory  T cell s in the human decidua. Clinical and experimental 
immunology  136:373 -378.
Hoos A. Development of immuno -oncology  drugs —from CTLA4 to PD1 to the next 
generations. Nat Rev Drug Discov. 2016;15(4):235 –47. pmid:26965203
2017N327572_0 7 CONFIDENTIA L
204686
118Hunt CM. Mitochondrial and immunoallergi c injury  increase risk of positive drug 
rechallenge after drug -induced liver injury : A s ystematic review. Hepatol. 2010;52:2216 -
2222.  
Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, et al. Phase I study  of 
OM-174, a lipid A analogue, with assessment of immunological response, in patients 
with refractory  solid tumors. BMC Cancer. 2013 Apr 2;13:172.
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et al. 
Pharmacokinetics of acetaminophen -adduct in adults with acetaminophen overdose and 
acute liver failure. Drug Metab Dispos. 2009;37:1779 -1784.  
Kanzler H, Barrat FJ, Hessel EM, Coffman RL . Therapeutic targeting of innate immunity  
with Toll -like receptor agonists and antagonists. Nat Med. 2007 May ;13(5):552 -9. 
Review.
KEYTRU DA (pembrolizumab) Drug Approval Package
Company :  [COMPANY_006] Application No.: 125514 Approval Date: 9/4/2014
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000PharmR.pdf
KEYTRUDA (pembrolizumab) Prescribing Information. [COMPANY_006] Sharp & Dohme 
Corporation, June, [ADDRESS_99899] Characteristics, [COMPANY_006] Sharp & Dohme Corporation 
May, [ADDRESS_99900] J, Hansen CM, Møller K, Fonsmark L, et al. 
Hypotension during endotoxemia in aged humans. Eur J Anaesthesiol. 20 01 
Sep;18(9):572 -5.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, et al.  Quantification of 
hepatitis delta virus RNA in serum by  [CONTACT_90644] -time pcr indicates different patterns 
of virological response to interferon therap y in chronica lly infected patients. J Clin 
Microbiol. 2005;43:2363 -2369. 
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts 
in the diagnosis and management of cy tokine release s yndrome. Blood. 2014;124:188 -
195.  
Lee JJ, L iu DD. A predi ctive probability  design for Phase II cancer clinical trials. Clin 
Trials. 2008;5:93 -106.  
Leung ACF, Kummar S, Agarwala SS, Nemunaitis JJ, Gonzales R, Dabrick JJ, et al. 
Phase 1b/2, open label, multicenter, study  of intratumoral SD -101 in combination wit h 
pembrolizumab in anti -PD-1 naive and experienced metastatic melanoma patients. J Clin 
Oncol. 2017;35 (abstr 9550).
Levey  AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A New 
Equation to Estimate Glomerular Filtration Rate. Ann Intern M ed. 2009;150:604 -612.
2017N327572_0 7 CONFIDENTIA L
204686
119Maude SL , Barrett D, Teachey  DT, Grupp SA. Managing cy tokine release sy ndrome 
associated with novel T cell -engaging therapi[INVESTIGATOR_014]. Cancer J. 2014;20:119 -222.  
Milhem M, Gonzales R, Medina T, Kirkwood JM, Buchbinder E, Mehmi I, et al.  
Intratumoral toll -like receptor 9 (TLR9) agonist, CMP -001, in combination with 
pembrolizumab can reverse resistance to PD -1 inhibition in a phase Ib trial in subjects 
with advanced melanoma . [Abstract #CT144] AACR Annual Meeting, April 17, 2018 ; 
Chicago, Illinois.
Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bay esian approach to 
phase I cancer trials. Statistics Med. 2008;27:2420 -2439. 
Nishino M, Giobbie -Hurder A, Gargano M, Suda M, Ramaiy a NH, Hodi FS. Developi[INVESTIGATOR_007] 
a common language for tum or response to immunotherap y: immune -related response 
criteria using unidimensional measurements. Clin Cancer Res. 2013;19:[ADDRESS_99901] VTX -2337 in Adult 
Subjects with Advanced Solid Tumors or Ly mphoma. Clinical Cancer Research. 
2014;20(14):3683 -3691.
NYHA: The Criteria Committee of the [LOCATION_001] Heart Association (NYHA).  
Nomenclature and criteria for diagnosis of d iseases of the heart and great vessels. 9th Ed. 
[LOCATION_011], Mass: L ittle, Brown & Co. 1994:253 -256.  
O’Quigley  J, Pepe M, Fisher L.  Continual Reassessment Method: A Practical Design for 
Phase I Clinical Trials in Cancer.  Biometrics. 1990;46:33 -48.
Oken MM, Creech RH, Tormey  DC, Horton J, Davis TE, McFadden ET, et al. Toxicity  
and response criteria of the Eastern Cooperative Oncology  Group. Am J Clin Oncol. 
1982;5:649 -655.  
Papay  JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, et al.  Drug -induced liver in jury 
following positive drug rechallenge . Regul Tox Pharm. 2009;54:84 -90. 
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev 
Cancer. 2012; 12:252 -264.  
Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, et al.  P hase II Trial 
of a Toll -Like Receptor 9 –Activating Oligonucleotide in Patients With Metastatic 
Melanoma. Journal of Clinical Oncology . 2006;24(36):5716 -5724.
Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela -Rohena A, Golovina TN, et al .
The Inducible Co stimulator (ICOS) Is Critical for the Development of Human T H17 
Cells . Sci Transl Med. 2010;2:55 -78.
Riella, L .V., S. Dada, L. Chabtini, B. Smith, L . Huang, P. Dakle, B. Mfarrej, F. D'Addio, 
L.-T. Adams, N. Kochupurakkal, A. Vergani, P. Fiorina, A.L. Mello r, A.H. Sharpe, H. 
2017N327572_0 7 CONFIDENTIA L
204686
120Yagita, and I. Guleria. 2013. B7h (ICOS -L) Maintains Tolerance at the Fetomaternal 
Interface. The American Journal of Pathology  182:[ADDRESS_99902] MGN1703 from healthy  
volunteers and cancer patients. Journal of Clinical Oncology . 2015;33(15_suppl):abstract 
e14015.
Schmoll H -J, Wittig B, Arnold D, Riera -Knorrenschild J, Nitsche D, Kroening H, et al. 
Mainte nance treatment with the immunomodulator MGN1703, a Toll -like receptor 9 
(TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after 
chemotherap y: a randomised, double -blind, placebo -controlled trial. Journal of Cancer 
Resear ch and Clinical Oncology . 2014;140(9):1615 -1624
Schwartz LB. Diagnostic value of try ptase in anaphy laxis and mastocy tosis. I mmunol 
Allergy  Clin. 2006; 26:[ADDRESS_99903], Suffredini AF, Danner 
RL. Brief rep ort: shock and multiple -organ d ysfunction after self -administration of 
Salmonella endotoxin. N Engl J Med. 1993;328(20):1457 -60.
van Eijk L T, Pi[INVESTIGATOR_90556] P, Smits P, Bouw MP, van der Hoeven JG. Severe vagal response 
after endotoxin administration in humans. I ntensive Care Med. 2004 Dec;30(12):[ADDRESS_99904] 26.
Vosika G, Barr C, Gilbertson D. Phase -I stud y of intravenous modified lipid A. Cancer 
Immunology  Immunotherapy . 1984;18(2).
Wacholtz MC, Patel SS, Lipsk y PE. Patterns of costimulation of T cell clones by  [CONTACT_12783] -
linking CD3, CD4/CD8, and class I MHC molecules. J Immunol. 1989 Jun 
15;142(12):[ADDRESS_99905] C .Convergent and divergent effects of costimulatory  
molecules in conventional and regulatory  CD4+ T cells. Proc Natl Ac ad Sci U S A. 2013 
Jan 15;110(3):1023 -8. doi: 10.1073/pnas.[PHONE_2137]. Epub 2012 Dec 31
Weber JS, Kahler KC, Hauschild A. Management of immune -related adverse events and 
kinetics of response with ipi[INVESTIGATOR_125]. J Clin Oncol. 2012;30:[ADDRESS_99906] MGN1703 in patients with 
metastatic solid tumours. European Journal of Cancer. 2015;51(2):146 -156.
Wolchok JD, Hoos A, O’Day  S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the 
Evaluation of Immune Therap y Activity  in Solid Tumors: I mmune -Related Response 
Criteria. Clin Cancer Res. 2009;15(23):7412 -20.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE]. APPENDICES
12.1. Appendix 1:Abbreviations and Trademarks
Abbrev iations
ADA Antidrug antibody
AE Adverse event(s)
AESI Adverse events of special interest
ALT Alanine aminotransferase
AST Aspartate aminotransferase
AUC(0 -) Area under the concentration -time curve over the dosing 
interval
BAL Bronchoalveolar lavage
cfDNA Cell-free DNA
CI Confidence interval
CKD -EPI [INVESTIGATOR_90557] s ystem
CPMS Clinical Pharmacology  Modeling and Simulation
CR Compl ete response
CRP C-reactive protein
CSR Clinical Study  Report
CT Computed tomograph y
CTL A-4 Cytotoxic T -lymphocy te-associated antigen 4
CV Cardiovascular
DILI Drug -induced liver injury
dL Deciliter
DLT Dose -limiting toxicity
DNA Deox yribonucleic a cid
ECG Electrocardiogram(s)
ECOG Eastern Cooperative Oncology  Group
EOI End of infusion
eCRF Electronic case report form
FACTS Fixed and Adaptive Clinical Trial Simulator
Fc Fragment cry stallizable region
FcR Fragment cry stallizable region receptor
FDG -PET Fluorodeox yglucose -positron -emission tomography
FSH Follicle stimulating hormone
FTIH First time in human
GCP Good Clinical Practice
G-CSF Granulocy te colony -stimulating factor
GFR Glomular filtration rate
GGT Gamma -glutam yltransferase
[COMPANY_004] GlaxoSmithKline
2017N327572_0 7 CONFIDENTIA L
204686
122h Hour(s)
HPV Human papi[INVESTIGATOR_90558] y
IB Investigator’s Brochure
ICH International Council on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use
IEC Independent Ethi cs Committee
IFN Interferon
IgG Immunoglobulin G
IgM Immunoglobulin M
IHC Immunohistochemistry
IL-10 Interleukin 10
INR International normalized ratio
irAE Immune -related adverse event(s)
IRB Institutional Review Board(s)
irRECI ST Immune -related R ECIST
IV Intravenous
kg Kilogram(s)
L Liter
LPS lipopoly saccharide
g Microgram
mAb Monoclonal antibody
MedDRA Medical Dictionary  for Regulatory  Activities
mg Milligram(s)
min Minute(s)
mL Milliliter(s)
mmHg Millimeters of mercury
MRI Magnetic resonance imaging
NCI-CTCAE National Cancer Institute -Common Terminology Criteria 
for Adverse Events
ng Nanogram
NOAEL No-observed -adverse -effect -level
nTregs Natural Tregs
NYHA [LOCATION_001] Heart Association
ORR Objective response rate
OS Overall sur vival
PAMP Pathogen -associated molecular pattern
PBMC Peripheral blood mononuclear cell
PD-1 Programmed death receptor -1
PD Progressive disease
pg Pi[INVESTIGATOR_90559] -free survival
PGx Pharmacogenetics
PK Pharmacokinetic(s)
PR Partial respons e
2017N327572_0 7 CONFIDENTIA L
204686
123PS Performance status
Q1W Every  1 week
Q3W Every  3 weeks
QTc Corrected QT interval duration
QTcFQT duration corrected for heart rate b y Fridericia’s 
formula
RAP Reporting and Anal ysis Plan
RECI ST Response Evaluation Criteria in Solid Tumors
RNA Ribonucleic acid
SAE Serious adverse event(s)
SCCHN Squamous cell carcinoma of the head and neck
SD Stable disease
SRM Study  Reference Manual
TCR T-cell receptor
TDV Treatment discontinuation visit
TLR4 Toll-like receptor [ADDRESS_99907] Upper limit of normal
WOCBP Women of childbearing potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_90645]
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].2. Appendix 2:Clinical Laboratory  Tests
The tests detailed in Table 18will be performed by [CONTACT_28130].
Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 6of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by [CONTACT_941] i nvestigator or required by  [CONTACT_427].
Table 18 Clinical Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
HematologyPlatelet Count RBC Indices : WBC count with Differential :
RBC Count MCV Neutrophils
Hemogl obin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry aBUN Potassium AST (SGOT) Total and direct bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatase Albumin
CrCl (Calculated)                      C-reactive proteinLipid panel
Thyroid function Thyroid stimulating hormone, free T4, free T3
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood and ketones by [CONTACT_19508] (if blood or protein is abnormal)
Other Screening 
TestsHepatitis B (HBsAg)
Hepatitis C (Hep C antibody)
Serum or urine -hCG Pregnancy test (as needed for WOCBP ) 
a. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver stoppi[INVESTIGATOR_007] o r 
monitoring event are given in Section 8and Section [IP_ADDRESS] . Laboratory assessments required for follow up after 
a liver event may require submission to the centra llab.  Details came be found in the SRM and Central 
Laboratory Manual.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; -hCG = beta -human chorionic gonadotropin; 
BUN = blood urea nitrogen; HBsAg = Hepatitis B surface antigen; MCV = mean corpuscular volume; MCH = mean 
corpuscular hemoglobin; RBC = red blood cells; WBC = white blood cells
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].3. Appendix 3:Stud y Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable International Council on Harmonizat ion of Technical 
Requirements for Registration of Pharmaceuticals for Human Use ( ICH)
Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, IB, and other relevant documents (e .g., 
advertisements) mu st be submitted to an I RB/IEC by  [CONTACT_31846]/IEC before the study  is initiated. 
Any amendments to the protocol will require IRB /IECapproval before 
implementation of changes made to the stud y design, except for ch anges 
necessary  to eliminate an immediate hazard to study  participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requir ements, policies, 
and procedures established by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 C FR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
finan cial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests du ring the 
course of the stud y and for 1 y ear after completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally  authorized representative and answer a ll 
questions regarding the study . 
2017N327572_0 7 CONFIDENTIA L
204686
126Participants must be informed that their participation is voluntary . Participants or 
their legally  authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_99908] (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained befor e the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The par ticipant must be informed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her m edical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed by  
[CONTACT_456], by  [CONTACT_90646] I RB/IEC members, and by  [CONTACT_55894].
Publication Policy
The results of this study  may  bepublished or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The s ponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support publication of multicenter studies only  in their entiret y and not as 
individual site d ata. I n this case, a coordinating investigator [INVESTIGATOR_55850].
Authorship will be determined by  [CONTACT_11403] I nternational 
Committee of Medical Journal Editors authorship requirements.
2017N327572_0 7 CONFIDENTIA L
204686
127Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an investigator signatory  
will be identified for the approval of the CSR .  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will ha ve 
the opportunity  to review the complete study  results at a [COMPANY_004] site or other 
mutually -agreeable location.
[COMPANY_004] will also provide the investigator with the full summary  of the stud y 
results.  The investigator is encouraged to share the summary  results with the 
study  participant s, as appropriate.
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] 
Policy .
A manuscript will be progressed for publication in th e scientific literature if the 
results provide important scientific or medical knowledge.
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or eCRF 
unless transmitted to the sponsor or designee electronically  (e.g., laboratory data). 
The investigator is responsible for verify ing that data entries are accurate and 
correct b y physically or electronicall y signing the CRF. 
The investigator must maintain accurate documentation (source data) that 
supports the informati on entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that the s afety and rights of participants are 
being protected; and that the study  is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, incl uding signed ICF, pertaining to the conduct of this 
study  must be retained by  [CONTACT_1732] 25 y ears from the issue of the final 
CSR /equivalent summary or as locall y agreed . No records may  be destroyed 
during the retention period without the writte n approval of the sponsor. No 
records may  be transferred to another location or party  without written 
notification to the sponsor. 
2017N327572_0 7 CONFIDENTIA L
204686
128Data Management
For this study  participant data will be entered into [COMPANY_004] defined eCRFs, 
transmitted electronically to [COMPANY_004] or designee, and combined with data provided 
from other sources in a validated data s ystem.  
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., re moving errors and inconsistencies in the data.
AEs and concomitant medications terms will be coded using MedDRA and an 
internal validated medication dictionary , [COMPANY_004]Drug.  
The eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and 
copi[INVESTIGATOR_014] w ill be made available to the investigator to maint ain as the investigator 
copy .  Participant initials will not be collected or transmitted to [COMPANY_004] according to 
[COMPANY_004] policy .
Source Documents
Source documents provide evidence for the existence of the participa nt and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the d iscrepancies 
must be explained. The investigator may  need to request previous medical records 
or transfer records, depending on the stud y. Also, current medical records must be 
available.
Definition of what constitutes source data can be found in the SRM.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of t he intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants b ythe investigator
Discontinuation of further study  treatment development
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].4. Appendix 4:Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and R eporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results ( hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments ( e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator ( i.e., not related 
to underly ing disease).
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatmen t administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
 "Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or S AE if they  fulfill the definition of an AE 
or SAE. 
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_90647]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
2017N327572_0 7 CONFIDENTIA L
204686
130participant’s cond ition.
Medical or surgical procedure ( e.g., endoscopy , appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the de finition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_90560], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been ap propriate in the phy sician’s office or 
outpatient setting. Hospi[INVESTIGATOR_90561] -recommended observation of vital 
sign trends should not be considered a SAE if done for logistical purposes alone .
Complications that occur during hospi[INVESTIGATOR_5186] n are AE. If a complication prolongs 
hospi[INVESTIGATOR_23919], the event is serious. When in doubt as 
to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE should be considered 
serious.
Hospi[INVESTIGATOR_90562] a pre -existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This defi nition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( e.g., sprained ankle) which may  interfere with or prevent 
2017N327572_0 7 CONFIDENTIA L
204686
131every day life fun ctions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medica l events t hat may  
not be immediately  life threatening or result in death or hospi[INVESTIGATOR_90563] 
1of the other outcomes listed in the above definition. These events s hould usually  be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or dev elopment of drug dependency  
or drug abuse.
g.Is associated with liver injury andimpaired liver function defined as:
ALT 3xULN and total bilirubin*2xUL N (>35% direct), or
ALT 3xULN and International harmonized ratio ( INR)**> 1.5.
* Serum bilirubin frac tionation should be performed if testing is available; if unavailable, 
measure urinary  bilirubin via dipstick.  I f fractionation is unavailable and ALT 3xULN 
and total bilirubin 2xULN, then the event is still to be reported as an SAE.
** INR testing not required per protocol and the threshold value does not apply  to 
participants receiving anticoagulants.  If INR measurement is obtained, the value is 
to be recorded on the SAE form.
Refer to Section [IP_ADDRESS] for the required liver chemistry  follow -up instructions
Definition of Cardiovascular Events
CV Events Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
2017N327572_0 7 CONFIDENTIA L
204686
132Deep venous thrombosis/pulmonary  embolism
Revascularization
Recording A E and S AE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e .g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
related to the event.
The investigator will then record all releva nt AE/SAE information in the eCRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004] . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and will grade it according to the NCI -CTCAE v4.0
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable poss ibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative cau ses, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the IBand/or Produ ct Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
2017N327572_0 7 CONFIDENTIA L
204686
133There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004] . However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  
assessment.
The causality  assessment is 1 of the criteria used when determining regulatory  
reporting re quirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may  be indicated or as requested by  [CONTACT_90648]/or causal ity of the AE or SAE.
The investigator is obligated to assist.  This may  include additional laboratory  tests 
or investigations, histopathological examinations or consultation with other health 
care professionals.
If a participant dies during participation in the study  or during a recognized follow -
up period, the investigator may  be asked to provide [COMPANY_004] with a copy  of any  post -
mortem findings, including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The investig ator will submit any  updated SAE data to [COMPANY_004] within the designated 
reporting time frames.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
Primary  mechanism for reporting SAEs to [COMPANY_004] will be the electronic data collection
tool
If the electronic s ystem is unavailable, the site will use the paper SAE data collection 
tool as outlined in the SRM .Site will enter the SAE data into the electronic sy stem 
as soon as it becomes available.
The investigator will be required to confir m review of the SAE causality  by [CONTACT_90649] ‘reviewed’ box at the bottom of the eCRF page within 72 hours of submission of 
the SAE.
After the stud y is completed at a given site, the electronic data collection tool (e.g., 
InForm s ystem) will be taken off -line to prevent the entry  of new data or changes to 
existing data
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, the site can report this information to the Medical Monitor by 
2017N327572_0 7 CONFIDENTIA L
204686
134telephone.
Contacts for SAE reporting can be found in the SRM .
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].5. Appendix 5:Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A wom an is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
Female participant: is eligible to participate if she is not pregnant (as confirmed by  a 
negative serum beta -human chorionic gonadotrophin ), not lactating, and at least one of 
the following conditions applies:
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documen ted bilateral oophorectom y
Note:  Documentation can come from the site personnel’s review of participant’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 month s without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may  be used to confirm a postmenopausal state in women 
not using hormonal contraception or hormon ereplacement therap y (HRT). 
However, in th e absence of 12 months of amenorrhea, a single FSH measurement 
is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to use 
[ADDRESS_99909] discontinue HRT to 
allow confirmation of postmenopausal status before study  enrollment.
2017N327572_0 7 CONFIDENTIA L
204686
136Contraception Guidance
Female participants
Female participants of childbearing potential are eligible to participate if they  agre e to 
use a highly  effective method of contraception consistently  and correctly  as described in 
Table 19. 
Table 19 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Metho ds That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing) hormonal contraception associated with inhibition of ovulation b
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation b
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of ovulation b
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm h as been confirmed. If not, an additional highly effective 
method of contraception should be used. )
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study treatment . The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.)
NOTES: 
a. Typi[INVESTIGATOR_90564]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants inclinical studies. 
b. Hormonal contraception may be susceptible to interaction with the study tr eatment , which may reduce the efficacy 
of the contra ceptive method. In this case [ADDRESS_99910] d oes not apply  to WOCBP with same sex partners, when this is their preferred 
and usual lifesty le or for participants who are and will continue to be abstinent from 
penile -vaginal intercourse on a long term and persistent basis.
2017N327572_0 7 CONFIDENTIA L
204686
137Pregnancy  Testing
WOCBP shoul d only  be included after a confirmed menstrual period and a negative 
highl y sensitive serum pregnancy  test 
Additional pregnancy  testing should be performed at monthly  intervals during the 
treatment period and at [ADDRESS_99911] dose of study  treat ment and as 
required locally  
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected 
Collection of Pregnancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy information on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24hours of learning of a participant's pregnancy .
Participant will be followe d to determine the outcome of the pregnancy . The 
investigator will collect follow -up information on mother and infant, which will be 
forwarded to [COMPANY_004].  Generall y, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy  for medical reasons will be 
reported as an AE or SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to th e study  treatment by  [CONTACT_90650]. 
While the investigator is not obligated to actively  seek this information in former 
study  participants, he or she may  learn of an SAE through spontaneous reporting.
Any female participant who b ecomes pregnant while participating
Will discontinue study  medication or be withdrawn from the study .
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].6. Appendix 6:Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant’s response to therap y, susceptibility , 
severit y and progression of dis ease. Variable response to therap y ma y be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology ; and/or molecular 
subty pe of the disease being treated. Therefore, where local regulations and I RB/IEC 
allow, a blood sample will be collected for DNA analy sis.
DNA samples will be used for research related to [COMPANY_004]1795091 , [COMPANY_004]3359609 , 
[COMPANY_004]3174998 , and pembrolizumab in combination with [COMPANY_004]1795091 or advanced 
solid tumors an d related diseases. They  may  also be used to develop tests/assay s 
including diagnostic tests related to [COMPANY_004]1795091 , [COMPANY_004]3359609 ,[COMPANY_004]3174998, and 
pembrolizumab combination treatment or study  treatments of this drug class, and 
advanced solid tumors. Genetic r esearch may  consist of the anal ysis of 1 or more 
candidate genes or the analy sis of genetic markers throughout the genome or anal ysis 
of the entire genome as appropriate .
 DNA samples will be analy zed if it is hy pothesized that this may  help further 
unders tand the clinical data .
DNA samples will be analy zed by  [CONTACT_42367]/or statistical 
analysis methods. A detailed description of any  planned analy ses will be documented 
in a RAP prior to initiation of the anal ysis. 
The samples may  be a nalyzed as part of a multi -study  assessment of genetic factors 
involved in the response to [COMPANY_004]1795091 , [COMPANY_004]3359609 , pembrolizumab and 
[COMPANY_004]3174998 or study  treatments of this class. The results of genetic anal yses may 
be reported in the CSR or in a separate s tudy summary .
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained while research on [COMPANY_004]1795091 , [COMPANY_004]3359609 , 
[COMPANY_004]3174998 , and pembrolizumab combination treatment orstudy  treatments of this 
class or advanced solid tumors and related diseases continues but no longer than [ADDRESS_99912] visit or other period as per local requirements.
US Food and Drug Administration states that an in vitro companion diagnostic device 
(IVD) could be essential for the safe and effective use of a corresponding therapeutic 
product to:
Identify  participants who are most likely  to benefit from a particular therapeutic 
product;
Identify  participants likely  to be at in creased risk for serious adverse reactions as 
a result of treatment with a particular therapeutic product;
Monitor response to treatment for the purpose of adjusting treatment ( e.g., 
schedule, dose, discontinuation) to achieve improved safet y or effectiven ess
2017N327572_0 7 CONFIDENTIA L
204686
139Identify  participants in the population for whom the therapeutic product has 
been adequatel y studied, and found safe and effective, i.e., there is insufficient 
information about the safety  and effectiveness of the therapeutic product in any  
other popul ation
Global regulatory  requirements for IVD companion diagnostic tests are evolving.  If a 
DNA -based IVD companion diagnostic device might be needed to identify  participants 
who are appropriate for the [COMPANY_004] medicinal product(s) under investigation in this 
protocol, then [COMPANY_004] should collect and retain DNA samples from participants who carry  
the genetic variant of interest as well as DNA samples from participants who do not carry  
the genetic variants of interest to validate the performance of the companion dia gnostic. 
Therefore, where local regulations and IRB/IEC allow, a sample will be collected for 
DNA anal ysis. Any  IVD companion diagnostic research objectives should be described 
in participant informed consent forms .
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].7. Appendix 7:Liver Safety : Required A ctions and Follow -up 
Assessments and Study  Treatment Rechallenge Guidelines
Phase I/II liver chemistry stoppi[INVESTIGATOR_90565] y and evaluate liver event etiology.
Phase I/II liver chemistry stop pi[INVESTIGATOR_90566] –Liver Stoppi[INVESTIGATOR_53053] -absolute ALT 5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin 1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN andcannot be monitored weekly for 4 weeks
Symptomatic 3ALT 3xULN associated with symptoms (new or worsening) believed to 
be related to liver injury or hypersensitivity
Require d Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
SAE data collection tool if th e event also meets 
the criteria for an SAE 2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries
resolve , stabilize, or return to within baseline 6
(see MONITORING below)
Do not restart/rechallenge participant with 
study treatment unless allowed per protocol and 
[COMPANY_004] Medical Governance approval is granted
(refer to Section 12.7.1 ) 
If restart/rechallenge not allowed per protocol 
or not granted , permanently discontinue study 
treatment and may continue participant in the 
study for any protocol specified follow up 
assessmentsViral hepatitis serology 4
Obtain INR and recheck with eac h liver chemistry 
assessment until the transaminases values show 
downward trend
Only in those with underlying chronic hepatitis B at 
study entry (identified by [CONTACT_23977] B 
surface antigen) quantitative hepatitis B DNA and 
hepatitis delta antibody 5.
Blood sample for PK analysis, obtained within [ADDRESS_99913] dose 6.
Serum creatine phosphokinase and lactate 
dehydrogenase.
Fractionate bilirubin, if total bilirubin 2xULN
Obtain complete blood count with differential to 
assess eosinophilia
Record th e appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on the 
AE report form
Record use of concomitant medications on the 
2017N327572_0 7 CONFIDENTIA L
204686
141MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up a ssessments within 24 hrs
Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 6
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within 24-72 
hrs 
Monitor participants weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 6concomitant medications report form including 
acetaminophen, herbal remedies, other over the 
counter med ications
Record alcohol use on the liver event alcohol 
intake CRF
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal 
antibodies, and quantitative total immunoglobulin 
G (IgG or gamma globu lins)
Serum acetaminophen adduct high-performance
liquid chromatography assay (quantifies potential 
acetaminophen contribution to liver injury in 
participants with definite or likely acetaminophen 
use in the preceding week [ James , 2009]). 
NOTE: not required in China
Liver imaging (ultrasound, MRI, or CT) and /or 
liver biopsy to evaluate liver disease ; complete 
Liver Imaging and/or Liver Biopsy CRF forms
1. Serum bilirubin fractionation should be performed if testing is a vailable. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectab le urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if 
INR measured which may indicate severe liver injur y (possible ‘Hy’s Law’), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the 
threshold value stated will not apply to participants receiving anticoagulants
3. New or worsening symptoms bel ieved to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, 
rash or eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); 
Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if 
unavailable, obtain heterophile antibody or monospot testing ); Hepatitis E IgM antibody 
5. If hepatiti s delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6. For the purpose of these guidelines “baseline” refers to laboratory assessments performe d closest and prior 
to first dose of study treatment
2017N327572_0 7 CONFIDENTIA L
204686
142Phase I/II Oncology liver chemistry increased monitoring criteria with continued 
therapy
Liver Chemistry Increased Monitoring Criteria –Liver Monitoring Event
Criteria Actions
ALT 3xULN but <5xULN and
bilirubin <2xULN, without symptoms 
believed to be related to liver injury or 
hypersensitivity andwho can be monitored 
weekly for 4 weeksNotify the medical monitor within 24 hours of 
learning of the abnormality to discuss participant 
safety. 
Participant can continue study treatment
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 1
If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_007] 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice monthly 
until liver chemistries normalize or return to within 
baseline 1.
1.for the purpose of these guidelines “baseline” refers to laboratory assessments performed closest 
and prior to first dose of study treatment
12.7.1. Liver Safety Drug Restart or Rechallenge Guidelines
In Canada, if liver chemistry  stoppi[INVESTIGATOR_23893], participants will not be allowed to
restart stud y drugs or be rechallenged.
If partici pant meets liver chemistry  stoppi[INVESTIGATOR_90549]/rechallenge participant 
with study  treatment unless:
[COMPANY_004] Medical Governance approval is granted (as described below),
Ethics and/or I RB approval is obtained, if required, and
Separate consent for treatment restart/rechallenge is signed by  [CONTACT_90651]/rechallenge participant with study  
treatment is not granted , then participant must permanently  discontinue study  treatment 
and may  continue in the stud y for protocol -specified follow up assessments .
1.Rechallenge Following Liver Stoppi[INVESTIGATOR_90568] -induced liver injury , drug rechallenge is associated with a 13% 
mortality across all drugs in prospectiv e studies [Andrade , 2009] . Clinical outcomes 
vary by [CONTACT_9934], with nearl y 50% fatalit y with hal othane re -administered within 1 month of 
initial injury . However, some drugs seldom result in recurrent liver injury  or fata lity.  
2017N327572_0 7 CONFIDENTIA L
204686
143Risk factors for a fatal drug rechallenge outcome include:
hypersensitivity [Andrade , 2009] with initial liver injury  (e.g., fever, rash, 
eosinophilia) 
jaundice or bilirubin >2xULN with initial liver injury  (direct bilirubin >35% of 
total)
participant currentl yexhibits severe liver injury  defined by : [CONTACT_42386] 3xUL N, 
bilirubin 2xUL N (direct bilirubin >35% of total), orINR1.5
serious AEor fatality  has earlier been observed with drug rechallenges [Papay , 
2009; Hunt , 2010]
evidence of drug -related preclinical liability  (e.g., reactive metabolites; 
mitochondrial impairment [Hunt , 2010] )
Rechallenge refer s to resuming study  treatment following DILI. Because of the risks 
associated with rechallenge after DILI this should only  be considered for a participant for 
whom there is compelling evidence of benefit from a critical or life -saving medicine, 
there is no alternative approved medicine available, and a benefit: risk assessment of 
rechallenge is considered to be favourable.
Approval b y [COMPANY_004] for rechallenge with study treatment can be considered where:
Investigator requests consideration of rechallenge with st udy treatment for a 
participant who is receiving compelling benefit (partial response or complete 
response) with study  treatment that exceeds risk, and no effective alternative therapy  
is available.  
  The ALT at the time of rechallenge is <3xUL N.
The par ticipant did not have additional risk factors for a fatal outcome following the 
initial injury  including hy persensitivity , jaundice, bilirubin >2xUL N (direct bilirubin 
>35% of total), or INR >1.5.
IRB or IEC approval for rechallenge with study  treatment mu st be obtained, as 
required.   
If the rechallenge is approved by  [CONTACT_90652], the 
participant must be provided with a clear description of the possible benefits and 
risks of study  treatment administration, including the possibility  of recurrent, more 
severe liver injury  or death.  
The participant must also provide signed informed consent specifically  for the 
rechallenge with study  treatment.  Documentation of informed consent must be 
recorded in the study  chart.  
Study  treatment mus t be administered at the dose specified b y [COMPANY_004].
Participants approved b y [COMPANY_004] Medical Governance for rechallenge with study  
treatment must return to the clinic twice a week for liver chemistry  tests until stable 
liver chemistries have been demonstrated and then standard laboratory  monitoring 
may resume as per protocol.
2017N327572_0 7 CONFIDENTIA L
204686
144If after study  treatment rechallenge, participant meets protocol -defined liver 
chemistry  stoppi[INVESTIGATOR_3418], study  treatment should be permanently  discontinued. 
Medical Monitor, and the IRB or IECas required, must be informed of the 
participant’s outcome following stud y treatment rechallenge. 
[COMPANY_004] to be notified of any AEs, as per Appendix 4. 
2.Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_90569] T Related to 
Study Treatment
Restart refers to resuming stud y treatment following liver stoppi[INVESTIGATOR_90570] a clear underl ying cause (other than DILI) of the liver event ( e.g., biliary  obstruction, 
pancreatic events, hy potension, acute viral hepatitis). Furthermore, there should be no 
evidence of alcoholic hepatitis or hy persensitivity
Approval b y [COMPANY_004] for study treatment restart can be considered where:
Investigator requests consideration for stud y treatment restart if liver chemistries 
have a clear underl ying cause (e.g., biliary  obstruction, hy potension and liver 
chemistries have improved to normal or are within 1.5 x baseline and AL T 
<3xUL N).
Possible study  treatment -induced liver injury  has been excluded by  [CONTACT_90653]. This includes the absence of markers of h ypersensitivity  
(otherwise unexplained fever, rash, eosinophilia). Where a stud y treatment has an 
identified genetic marker associated with liver injury  (e.g., lapatinib, abacavir, 
amoxicillin/clavulanate), the presence of the marker should be excluded. If study  
treatment -related liver injury  cannot be excluded, the guidan ce on rechallenge in 
Section [IP_ADDRESS] will apply .
There is no evidence of alcoholic hepatitis.
IRB or IEC approval of study  treatment restart must be obtained, as required.
If restart of stud y treatment is approved b y [COMPANY_004] Medical Governance in writing, the 
participant must be provided with a clear description of the possible benefits and 
risks of study  treatment administration, including the possibility  of recurrent, more 
severe liver injury  or death.  
The participant must also provide signed informed consent specifically  for the study  
treatment restart.  Documentation of informed consent must be record ed in the study  
chart.  
Study  treatment must be administered at the dose specified by  [CONTACT_23983].
Participants approved b y [COMPANY_004] Medical Governance for restarting study  treatment 
must return to the clinic once a week for liver chemistry  tests until stable liver 
chemistries have been demonstrated and then laboratory  monitoring may  resume as 
per protocol. 
If after study  treatment re -start, participant meets protocol -defined liver chemistry  
stoppi[INVESTIGATOR_3418], follow usual stoppi[INVESTIGATOR_53058].
2017N327572_0 7 CONFIDENTIA L
204686
145Medical Monit or, and the IRB or IEC as required, must be informed of the 
participant’s outcome following stud y treatment restart. 
[COMPANY_004] to be notified of any AEs, as per Appendix 4.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].8. Appendix 8:Country -specific requirements : Canada
The following country  specific requirements apply to Canada only :
Section # and 
NameCountry  Requirement
Section 5.1, 
Overall DesignParticipants with confirmed PR or CR will be followed for response 
duration and may be eligi ble (outside of Canada) for continued 
study treatment at the time of relapse/progression. The decision 
whether a participant will receive additional treatment will be 
discussed and agreed upon by [CONTACT_90654]/Medical Monitor on a case -by-case basis.
Section 2, 
Schedule of 
Activities and 
Section 9, 
Study 
Assessments 
and 
procedures, 
Section 9.5.1 , 
Blood Sample 
Collection and 
Section 
[IP_ADDRESS] , 
ImmunogenicitySection 2:
Two bullets belo w do not apply  to those sites in 
Canada .
The timing and number of planned study assessments, 
including safety, laboratory, imaging, tumor biopsy, 
pharmacokin etic (PK), and pharmacodynamic/biomarker 
assessments included in the tables below may be altered 
during the course of the study based on newly available 
data (e.g., to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate moni toring. 
Any changes in the timing or addition of time points for any 
planned study assessments must be documented and 
approved by [CONTACT_90655], but will not 
constitute a protocol amen dment. The Institutional Review 
Board (IRB) /Independent Ethics Committees (IEC) will be 
informed of any safety issues that require alteration of the 
safety monitoring scheme or amendment of the informed 
consent form (ICF).
Section 9:
The timing and number of planned study assessments may be 
altered during the course of the study based on newly available data 
(e.g., to obtain data closer to the time of peak plasma 
concentrations) to ensure appropriate monitoring for the followin g 
assessments: safety, PK, pharmacodynamics/biomarker, or other 
assessments (not applicable for participants in Canada).  
Section 9.5.1 :
The timing of PK samples may be altered and/or PK samples may be 
obtained at additional t ime points to ensure thorough PK monitoring.  
Any change to the number and timing of PK samples is not 
applicable for participants enrolled in Canada .
2017N327572_0 7 CONFIDENTIA L
204686
147Section # and 
NameCountry  Requirement
Section [IP_ADDRESS] :
The timing and number of planned immunogenicity samples ma y be 
altered during the course of the study, based on newly available data 
to ensure appropriate safety monitoring (any change to the number 
and timing of immunogenicity samples is not applicable for 
participants enrolled in Canada).
Section [IP_ADDRESS] , 
Management of 
Hepatotoxicity, 
Section [IP_ADDRESS] , 
Study 
Treatment 
Restart and 
Rechallenge 
and Section 
12.7.1 , Liver 
Safety Drug 
Restart or 
Rechallenge 
GuidelinesIn Canada, i f liver chemistry  stoppi[INVESTIGATOR_23893], 
participants will not be allo wed to restart study  drugs or be 
rechallenged.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].9. Appendix 9:Guidelines for A ssessment of Disease , Disease 
Progression and Response Criteria –adapted from RECIST 
version 1.1
Assess ment Guidelines
Please note the following:
The same diagnostic method, including use of contrast when applicable, must be 
used throughout the study to evaluate a lesion.   Contrast agents must be used in 
accordance with the Image Acquisition Guidelines.
All measurements should be taken and recorded in millimeters (mm), using a ruler or 
calipers.
Ultrasound is not a suitable modality  of disease assessment.  If new lesions are 
identified by  [CONTACT_2207], confirmation by  [CONTACT_90656].
Fluorodeox yglucose (FDG) -PET is generally  not suitable for ongoing assessments of 
disease.  However, FDG -PET can be useful in confirming new sites of disease where 
a positive FDG -PET scans correlates with the new site of disease present on CT/MRI  
or when a baseline FDG -PET was previousl y negative for the site of the new lesion. 
FDG -PET may  also be used in lieu of a standard bone scan providing coverage 
allows interrogation of all likely  sites of bone disease and FDG -PET is performed at 
all assessments.
If PET/CT is performed then the CT component can only  be used for standard 
response assessments if performed to diagnostic quality , which includes the required 
anatomical coverage and prescribed use of contrast.  The method of assessment 
should be noted as CT on the CRF.
Clinic al Examination: Clinically  detected lesions will only  be considered measurable 
when they  are superficial (e.g., skin nodules).  In the case of skin lesions, documentation 
by [CONTACT_90657] y, including a ruler /calipers to measure the size of the lesion , is 
required [ Eisenhauer ,2009].
CT and MRI: Contrast enhanced CT with 5mm contiguous slices is recommended.
Minimum size of a measurable baseline lesion should be twice the slice thickness, with a 
minimum lesion s ize of [ADDRESS_99914] b y use of the same imaging examinations.  Whenever possible the same 
scanner should be used [ Eisenhauer , 2009].
X-ray: In general, X -rayshould not be used for target lesion measurements owing to 
poor lesion definition.  Lesions on chest X -ray may  be considered measurable if they  are 
clearl y defined and surrounded by [CONTACT_6776]; however, chest CT is preferred over 
chest X -ray [Eisenhauer , 2009].
2017N327572_0 7 CONFIDENTIA L
204686
149Guidelines for Eval uation of Disease
Measurable and Non -Measurable Definitions
Measurable lesion:
A non -nodal lesion that can be acc uratel y measured in at least 1 dimension (longest 
dimension) of
[ADDRESS_99915] double the slice thickness (e.g., if the slice thickness is [ADDRESS_99916] be 20 mm).
10 mm caliper/ruler measurement b y clinical exam or medical photography. 
[ADDRESS_99917] x -ray.
Additionally ,lymph nodes can be considered pathologicall y enlarged and measurable if
15mm in the short axis when assessed b y CT or MRI  (slice thickness recommended 
to be no more than 5mm).  At baseline and fol low-up, only  the short axis will be 
measured [ Eisenhauer , 2009].
Non-measurable lesion:
All other lesions including lesions too small to be considered measurable (longest 
diameter <10 mm or pathological l ymph nod es with ≥ 10 mm and <15 mm short axis) as 
well as truly  non-measurable lesions, which include: leptomeningeal disease, ascites, 
pleural or pericardial effusions , inflammatory  breast disease, l ymphangitic involvement 
of the skin or lung, abdominal masses/ab dominal organomegal y identified by [CONTACT_90658] [ Eisenhauer , 2009].
Measurable disease : The presence of at least 1 measurable lesion.  Palpable lesions th at 
are not measurable b y radiologic or photographic evaluations may  not be utilized as the 
only measurable lesion.
Non-Measurable only disease : The presence of only  non-measurable lesions. Note: non -
measurable onl y disease is not allowed per protocol.
2017N327572_0 [ADDRESS_99918] Response Criteria
Table 20 Evaluation of Target Lesions
New, measurable alesions Incorporated into tumor burden
New, non -measurable lesions Do not define progression (but preclude CR)
irCRDisappearance of all lesions in 2 consecutive observations not less than 4 weeks 
apart. Any pathological lymph nodes (whether target or non -target) must have 
reduction in short axis to <10 mm.
irPR30% decrease in tumor burden compared with baseline in 2 observations at leas t 4 
weeks apart
irSD30% decrease in tumor burden compared with baseline cannot be established nor 
20% increase compared with nadir
irPDbAt least 20 % increase in tumor burden compared with nadir ( at any single time point) 
in 2consecutive observations a t least 4 weeks apart. In addition to the relative 
increase of 20%, the sum must also demonstrate an absolute increase of at least [ADDRESS_99919][Wolchok , 2009;
Nishino , 2013] , the initial target ( ‘index”) and measurable new lesions are taken into 
account. At the baseline tumor assessment, the sum of the diameters in the plane of 
measurement of all target lesions (maximum of 5 lesio ns in total and a maximum of 2
lesions per organ representative of a ll involved organs) is calculated.
Note: If pathological l ymph nodes are included in the sum of diameters, the short axis of 
the ly mph node(s) is added into the sum. The short axis is the longest perpendicular 
diameter to the longest diameter of a l ymph no de or nodal mass. At each subsequent 
tumor assessment, the sum of diameters of the baseline target lesions and of new, 
measurable nodal and non -nodal lesions ( 10mm), up to 2 new lesions per organ are 
added together to provide the total tumor burden:
Tumo r Burden = Sum of diameters target lesions + sum of diameters new, measurable lesions
Time -point response assessment using the Immune -Related RECIST criteria
Percentage changes in tumor burden per assessment time point describe the size and 
growth kinetics o f both conventional and new, measurable lesions as they  appear. At each 
tumor assessment, the response in index and new, measurable lesions is defined based on 
the change in tumor burden (after ruling out irPD). Decreases in tumor burden must be 
assessed r elative to baseline measurements (i.e., the sum of diameters of all target lesions 
at screening).  
2017N327572_0 7 CONFIDENTIA L
204686
151Response Criteria
Evaluation of target lesions
Definitions for assessment of response for target lesion(s) are as follows:
CR:  Disappearance of all target lesions.  Any  pathological l ymph nodes must be 
<10mm in the short axis.
PR:  At least a 30% decrease in the sum of the diameters of target lesions, taking as a 
reference, the baseline sum of the diameters ( e.g., percent change from baseline).
SD:  Neither sufficient shrinkage to qualify  for PR nor sufficient increase to qualify  
for PD.
PD: At least a 20% increase in the sum of the diameters of target lesions, taking as a 
reference, the smallest sum of diameters recorded since the treatment started ( e.g., 
percent change from nadir, where nadir is defined as the smallest sum of diameters 
recorded since treatment start). In addition, the sum must have an absolute increase 
from nadir of 5mm.
Not Applicable (NA): No target lesions at baseline.
Not Evaluable ( NE): Cannot be classified by  1 of the 5 preceding definitions.
Note:
If lymph nodes are documented as target lesions the short axis is added into the sum 
of the diameters ( e.g., sum of diameters is the sum of the longest diameters for non -
nodal lesions and the short axis for nodal lesions).  When ly mph nodes decrease to 
non-pathological size (short axis <10mm) they  should still have a measurement 
reported in order not to overstate progression.
If at a given assessment time point all target lesions identified at baseline are not
assessed, sum of the diameters cannot be calculated for purposes of assessing CR, 
PR, or SD, or for use as the nadir for future assessments.  However, the sum of the 
diameters of the assessed lesions and the percent change from nadir shou ld be 
calculated to ensure that progression has not been documented.  If an assessment of 
PD cannot be made, the response assessment should be NE.
All lesions (nodal and non -nodal) should have their measurements recorded even 
when very  small ( e.g., 2 mm). If lesions are present but too small to measure, 5 mm 
should be recorded and should contribute to the sum of the diameters, unless it is 
likely  that the lesion has disappeared in which case 0 mm should be reported.
If a lesion disappears and reappears at a subsequent time point it should continue to 
be measured.  The response at the time when the lesion reappears will depend upon 
the status of the other lesions.  For example, if the disease had reached a CR status 
then PD would be documented at the time of reappearance.  However, if the response 
status was PR or SD, the diameter of the reappearing lesion should be added to the 
remaining diameters and response determined based on percent change from baseline 
and percent change from nadir.
2017N327572_0 7 CONFIDENTIA L
204686
152Evaluation of non -target lesions
Definitions for assessment of response for non -target lesions are as follows:
Complete Response:  The disappearance of all non -target lesions. All ly mph nodes 
identified as a site of disease at baseline must be non -pathological ( e.g., <10 mm 
short axis).
Non-CR/Non -PD:  The persistence of 1 or more non -target lesion(s) or ly mph nodes 
identified as a site of disease at baseline ≥ 10 mm short axis.
Progressive Disease: Unequivocal progression of existing non -target lesions. 
Not Applicable (NA):   No non -target lesions at baseline.
Not Evaluable (N E):  Cannot be classified by  1 of the 4 preceding definitions.
Note:
In the presence of measurable disease, progression on the basis of solely  non-target 
disease requires substantial worsening such that even in the presence of SD or PR in 
target disease, the overall tumor burden has increased sufficientl y to merit 
discontinuation of therapy .
Sites of non -target lesions, which are not assessed at a particular timepoint based on 
the assessment schedule, sho uld be excluded from the response determination ( e.g., 
non-target response does not have to be "Not Evaluable"). 
New lesions
New malignancies denoting disease progression must be unequivocal.  Lesions identified 
in follow -up in an anatomical location not scanned at baseline are considered new 
lesions.
Any equivocal new lesions should continue to be followed.  Treatment can continue at 
the discretion of the investigator until the next scheduled assessment.  If at the next 
assessment the new lesion is consid ered to be unequivocal, progression should be 
documented.
Evaluation of overall response
Table 21presents the overall response at an individual time point for all possible 
combinations of tumor responses in target and non -target lesions with or without the 
appearance of new lesions for participants with measurable disease at baseline.
2017N327572_0 7 CONFIDENTIA L
204686
153Table 21 Evaluation of Overall Response for Participants with Measurable 
Disease at Baseline
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR or NA No CR
CR Non-CR/Non -PD or NE No PR
PR Non-PD or NA or NE No PR
SD Non-PD or NA or NE No SD
NE Non-PD or NA or NE No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR=complete r esponse, PR = partial response, SD=stable disease, PD=progressive disease, NA= Not applicable, and 
NE=Not Evaluable
Note:
Participants with a global deterioration of health status requiring discontinuation 
of treatment without objective evidence of diseas e progression at that time should 
be classified as having "symptomatic deterioration." Objective response status is 
determined b y evaluations of disease burden. Every effort should be made to 
document the objective progression even after discontinuation of treatment.  
In some circumstances, it may  be difficult to distinguish residual disease from 
normal tissue. When the evaluation of CR depends on this determination, it is 
recommended that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) 
to confirm the CR.
Evaluation of best overall response
The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence and will be determined programmatically  by [CONTACT_90659]. 
To be assigned a status of SD, follow -up disease assessment must have met the 
SD criteria at least once after the first dose at a minimum interval of the first 
scheduled tumor evaluation .  
If the minimum time for S D is not met, best response will depend on the 
subsequent assessments.  For example, if an assessment of PD follows the 
assessment of SD and SD does not meet the minimum time requirement the best 
response will be PD.  Alternativel y, participant s lost to fo llow-up after an SD 
assessment not meeting the minimum time criteria will be considered not 
evaluable.  
Confirmation Criteria:
To be assigned a status of PR or CR, a confirmatory  disease assessment should be 
performed no less than 4 weeks (28 day s) after the criteria for response are first met.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].10. Appendix 10:CKD -EPI [INVESTIGATOR_90571] (CKD) stage: Kidney  Disease Outcomes Qualit y Initiative CKD 
stages 3/4/5 defined b y estimated glomular filtration rate (GFR) using the CKD 
Epi[INVESTIGATOR_90572] [Levey, 2009] .
GFR = 141 × min (S cr/κ, 1)α× max(S cr/κ, 1)-1.209× 0.993Age× 1.018 [if female] × 
1.159 [if black]
where:
Scris serum creatinine in mg/dL,
κ is 0.7 for females and 0.9 for males,
α is -0.329 for females and -0.411 for males,
min indicates the minimum of S cr/κ or 1, and
max indicates the maximum of S cr/κ or 1.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].11. Appendix 11:Adverse Events of Special Interest
The list of terms and reporting requirements for AESI  are provided below.  These are 
selected non -serious AEs and SAEs that must be reported to the [COMPANY_004] medical monitor
within [ADDRESS_99920] be reported regardless of investigator -determined 
relationship to study  treatment or if considered immune -related (unless otherwise 
specified).   Investigators/study  coordinators/designated site personnel are required to 
record these experiences in the eCRF (as described in the eCRF completion guidance 
document) and to provide supplemental information (such as medical history , 
concomitant medications, investigations, etc.) about the event.
Cytokine -related AEs
Cardiopulmonary  or hemody namic toxicity  starting within 24 hours of study  treatment 
that requires > 40% FiO2 , vasopressor administration, antiarrhy thmic agent or other 
significant medi cal intervention. Asystole, as measured by  [CONTACT_90660], or brady cardia that is 
symptomatic and requires medical intervention.
Immune -related AEs
Pneumonitis (reported as AESI if ≥Grade 2)
Acute interstitial pneumonitis Interstitial lung disease Pneumonitis
Colitis (reported as AESI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to 
treat the AE)
Intestinal Obstruction Colitis Colitis mic roscopic
Enterocolitis Enterocolitis hemorrhagic Gastrointestinal perforation
Necrotizing colitis Diarrhea
Endocrine (reported as AESI if ≥Grade 3 or ≥ Grade 2 and resulting in dose modification or use of systemic 
steroids to treat the AE)
Adrenal In sufficiency Hyperthyroidism Hypophysitis
Hypopi[INVESTIGATOR_90573], if ≥Grade 3 and associated with ketosis or metabolic 
acidosis (DKA)
Endocrine (reported as AESI)
Type 1 diabetes mellitus (if new onset)
Hematologic (reported as AESI if ≥Grade 3 or any grade resulting in dose modification or use of systemic steroids 
to treat the AE)
Autoimmune hemolytic anemia Aplastic anemia Thrombotic Thrombocytopenic 
Purpura (TTP)
Idiopathic (or immune) 
Thrombo cytopenia Purpura ( ITP)Disseminated Intravascular 
Coagulation (DIC)Hemolytic Uremic Syndrome 
(HUS)
Any Grade 4 anemia regardless of underlying mechanism
Hepatic (reported as AESI if ≥Grade 2, or any grade resulting in dose modification or use of syste mic steroids to 
treat the AE)
Hepatitis Autoimmune hepatitis Transaminase elevations (ALT 
and/or AST)
Infusion Reactions (reported as AESI for any grade)
Allergic reaction Anaphylaxis
2017N327572_0 7 CONFIDENTIA L
204686
156Serum sickness Infusion reactions Infusion -like reactions
Neurol ogic (reported as AESI for any grade)
Autoimmune neuropathy Guillain -Barré syndrome Demyelinating polyneuropathy
Myasthenic syndrome
Ocular (report as AESI if ≥Grade 2 or any grade resulting in dose modification or use of systemic steroids to treat 
the AE)
Uveitis Iritis
Renal (reported as AESI if ≥Grade 2)
Nephritis Nephritis autoimmune Renal Failure
Renal failure acuteCreatinine elevations (report as AESI if ≥Grade 3 or any grade resulting 
in dose modification or use of systemic steroids to treat the AE)
Skin (reported as AESI for any grade)
Dermatitis exfoliative Erythema multiforme Stevens -Johnson syndrome
Toxic epi[INVESTIGATOR_90574] (re ported as AESI if ≥ Grade 3)
Pruritus Rash Rash generalized
Rash maculo -papular
Any rash considered clinically significant in the physician’s judgment 
Other (reported as AESI for any grade)
Myocarditis Pancreatitis Pericarditis
Any other Grade 3 e vent which is considered immune -related by [CONTACT_099]
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].12. Appendix 12:ECOG Performance Statusa
Grade Descriptions
a. Oken , 1982.
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are 
protected by [CONTACT_14561].
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].13. Appendix 13: mAb Monotherap yDosing Period
The following information is a guidance for participants who are treated with mAb 
monotherap y.
Schedule of Activities in Section 2should be followed with the following clarifications:
Table 1: Part 1 Dose Escalation and PK/Pharmacody namic Cohorts: Safety , Laboratory , 
Efficacy , Study  Treatment Procedures
1.Vital Signs: Predose mAb and mAb EOI+2h. After 2h, as clinicall y indicated.
2.ECG: As single measurement, Predose mAb and mAb EOI+2h. After 2h as 
clinically  indicated.
3.Optional Consent Procedures
a.Tumor Biopsies: Participants can opt out of the optional procedure 
including those in the PK/PD cohort.
b.Telephone Interview: Participants can opt out of the optional procedure
4.PK/PD subjects: Participants can opt out of the mandatory  fresh biops y required 
at Week 9. Optional Week 12 fresh biops y is not mandatory per protocol.
Table 2: Part 1 Dose Escalation and PK/Pharmacody namics Cohorts: Pharmacokinetic, 
Pharmacod ynamic, Anti -drug Antibody , and Genetic Assessments
Scheduled assessments will not be collected. However, even t-driven collections 
(e.g. in response to hypersensitivity  including infusion reactions) will be 
performed per Table 2(footnote h and i) and Section [IP_ADDRESS] .  
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].14. Appendix 1 4: COVID -[ADDRESS_99921] of an y travel restrictions 
implemented by  [CONTACT_5737]/regional health authorities and local institutions, and individual 
benefit /risk when m aking enrollment and treatment decisions for trial participants.
Every  effort should be made to adhere to protocol -specified assessments for participants 
on study  intervention, including follow up however when not possible, for the duration of 
these speci al circumstances, the following measures may  be implemented for enrolled 
participants.Clinical investigators should document in [site files and in participant 
notes/Electronic Heath Records as appropriate] how restrictions related to COVID -[ADDRESS_99922] and duration of those changes and indicate which trial 
participants were impacted and how those trial participants were impacted (as per the 
current local COVID -19 related regulatory  guidance). 
Missing protocol required data/visits due to COVID -19 should be noted in participant 
notes and recorded as a COVID -19 protocol deviation.
2017N327572_0 7 CONFIDENTIA L
204686
[ZIP_CODE].15. Appendix 15: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of C ontents (TOC).
Amendment 1 08-December -2017
Overall Rationale for the Amendment: Amendment 1 incorporates changes to the 
protocol as requested b y the [LOCATION_002] Food and Drug Administration (FDA).
Section # and 
NameDescription of Change Brief Rationale
Whole 
DocumentAdministrative corrections 
of minor typographical, 
and/or inconsistent 
language throughout the 
protocolProvide clarity and correction
Synopsis Updated study design to 
remove 240 mg dose level of 
[COMPANY_004]3174998
Reduced overall number of 
study participants in line with 
the removal of the 
[COMPANY_004]3174998 240 mg dose 
levelUpdated in line with main document
Section 2 S oA Table 1 and Table 3:
Added additional vital sign and 
ECG monitoring at specified 
study visits
Removal of Circulating Tumor 
Cells (CTC) collection
Table 2 a nd Table 4:
Added additional [COMPANY_004]1795091 
PK assessments at [ADDRESS_99923] [COMPANY_004]1795091 
injection at Day 1 to align with 
ECG assessmentsTable 1 and Table 3:
Additional monitoring and alignment of 
ECG assessments with PK 
[COMPANY_004]1795091 assessments as 
requested by [CONTACT_8415]
Clarified timing of pre dose 
[COMPANY_004]1795091 and [COMPANY_004]3174998 vital 
sign and ECG assessments
Expected limited expression of CTCs 
in this patient pollution .
Table 2 and Table 4:
Request of FDA to capture the PK 
profile aft er intravenous injection 
coinciding with ECG assessments
Section 5, Section 5.1, Section 5.4, Section Updated as requested and agreed with 
2017N327572_0 7 CONFIDENTIA L
204686
161Section # and 
NameDescription of Change Brief Rationale
Study Design 5.5:
Updates made through out 
section to remove 
[COMPANY_004]3174998 240 mg dose 
level in Part 1 Dose Escalation 
and Part 2 Expansion Cohort 
and conf irm one dose of 
[COMPANY_004]3174998 (24 mg) to be 
used in combination with 
[COMPANY_004]1795091
Included [COMPANY_004]3174998 -1 dose 
level (8 mg) in case dose 
reduction is needed below 
[COMPANY_004]3174998 24 mg + 
[COMPANY_004]1795091 50 ng
Updated DLT criterial in Table 
6 
Section 5.2, Number of 
Partic ipants:
Reduced overall number of 
study participants in line with 
the removal of the 
[COMPANY_004]3174998 240 mg dose 
levelFDA
Section 6, 
Study 
PopulationUpdated inclusion criteria for 
participants in Part 2Provided addition al inclusion criteria for 
prior lines of treatment
Section 7, 
Treatments 
AdministeredAdded additional safety 
monitoring following first dose 
of [COMPANY_004]1795091 and first two 
doses of combination
[COMPANY_004]3174998 and 
[COMPANY_004]1795091
Clarified meaning of phrase, 
“that req uires oxygen > 40%” 
by [CONTACT_90661] “oxygen 
>40% FiO2”. Also updated in 
Section 5/DLT criteria
Updated Table 8Extended duration of monitoring for 
AEs including changes to vital signs 
and ECGs following first doses of 
[COMPANY_004]1795091 monotherapy and in 
combination with [COMPANY_004]3174998
Clarification supported by [CONTACT_90662]
Table updated to remove 240 mg dose 
2017N327572_0 7 CONFIDENTIA L
204686
162Section # and 
NameDescription of Change Brief Rationale
of [COMPANY_004]3174998
Section 7.3 Removed direction to register 
participants into [COMPANY_004] registration 
and medication ordering system  System will not be used for participant 
registration.  Study Reference Manual will
include details for participant registration 
and enrollment
Section 10, 
Statistical 
Considerations 
and Data 
Analysis (10.1, 
10.3.4, 10.4.2)
Immunogenicity 
Analysis 
([IP_ADDRESS])Removed refer ence to two 
cohorts in Part 2 Expansion 
Cohort
Added option for development 
of a neutralizing ADA assay240 mg dose level of [COMPANY_004]3174998 
removed
Included per recommendation from 
FDA to allow for further 
characterization of stored samples
Section 12.7 .1, 
Liver Safety 
Drug Restart or 
Rechallenge 
GuidelinesAdded additional criteria for 
consideration of rechallenge with 
study treatment after a liver eventCriteria added to increase safeguards 
when considering possible study treatment 
rechallenge
Amendm ent 01, Country Specific ( Canada) 06-MAR -2018
Overall Rationale for the Amendment: Prot-Ament1 -CAN -1incorporates changes to 
the protocol specific to sites in Canada only as requested by [CONTACT_90663] .
Section # and 
NameDescription of Chan ge Brief Rationale
Section 5.1, 
Overall DesignRemoved text to allow participants 
who progress after confirmed CR 
or PR to continue on study 
treatment if in agreement with 
sponsor and study investigatorRequested by [CONTACT_90664][INVESTIGATOR_90575] a 
participant continue to receive study drugs
Section 5.1.1, 
Part 1: Dose 
Escalation of 
[COMPANY_004]1795091 
and 
[COMPANY_004]3174998 Removed text to allow participants 
who experienced a DLT, 
unacceptabi lity or an increase in 
ALT, and not attributable to 
another cause, to continue on 
study treatment if in agreement 
with investigator and sponsorRequested by [CONTACT_90664][INVESTIGATOR_90576] 
a participant experiencing DLT or 
unacceptable toxicity stop study treatment
2017N327572_0 7 CONFIDENTIA L
204686
163Section # and 
NameDescription of Chan ge Brief Rationale
Section 5.1.3, 
Alternative 
Dosing 
ScheduleRemoved text that an alternative 
dosing schedule for [COMPANY_004]1795091 
may be evaluated if emerging data 
suggest that the protocol -specified 
schedule will result in excessi ve 
toxicity or limited efficacyRequested by [CONTACT_90665] a protocol amendment
5.1.4, Dose -
Limiting 
ToxicityRemoved text to allow participants 
who experienced a DLT to 
continue on study treatment if in 
agreement with sponsor and study 
investigatorRequested by [CONTACT_90664][INVESTIGATOR_90575] a 
participant continue to receive study drugs
Section 2, 
Schedule of 
Activities and 
Section 9, 
Study 
Assessments 
and 
procedures, 
Section 9.5.1, 
Blood Sample 
Collection and 
Section 
[IP_ADDRESS], 
ImmunogenicityRemoved text to allow adjustment 
for the timing and number of 
planned study assessments during 
the course of the study based on 
newly available data.Requested by [CONTACT_90666] a protocol 
amendment
Section [IP_ADDRESS], 
Management of 
Hepatotoxicity, 
Section [IP_ADDRESS], 
Study 
Treatment 
Restart and 
Rechallenge 
and Section 
12.7.1, Liver 
Safety Drug 
Restart or 
Rechallenge 
GuidelinesAdded text that the option to 
restart or rechallenge study 
treatment following meeting the 
liver chemistry stoppi[INVESTIGATOR_90577] f ollow 
stoppi[INVESTIGATOR_90578] 10.1, 
Sample Size Added text describing the 
application of enrolment stoppi[INVESTIGATOR_90579] 2 
2017N327572_0 7 CONFIDENTIA L
204686
164Section # and 
NameDescription of Chan ge Brief Rationale
Determination in Table 17 and assessment of 
futility will be applied for Part 2 
Expansion Cohort.Expansion Cohort
Amendment 225-JUL-2018
Overall Rationale for the Amendment: Amendment 2incorpora tes changes to the 
protocol to consolidate Canada country -specific amendment 01 CAN -1 and include two 
additional immunotherapy combination partners. 
Section # and 
NameDescription of Change Brief Rationale
Whole 
DocumentAdministrative corrections of 
minor typographical, and/or 
inconsistent language 
throughout the protocol
Language updated throughout 
to add two treatment arms: 
[COMPANY_004]1795091 with 
[COMPANY_004]3359609, and 
[COMPANY_004]1795091 with 
pembrolizumab
Combined with country -specific 
(Canada) protocol amendment Provide sclarity and correction
To expand the assessment of 
[COMPANY_004]1795091 administered in 
combination with other 
immunotherapi[INVESTIGATOR_014]
Incorporate schanges requested by 
[CONTACT_90667] -specific 
amendment into global document
Synopsis Aligned with changes to study 
design and participant number 
in main textUpdated in line with main document
Section 2 SoA Table 1, Table 3:
Added evaluations for new 
treatment arms
Added microbiome specimen 
collection
Table 2, Table 4:
Added assessments for new 
treatment armsTable 1, Table 3:
Provides instruction for new treatment 
arms
Table 2, Table 4:
Provides instruction for new treatment 
arms 
Section 3 
IntroductionAdded background information 
and rationale for targeting 
ICOS and PD -1 in combination Support sdecision to include new 
treatment arms
2017N327572_0 7 CONFIDENTIA L
204686
165Section # and 
NameDescription of Change Brief Rationale
with [COMPANY_004]1795091
Added risk considerations for 
[COMPANY_004]3359609 and 
pembrolizumab in Risk 
Assessment table
Section 4 
Objectives and 
EndpointsAdded exploratory endpoint for 
Microbiome Analysis
Added exploratory endpoint for 
PK of com bination partnersProvides additional information for new 
treatment arms
Section 5, 
Study DesignSection 5.1, Overall Design
Study schematic updated
Exclusions to Canadian 
participants identified
Table 5 removed from
Section 5.2, Number of 
Participants
Part [ADDRESS_99924] new treatment 
combinationsProvide sspecific instructions for 
conducting modified study
Section 6, 
Study 
PopulationUpdated inclusion and 
exclusion criteria for 
participants in Part 2cProvide sadditional criteria for pr ior 
lines of treatment
Section 7, 
Treatments 
AdministeredUpdated Table 8 and Table 9
Added Table 10 and Table 11Includes descriptions for [COMPANY_004]3359609 
and pembrolizumab
Dose Modification and Treatment 
Guidelines presented in table format
Section 8, 
Discontinuation 
CriteriaAdded withdrawal of subjects 
is to be based on an average 
QTcF value of triplicate ECGsClarification of QTcF Stoppi[INVESTIGATOR_90580] 9, 
Study 
AssessmentsAdded description for Stool 
Specimen collectionProvides direction for sample collection
Section 10, Clarifications to sample size Provides updated numbers of study 
2017N327572_0 7 CONFIDENTIA L
204686
166Section # and 
NameDescription of Change Brief Rationale
Statistical 
Considerations 
and Data 
Analysisdetermination to account for 
new treatment armsparticipants
Section 11, 
ReferencesReferences added for ICOS 
and pembrol izumab 
information Supports new treatment arms
Amendment 314-SEP-2018
Overall Rationale for the Amendment: Amendment 3incorporates changes to the 
protocol to include the most recent information for pembrolizumab combination studies 
and changes to biom arker sample collections to evaluate TLR4 responses. 
Section # and Name [CONTACT_19523] [ADDRESS_99925] TLR4 
administration to evaluate TLR4 
responses as opposed to the 
combination partners
Section 3.2.4 .1
Clinical Experience in 
Combination with other 
TLR AgonistsConclusions from other 
pembrolizumab studies and 
the frequency of cytokine -
associated AEs and were 
includedAlignment with the updated CRA 
report
Section 3.2.5
Combination BackgroundPembrolizumab survival 
curve duration updatedAlignment with published report
Section 3.3.1 Risk 
Assessment TableInformation added to CRS 
Mitigation StrategiesProvides additional information on 
risk mitigation
Section [IP_ADDRESS] 
Combination 
ConsiderationsDose justifications for 
combination treatments were 
addedAlignment with the updated CRA 
report
Section 7.2.1 General 
Guideli nes for Cytokine -
Related Adverse Events 
and Infusion ReactionsClarification of verbatim 
terms used to report 
“cytokine -related AEs” or 
“infusion reactions”Provides instruction on AE 
terminology
Section 12.11 Adverse 
Events of Special InterestCytokine R elease Syndrome 
removed from Infusion 
Reactions (reported as AESI 
for any grade)Provides instruction on AE 
terminology
Whole Document Minor typographical errors 
corrected, clarifications and 
formatting changes
2017N327572_0 7 CONFIDENTIA L
204686
167Amendment 4:12-AUG -2019
Overall Rational e for the Amendment: Amendment 4incorporates changes to the 
protocol to include the most recent safet y information, changes to futility stoppi[INVESTIGATOR_90581]. 
Section # and 
NameDescription of Change Brief Rationale
Section 2 
Schedule of 
Activities TablesNumber of biomarker and clinical 
chemistry samples collected increased Ensures sufficient cytokine 
response data and flow cytometry 
data collected to evaluate TLR4 
responses 
Section 2 
Schedule of 
Activities TablesTable 1 :Footnote for tumor biopsy clarified 
to state biopsy can be collected next visit if 
missed for treatment delay Ensures appropriate biopsy 
sample may be collected 
Section 2 
Schedule of 
Activities TablesTable 4:Footnotes for immunogenicity and 
hypersensi tivity reactions clarified that 
participants will be with drawn from 
treatment, not studyClarification
Section 
[IP_ADDRESS].1Descripton of another participant with 
elevated ALT added from new safety dataAccuracy and completeness of 
safety data
Section 5.1 Minimum number of participants in the Part 
2 expansion cohorts changed from 6 to 8Improves chances of seeing 
efficacious response
Section 5.1.3 Text added to describe replacement of 
participants with DLT Clarification
Section 5.2 Text added to describe the replacement of 
participants in Part 2Clarification
Section 6 Modified requirements for previous therapy More reflective of real -world study 
population
Section 7 Table 
8Removed unit dose strength and dosing 
instructionsAvailable in the investigato r’s 
brochure
Section 7.2 Stated AEs wil be graded by [CONTACT_12134] -CTCAE 
unless otherwise specifiedInclude Lee 2014 reference
Section 10 Alternative hypothesis adjusted based on 
change to minimum numbers, Table 19 
and Table 20 updatedReflects change to minimum 
number of participants
Whole 
documentReferences updated New references available
Amendment 5: 02-Mar-2020
Overall Rationale for the Amendment: Amendment 5 addresses mAb monotherapy  
([COMPANY_004]3174998, [COMPANY_004]3359609, or pembrolizumab )and the a ctivities that are modified for this 
occurrence.
2017N327572_0 7 CONFIDENTIA L
204686
168Section # and 
NameDescription of Change Brief Rationale
Section 2 
Schedule of 
Activities 
Tables: Table [ADDRESS_99926] reader to
Appendix 13 for SOA modifications. Ensures that only those activities 
that are required are collected 
from the participant. Reduces 
burden on participant.  
Section 7.2 
Dose 
Modification Included language allowing continued 
treatment if only mAb monotherapy is 
administered.Provides instruction for continuing 
in the trial on mAb monotherapy
Appendix 13: 
mAb 
Monotherapy 
Dosing PeriodAdded guidance on modifications that 
should be taken if only mAb monotherapy 
is administered.Provided details on the changes 
to the activities required. Reduces 
burden on participant.